COVER DESIGN
Medical Arts Branch, Office of Research Services, National Institutes of Health

COPYRIGHT INFORMATION
All material appearing in this report is in the public domain and may be reproduced or copied. A suggested citation follows.

SUGGESTED CITATION
# Table of Contents

ABOUT THE IACC ................................................................. IV

INTRODUCTION ..................................................................... 1

WHO FUNDED ASD RESEARCH IN 2011 AND 2012? ................. 2
  How much ASD research was funded in 2011 and 2012? ................. 4
  What funding trends were observed? ........................................... 6
  Where is research being funded in the U.S.? ................................. 8
  What types of research are funded by the different agencies and organizations? ........................................... 10
  Federal agency and private organization mission statements .......... 13
  What was the breakdown of funding in 2011? ............................... 18
  What was the breakdown of funding in 2012? ............................... 20
  Summary ........................................................................... 22

WHAT TYPES OF ASD RESEARCH WERE FUNDED? .................. 23

HOW DID THE RESEARCH PROJECTS FUNDED IN 2011 AND 2012 ALIGN WITH THE OBJECTIVES IN THE IACC STRATEGIC PLAN? ......................................................... 27

SUBCATEGORY CLASSIFICATION ............................................. 31

ANALYSIS OF PROGRESS TOWARD IACC STRATEGIC PLAN OBJECTIVES ................................................................. 32
  Question 1: Screening and Diagnosis ........................................... 34
  Question 2: Biology ................................................................. 46
  Question 3: Risk Factors .......................................................... 57
  Question 4: Treatments and Interventions ................................... 71
  Question 5: Services ............................................................... 84
  Question 6: Lifespan Issues ....................................................... 97
  Question 7: Infrastructure and Surveillance .................................. 105

SUMMARY AND CONCLUSION ................................................ 121

Appendices:

APPENDIX A: ASD-RELATED RESEARCH PROJECTS NOT INCLUDED IN IACC PORTFOLIO ANALYSIS ................................................................. 122

APPENDIX B: ASD RESEARCH PROGRESS ON IACC STRATEGIC PLAN OBJECTIVES: SUMMARY OF YEARS 2008 TO 2012 ......................................................... 124

APPENDIX C: SUBCATEGORY DEFINITIONS ...................................... 126

INTERAGENCY AUTISM COORDINATING COMMITTEE MEMBER ROSTER ........ 132

OFFICE OF AUTISM RESEARCH COORDINATION STAFF ROSTER ............... 135
About the IACC

The Interagency Autism Coordinating Committee (IACC) is a Federal advisory committee charged with coordinating all activities concerning autism spectrum disorder (ASD) within the U.S. Department of Health and Human Services (HHS) and providing advice to the Secretary of HHS on issues related to autism. It was established by Congress under the Children’s Health Act of 2000, reconstituted under the Combating Autism Act (CAA) of 2006, and renewed under the Combating Autism Reauthorization Act (CARA) of 2011 and the Autism Collaboration, Accountability, Research, Education, and Support (CARES) Act of 2014.

Membership of the Committee includes a wide array of Federal agencies involved in ASD research and services, as well as public stakeholders, including self-advocates, parents of children and adults with ASD, advocates, service providers, and researchers, who represent a variety of perspectives from within the autism community. This makeup of the IACC membership is designed to ensure that the Committee is equipped to address the wide range of issues and challenges faced by families and individuals affected by autism.

Under the CAA and subsequent authorizations, the IACC is required to (1) develop and annually update a strategic plan for ASD research, (2) develop and annually update a summary of advances in ASD research, and (3) monitor Federal activities related to ASD.

Through these and other activities, the IACC provides guidance to HHS and partners with the broader autism community to accelerate research and enhance services with the goal of profoundly improving the lives of people with ASD and their families.

***

For more information about the IACC, see http://www.iacc.hhs.gov.

Introduction

In 2009, the Interagency Autism Coordinating Committee (IACC) launched its Strategic Plan for Autism Spectrum Disorder Research, providing a framework to guide the efforts of Federal and private funders of autism research. The IACC Strategic Plan, developed with extensive input from a broad array of Federal and public stakeholders, organizes research priorities around seven general topic areas represented as consumer-focused “Questions.” Each question is divided further into 78 research objectives that address key research needs, gaps, and opportunities identified by the Committee. Each objective includes a recommended budget that serves as an estimate of how much the Committee projects it might cost to conduct the research-related activities described.

Following the development of the IACC Strategic Plan, the Office of Autism Research Coordination – the office within the National Institutes of Health (NIH) that manages the activities of the IACC – began issuing a series of IACC Autism Spectrum Disorder (ASD) Research Portfolio Analysis Reports to provide the IACC with comprehensive information about the status of autism research funding among Federal agencies and private research organizations in the U.S. The reports align data on individual research-related projects with objectives in the IACC Strategic Plan, providing an accounting of how much funding has gone toward support of projects related to Strategic Plan objectives and highlighting trends. This information has been used to help the IACC in their efforts to monitor ASD research efforts and track progress made each year toward achievement of objectives in the IACC Strategic Plan for ASD Research. The 2011-2012 IACC ASD Research Portfolio Analysis Report, in addition to information on progress made toward each of the 78 objectives in the IACC Strategic Plan in 2011 and 2012, also provides an analysis of progress that was made over the five-year period from 2008-2012.

To accompany the IACC 2011-2012 ASD Research Portfolio Analysis Report, detailed 2011 and 2012 Federal and private organization project data are available in the IACC/OARC Autism Spectrum Disorder Research Portfolio Analysis Web Tool, a database accessible via the IACC website (https://iacc.hhs.gov/apps/portfolio-analysis-web-tool/projects). The database can be browsed and sorted by several categories, such as “Funder” or “Strategic Plan question.” A search tool enables inquiries based on more specific parameters, such as keywords that may appear in a title or project description. Launched in 2012, this database provides stakeholders with a centralized place from which to gather valuable information about ASD research that can support their efforts to serve the autism community.
Who funded ASD research in 2011 and 2012?

The Office of Autism Research Coordination (OARC) requested 2011 and 2012 autism-related research project and funding information from several Federal agencies and private organizations, including the annual budget for each project and its relevance to the seven critical questions/chapters of the 2011 IACC Strategic Plan for ASD Research, illustrated below (Figure 1).

**IACC Strategic Plan Questions and Corresponding Research Areas**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening &amp; Diagnosis</td>
<td>Biology</td>
<td>Risk Factors</td>
<td>Treatments &amp; Interventions</td>
<td>Services</td>
<td>Lifespan Issues</td>
<td>Infrastructure &amp; Surveillance</td>
</tr>
</tbody>
</table>

**Figure 1.** The research areas corresponding to the seven questions of the 2011 IACC Strategic Plan for ASD Research are designated in the oval above each question.

Twelve Federal agencies and eight private funders provided their autism funding data for this analysis. These 20 agencies and organizations are listed in Table 1. Funders submitting data for the first time include: the Administration for Community Living (ACL), a component agency within HHS that was formed in 2012; the U.S. Air Force (AF); the Substance Abuse and Mental Health Services Administration (SAMHSA); and the Brain & Behavior Research Foundation (BBRF).
### Agencies and Organizations Included in the **2011-2012 IACC Portfolio Analysis**

<table>
<thead>
<tr>
<th>FEDERAL AGENCIES</th>
<th>PRIVATE ORGANIZATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Administration for Children and Families (ACF)</td>
<td>• Autism Research Institute (ARI)</td>
</tr>
<tr>
<td>• Administration for Community Living (ACL)</td>
<td>• Autism Science Foundation (ASF)</td>
</tr>
<tr>
<td>• Agency for Healthcare Research and Quality (AHRQ)</td>
<td>• Autism Speaks (AS)</td>
</tr>
<tr>
<td>• Centers for Disease Control and Prevention (CDC)</td>
<td>• Brain &amp; Behavior Research Foundation (BBRF)</td>
</tr>
<tr>
<td>• Centers for Medicare &amp; Medicaid Services (CMS)</td>
<td>• Center for Autism and Related Disorders (CARD)</td>
</tr>
<tr>
<td>• Department of Defense (DoD)*</td>
<td>• Organization for Autism Research (OAR)</td>
</tr>
<tr>
<td>– Air Force (AF)</td>
<td>• Simons Foundation (SF)</td>
</tr>
<tr>
<td>– Autism Research Program (ARP)</td>
<td>• Southwest Autism Research &amp; Resource Center (SARRC)</td>
</tr>
<tr>
<td>• Department of Education (ED)</td>
<td></td>
</tr>
<tr>
<td>• Environmental Protection Agency (EPA)</td>
<td></td>
</tr>
<tr>
<td>• Health Resources and Services Administration (HRSA)</td>
<td></td>
</tr>
<tr>
<td>• National Institutes of Health (NIH)</td>
<td></td>
</tr>
<tr>
<td>• National Science Foundation (NSF)</td>
<td></td>
</tr>
<tr>
<td>• Substance Abuse and Mental Health Services Administration (SAMHSA)</td>
<td></td>
</tr>
</tbody>
</table>

* The DoD Autism Research Program and Air Force reported as two separate entities for the purpose of this Portfolio Analysis

**Table 1.** Projects from 12 Federal agencies and eight private organizations were included in the 2011-2012 IACC Autism Spectrum Disorder Research Portfolio Analysis Report.
How much ASD research was funded in 2011 and 2012?

Combined, the estimated Federal and private investment in ASD research in 2011 and 2012 was $299,879,145 and $331,949,933 respectively. While overall funding for autism research increased by $32 million from 2011 to 2012, the proportions of Federal and private funding remained constant over this period. In both 2011 and 2012, the Federal government provided 78% ($233.1 million in 2011 and $260.1 million in 2012) and private organizations provided 22% ($66.8 million in 2011 and $71.8 million in 2012) of the total funding for ASD research (Figures 2 and 3).
In 2011 and 2012, 78% of ASD research funding was provided by Federal sources, while 22% of funding was provided by private organizations.
WHAT FUNDING TRENDS WERE OBSERVED?

• Combined Federal and private investment in ASD research decreased from 2010 ($348.6 million) to 2011 ($299.9 million) and 2012 ($331.9 million).

• Private investment in ASD research was lower in 2011 ($66.8 million) and 2012 ($71.8 million) than in previous years (compare to $78.5 million in 2008, $77 million in 2009, and $74.1 million in 2010), possibly reflecting changes in the U.S. economy. However, there was an increase in private funding for autism research from 2011 to 2012.

• The amount of Federal investment in autism research reported in 2011 ($233.1 million) and 2012 ($260.1 million) was lower than the amount reported in 2010 ($334.4 million).

• One factor that may have contributed to the decrease in overall and Federal funding for ASD research from 2010 to 2011 and 2012 is the American Recovery and Reinvestment Act (ARRA), which provided an additional $63.9 million in 2009 and $59.9 million in 2010 that was used to support autism research projects, creating a temporary increase in autism research funding levels during those years (Figure 4).

• Another factor that may have contributed to changes in overall funding levels is that adjustments were made in the reporting of funding for some ASD services research-related projects starting in 2011. Services projects in which the research component was minimal or projects that were not ASD-specific, but focused on disabilities in general, were not included. Additionally, some large services-related projects that included ASD among multiple disabilities or contained specific portions that pertain to services research were prorated in 2011 and 2012 to reflect only the portions of the projects that are directly relevant to autism research described in the IACC Strategic Plan objectives.

• Finally, additional Federal funders were added to the 2011-2012 Portfolio Analysis, in accordance with the IACC’s goal to make the analysis as comprehensive and current as possible and to ensure it reflects the actual state of the field. It should be noted, however, that the funders added to the analysis in 2011 and 2012 contributed only a small number of projects, so the impact of these new projects on the total funding figures was relatively small.
Figure 4. This figure illustrates levels of autism research funding from combined Federal and private sources during 2008-2012 based on data collected for the IACC Portfolio Analysis of those years.
WHERE IS RESEARCH BEING FUNDED IN THE U.S.?

Figure 5 shows the distribution of autism research projects across the U.S. funded by both Federal agencies and private organizations in 2012. The map shows that research is concentrated along the east and west coasts of the U.S. and in major metropolitan areas or areas with large universities in the middle portion of the country. Figure 6 provides some additional information about the institutions and states that received the most research funding in 2011 and 2012.

Figure 5. A map of the U.S. and Canada displaying the distribution of autism-related research projects funded by Federal agencies and private organizations.
Which U.S. institutions received the most autism research funding in 2011 and 2012?

<table>
<thead>
<tr>
<th>Institution</th>
<th>2011 Funding</th>
<th>2011 Project Count</th>
<th>Institution</th>
<th>2012 Funding</th>
<th>2012 Project Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Institutes of Health-Intramural Research Program</td>
<td>$19,983,481</td>
<td>15</td>
<td>National Institutes of Health-Intramural Research Program</td>
<td>$28,959,454</td>
<td>18</td>
</tr>
<tr>
<td>Yale University</td>
<td>$15,492,159</td>
<td>38</td>
<td>University of North Carolina at Chapel Hill</td>
<td>$16,836,300</td>
<td>44</td>
</tr>
<tr>
<td>University of California, Davis</td>
<td>$12,912,674</td>
<td>45</td>
<td>Yale University</td>
<td>$15,404,956</td>
<td>49</td>
</tr>
<tr>
<td>University of North Carolina at Chapel Hill</td>
<td>$12,736,747</td>
<td>40</td>
<td>University of California, Los Angeles</td>
<td>$13,528,767</td>
<td>44</td>
</tr>
<tr>
<td>University of California, Los Angeles</td>
<td>$10,879,866</td>
<td>35</td>
<td>University of California, Davis</td>
<td>$9,702,143</td>
<td>47</td>
</tr>
<tr>
<td>University of California, San Diego</td>
<td>$6,350,978</td>
<td>27</td>
<td>Stanford University</td>
<td>$9,606,691</td>
<td>26</td>
</tr>
<tr>
<td>Stanford University</td>
<td>$6,077,507</td>
<td>29</td>
<td>Massachusetts Institute of Technology</td>
<td>$8,739,708</td>
<td>16</td>
</tr>
<tr>
<td>University of Washington</td>
<td>$6,037,668</td>
<td>24</td>
<td>Cold Spring Harbor Laboratory</td>
<td>$8,402,335</td>
<td>9</td>
</tr>
<tr>
<td>Vanderbilt University</td>
<td>$5,507,610</td>
<td>25</td>
<td>Emory University</td>
<td>$7,724,973</td>
<td>31</td>
</tr>
<tr>
<td>Rutgers, The State University of New Jersey</td>
<td>$5,468,663</td>
<td>3</td>
<td>Boston Children's Hospital</td>
<td>$7,489,814</td>
<td>21</td>
</tr>
</tbody>
</table>

Which states received the most autism research funding in 2011 and 2012?

<table>
<thead>
<tr>
<th>State</th>
<th>2011 Funding</th>
<th>2011 Project Count</th>
<th>2012 Funding</th>
<th>2012 Project Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>California</td>
<td>$55,702,245</td>
<td>234</td>
<td>$59,927,726</td>
<td>254</td>
</tr>
<tr>
<td>Maryland</td>
<td>$32,352,288</td>
<td>67</td>
<td>$41,256,045</td>
<td>67</td>
</tr>
<tr>
<td>Massachusetts</td>
<td>$25,109,363</td>
<td>119</td>
<td>$34,417,099</td>
<td>124</td>
</tr>
<tr>
<td>New York</td>
<td>$24,514,924</td>
<td>103</td>
<td>$31,300,062</td>
<td>126</td>
</tr>
<tr>
<td>Connecticut</td>
<td>$22,748,500</td>
<td>57</td>
<td>$22,293,367</td>
<td>69</td>
</tr>
</tbody>
</table>

Figure 6. Institutions and states with the most ASD research funding from Federal and private sources in 2011 and 2012.
WHAT TYPES OF RESEARCH ARE FUNDED BY THE DIFFERENT AGENCIES AND ORGANIZATIONS?

The government agencies and private organizations included in this Portfolio Analysis Report fund a wide range of autism-related research projects. Taken together, these projects span the entire scope of the IACC Strategic Plan for ASD Research, but the type of research represented in the portfolios of individual funders vary based on the mission of each individual agency or organization. Table 2 lists the agencies and organizations that funded projects in 2012 in each of the seven question areas of the IACC Strategic Plan. Figure 7 provides a graphic illustrating the breadth of the mission areas of the funding agencies and organizations included in the IACC Portfolio Analysis Report. While some agencies and organizations have broad portfolios that cover many different research areas described in the IACC Strategic Plan, others focus their efforts on a narrower range of research topics. Brief summaries of the mission areas and portfolios of the different Federal agencies and private organizations included in this analysis appear after Figure 7.
### Which Organizations Funded Research in Each of the 7 Strategic Plan Question Areas? 2012

#### Question 1. Screening and Diagnosis
- Administration for Children and Families
- Agency for Healthcare Research and Quality
- Autism Science Foundation
- Autism Speaks
- Brain & Behavior Research Foundation
- Department of Defense - Autism Research Program
- Department of Education
- Health Resources and Services Administration
- National Institutes of Health
- National Science Foundation
- Organization for Autism Research
- Simons Foundation
- Southwest Autism Research & Resource Center
- Substance Abuse and Mental Health Services Administration

#### Question 2. Biology
- Autism Research Institute
- Autism Science Foundation
- Autism Speaks
- Brain & Behavior Research Foundation
- Department of Defense - Air Force
- Department of Defense - Autism Research Program
- Health Resources and Services Administration
- National Institutes of Health
- National Science Foundation
- Organization for Autism Research
- Simons Foundation

#### Question 3. Risk Factors
- Autism Research Institute
- Autism Science Foundation
- Autism Speaks
- Centers for Disease Control and Prevention
- Department of Defense - Autism Research Program
- Environmental Protection Agency
- Health Resources and Services Administration
- National Institutes of Health
- National Science Foundation
- Organization for Autism Research
- Simons Foundation

#### Question 4. Treatments and Interventions
- Autism Research Institute
- Autism Science Foundation
- Autism Speaks
- Brain & Behavior Research Foundation
- Center for Autism and Related Disorders
- Department of Defense - Autism Research Program
- Department of Education
- Health Resources and Services Administration
- National Institutes of Health
- National Science Foundation
- Organization for Autism Research
- Simons Foundation
- Southwest Autism Research & Resource Center

#### Question 4. Treatments and Interventions (cont)
- Center for Autism and Related Disorders
- Department of Defense - Autism Research Program
- Department of Education
- Health Resources and Services Administration
- National Institutes of Health
- National Science Foundation
- Organization for Autism Research
- Simons Foundation
- Southwest Autism Research & Resource Center

#### Question 5. Services
- Administration for Community Living
- Agency for Healthcare Research and Quality
- Autism Science Foundation
- Autism Speaks
- Center for Autism and Related Disorders
- Centers for Disease Control and Prevention
- Department of Defense - Autism Research Program
- Department of Education
- Health Resources and Services Administration
- National Institutes of Health
- National Science Foundation
- Organization for Autism Research
- Southwest Autism Research & Resource Center

#### Question 6. Lifespan Issues
- Autism Science Foundation
- Autism Speaks
- Centers for Disease Control and Prevention
- Centers for Medicare & Medicaid Services
- Department of Defense - Air Force
- Department of Education
- Health Resources and Services Administration
- National Institutes of Health
- National Science Foundation
- Organization for Autism Research
- Southwest Autism Research & Resource Center

#### Question 7. Infrastructure and Surveillance
- Autism Science Foundation
- Autism Speaks
- Centers for Disease Control and Prevention
- Centers for Medicare & Medicaid Services
- Department of Defense - Air Force
- Department of Education
- Health Resources and Services Administration
- National Institutes of Health
- Simons Foundation
- Southwest Autism Research & Resource Center

---

**Table 2.** A list of each Federal agency and private organization in the Portfolio Analysis organized by IACC Strategic Plan question for 2012.
Figure 7. The portfolio of each Federal agency and private organization’s autism-related projects by Strategic Plan question for 2012. Please note that this figure is based on funding amount from 2012. Thus, while funders may support additional areas of research, that may not be reflected in this particular year. For example, AHRQ also supports studies on autism interventions, but did not provide funding for such studies in 2012.
FEDERAL AGENCY AND PRIVATE ORGANIZATION MISSION STATEMENTS

Federal Agencies – Department of Health and Human Services (HHS)

Administration for Children and Families (ACF)

The mission of ACF is to foster health and well-being by providing Federal leadership, partnership, and resources for the compassionate and effective delivery of human services. The ACF autism-related research portfolio includes projects focused on ensuring that effective and culturally appropriate developmental screening tools and interventions are being developed and deployed in early education settings.

Administration for Community Living (ACL)

Formed in 2012, ACL serves as the Federal agency responsible for increasing access to community supports, while focusing attention and resources on the unique needs of older Americans and people with disabilities across the lifespan. ACL funds the AutismNOW web resource, which provides information for the ASD community on topics including detection, intervention, education, transition from high school into early adulthood, employment, advocacy, community inclusion, aging issues, and public policy.

Agency for Healthcare Research and Quality (AHRQ)

The mission of AHRQ is to improve the quality, safety, efficiency, and effectiveness of health care for all Americans. Their portfolio includes projects to evaluate the comparative effectiveness of autism interventions and to conduct systematic reviews of the literature on topics such as autism screening and autism interventions, with the goal of evaluating the strength of the evidence supporting practices and identifying gaps in research. AHRQ also funds projects aimed at disseminating information about best practices and other findings from their reviews to researchers, practitioners, the patient community, and other stakeholders.

Centers for Disease Control and Prevention (CDC)

The mission of CDC is to create the expertise, information, and tools that people and communities need to protect their health. This is achieved through health promotion, prevention of disease, injury and disability, and preparedness for new health threats. CDC’s autism research portfolio includes projects to collect data on ASD prevalence and risk factors, and projects to improve awareness, early detection, and intervention.

Centers for Medicare & Medicaid Services (CMS)

CMS administers the Medicare program and works in partnership with State governments to administer Medicaid, the State Children’s Health Insurance Program (SCHIP), and health insurance portability standards. CMS funds studies to evaluate ASD service provision, access, and coverage, and has commissioned several reports on state-provided services for ASD.
Health Resources and Services Administration (HRSA)

HRSA is the primary Federal agency for improving access to health care services for people who are uninsured, isolated, or medically vulnerable. The Maternal and Child Health Bureau (MCHB) supports autism-related programs through its Combating Autism Act Initiative (CAAI), including projects to increase awareness, reduce barriers to screening and diagnosis, promote the development of guidelines for evidence-based practices, and train health care professionals to provide screening as well as diagnostic and early, evidence-based intervention. Flagship programs include the Autism Intervention Research Networks (AIR-B and AIR-P), the Developmental Behavioral Pediatrics Research Network (DBPNet), and the Leadership Education in Neurodevelopmental and Related Disabilities (LEND) program.

National Institutes of Health (NIH)

The mission of NIH is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The NIH supports a broad range of research on ASD, including projects on the basic neuroscience of ASD, risk factors, diagnosis, intervention, and services research. One of the flagship autism programs funded by NIH, the Autism Centers of Excellence (ACE), is a collection of research centers and networks across the country that conduct research on ASD. NIH also funds interdisciplinary data repositories such as the National Database for Autism Research (NDAR) to facilitate the sharing of autism research data among scientists worldwide.

Substance Abuse and Mental Health Services Administration (SAMHSA)

SAMHSA leads public health efforts to advance the behavioral health of the nation by reducing the impact of substance abuse and mental illness on America’s communities. SAMHSA funds a project to develop electronic measures of primary care screening for many conditions, including autism.

Federal Agencies – Other

Department of Defense (DoD)

The Department of Defense (DoD) is charged with coordinating and supervising all agencies and functions of the government concerned directly with national security and the United States Armed Forces. Within the DoD’s Defense Health Research Program, the Congressionally Directed Medical Research Program’s Autism Research Program (ARP) was established in 2007, with the mission to improve the lives of individuals with ASD by promoting innovative research that advances the understanding of ASD and leads to improved outcomes for those with ASD. The projects that the ARP funds span the scope of the IACC.

The U.S. Air Force (DOD-AF) also funds research on ASD, and is developing a multidisciplinary autism research and services program for military families, part of which involves the creation of a comprehensive registry to provide higher quality data for autism clinical and genetics research.
The mission of the U.S. Department of Education is to promote student achievement by fostering educational excellence and ensuring equal access. The department funds a portfolio of ASD-related projects relating to development and delivery of educational interventions and services, particularly for children and transition-aged youth. A large portion of ED’s funding goes towards developing practitioner training as well as investment in training researchers.

**Environmental Protection Agency (EPA)**

The mission of the U.S. EPA is to protect human health and the environment. EPA co-funds the Center for Children’s Environmental Health (CCEH) at the University of California at Davis with the National Institute of Environmental Health Sciences (NIEHS)/NIH, which conducts research into how environmental exposure to toxins might interact with a person’s genes and immune system to influence the risk and severity of ASD.

**National Science Foundation (NSF)**

NSF is an independent Federal agency, formed by Congress to promote the progress of science and to advance the national health, prosperity, and welfare. NSF funds basic research in biology, mathematics, computer science, and the social sciences as well as technology development, but it does not focus on health or disease-related research. Although NSF does not have a program focused on ASD, it funds several projects that involve basic science or technologies with the potential to be applied to ASD in the future. NSF is a leading funder of projects involving technological interventions and supports, including robotics and virtual reality technologies that could be used to enhance daily living skills and activities of individuals with disabilities.

**Private Organizations**

**Autism Speaks (AS)**

AS is the world’s largest autism science and advocacy organization, dedicated to funding research into the causes, prevention, treatments, and a cure for autism; increasing awareness of autism spectrum disorders; and advocating for the needs of individuals with autism and their families. AS funds a broad profile of ASD research ranging from basic neuroscience and the molecular causes of autism to implementation and testing of interventions for those diagnosed with autism. Autism Speaks supports the Autism Treatment Network, a collaboration of 14 specialty centers dedicated to providing families with state-of-the-art, multidisciplinary healthcare for children and teens affected by autism.
Autism Research Institute (ARI)

ARI’s mission is to meet the needs of the global autism community through research, networking, education, and support for families and people of all ages on the autism spectrum. ARI is dedicated to developing a standard of care for individuals with autism spectrum disorders and their families, and funds a range of work with a particular emphasis on investigation of the biological underpinnings of autism, including immune and metabolic pathways.

Autism Science Foundation (ASF)

ASF’s mission is to support autism research by providing funding and other assistance to scientists and organizations conducting, facilitating, publicizing, and disseminating autism research. The organization also provides information about autism to the general public and serves to increase awareness of autism spectrum disorders and the needs of individuals and families affected by autism. ASF funds pre- and postdoctoral trainees to conduct basic and clinical research relevant to ASD, including studies focused on a wide range of topics such as identification of biomarkers, molecular and cellular mechanisms, genetic and environmental risk factors, treatments, and service delivery.

Brain & Behavior Research Foundation (BBRF)

BBRF funds basic neuroscience research to elucidate the molecular mechanisms underlying brain disorders and conditions. BBRF’s autism research portfolio primarily includes studies on the genetics and molecular mechanisms underlying autism.

Center for Autism and Related Disorders (CARD)

CARD is one of the world’s largest organizations using applied behavior analysis (ABA) in the treatment of ASD, and other related disorders. CARD’s research portfolio is centered around developing new behavioral interventions, assessing existing behavioral interventions, and developing and implementing training/intervention programs for individuals on the autism spectrum from birth to age 21.

Organization for Autism Research (OAR)

The mission of OAR is to support research that directly impacts the day-to-day quality of life of those with ASD. This includes research to inform and improve education, communication, self-care, social skills, employment, behavior, and adult and community living. In this context, it extends to issues related to family support, the efficacy of service delivery systems, and demographic analyses of the autism community.
Simons Foundation (SF)/Simons Foundation Autism Research Initiative (SFARI)

The mission of SF is to advance the frontiers of research in mathematics and the basic sciences. SF’s single largest initiative is the Simons Foundation Autism Research Initiative (SFARI), which seeks to improve the diagnosis and treatment of ASD by funding, catalyzing, and driving innovative research of the greatest quality and relevance. The SF ASD portfolio includes research on genetic and cellular factors underlying autism, identification of genetic and environmental risk factors, and development of potential treatments.

Southwest Autism Research & Resource Center (SARRC)

SARRC’s mission is to advance research and provide a lifetime of support for individuals with autism and their families. SARRC undertakes self-directed research, serves as a satellite site for national and international projects, and provides up-to-date information, training, and assistance to families and professionals about autism. Through integrative research, educational outreach, model programs, and collaborative initiatives, SARRC sets forth, promotes, and facilitates best practices for early intervention and the long-term care of individuals with ASDs. Their current projects focus on screening tools, data monitoring, and implementing interventions.
WHAT WAS THE BREAKDOWN OF FUNDING IN 2011?

Of the 20 stakeholders, agencies, and organizations that participated in the 2011-2012 Portfolio Analysis, 19 had ASD research projects that were active in 2011. In all, 1,227 projects were funded in 2011, totaling $299,879,145 (Table 3).

The National Institutes of Health (NIH) was the leading Federal (and overall) contributor of funding for ASD research in 2011 with a total of $169.2 million, funding 446 projects. The NIH funding represented an increase from the corresponding 2010 non-ARRA funding level of $159.6 million, but a decrease from the total 2010 funding figure ($217.1 million) which also included $57.5 million in ARRA funding. The next largest Federal funder was the Department of Education, with $29.5 million, followed by the Centers for Disease Control and Prevention (CDC), with $16.1 million. As in previous years, the Simons Foundation and Autism Speaks were the largest private funders of ASD research in 2011, with investments of $50.5 million and $14.9 million, respectively.
### 2011 ASD Research Funding by Agency/Organization

<table>
<thead>
<tr>
<th>FUNDING AGENCY/ORGANIZATION</th>
<th>PROJECT COUNT</th>
<th>2011 FUNDING</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Institutes of Health (NIH)</td>
<td>446*</td>
<td>$169,199,177</td>
</tr>
<tr>
<td>Simons Foundation (SF)</td>
<td>185</td>
<td>$50,451,927</td>
</tr>
<tr>
<td>Department of Education (ED)</td>
<td>140</td>
<td>$29,529,855</td>
</tr>
<tr>
<td>Centers for Disease Control and Prevention (CDC)</td>
<td>28</td>
<td>$16,083,474</td>
</tr>
<tr>
<td>Autism Speaks (AS)</td>
<td>179</td>
<td>$14,872,052</td>
</tr>
<tr>
<td>Health Resources and Services Administration (HRSA)</td>
<td>36</td>
<td>$9,950,267**</td>
</tr>
<tr>
<td>Department of Defense - Autism Research Program (DoD-ARP)</td>
<td>72</td>
<td>$5,599,296</td>
</tr>
<tr>
<td>National Science Foundation (NSF)</td>
<td>51</td>
<td>$1,428,639</td>
</tr>
<tr>
<td>Administration for Community Living (ACL)</td>
<td>1</td>
<td>$750,000</td>
</tr>
<tr>
<td>Center for Autism and Related Disorders (CARD)</td>
<td>19</td>
<td>$615,801</td>
</tr>
<tr>
<td>Agency for Healthcare Research and Quality (AHRQ)</td>
<td>5</td>
<td>$491,768**</td>
</tr>
<tr>
<td>Autism Research Institute (ARI)</td>
<td>16</td>
<td>$257,282</td>
</tr>
<tr>
<td>Southwest Autism Research &amp; Resource Center (SARRC)</td>
<td>5</td>
<td>$250,000</td>
</tr>
<tr>
<td>Brain &amp; Behavior Research Foundation (BBRF)</td>
<td>18</td>
<td>$146,730</td>
</tr>
<tr>
<td>Organization for Autism Research (OAR)</td>
<td>14</td>
<td>$139,723</td>
</tr>
<tr>
<td>Centers for Medicare &amp; Medicaid Services (CMS)</td>
<td>3</td>
<td>$88,154</td>
</tr>
<tr>
<td>Autism Science Foundation (ASF)***</td>
<td>7</td>
<td>$25,000</td>
</tr>
<tr>
<td>Environmental Protection Agency (EPA)</td>
<td>1</td>
<td>$0</td>
</tr>
<tr>
<td>Department of Defense - Air Force (DoD-AF)</td>
<td>1</td>
<td>$0</td>
</tr>
<tr>
<td><strong>GRAND TOTAL</strong></td>
<td><strong>1,227</strong></td>
<td><strong>$299,879,145</strong></td>
</tr>
</tbody>
</table>

*The NIH project number shown reflects unique NIH projects. Projects funded by more than one NIH institute (“co-funds”) were combined and only counted as a single project. This approach differs from that used in the NIH RePORT database, where each co-fund is counted as a separate project.

**The annual funding amount for some projects reported by AHRQ and HRSA are prorated estimates for the autism-related portion of a larger project.

***In 2011 ASF made a change in the timing of funding of new grant awards. Funding for some of the 2011 grants was awarded early (in late 2010) and some was awarded late (in early 2012). No funding for new awards was released in 2011, and so only ongoing investments are reported this year. However, some funding from both the 2010 and 2012 cycles supported projects that were being conducted in 2011.

Table 3. The table lists the total funding provided by the 19 Federal agencies and private organizations included in the 2011 Portfolio Analysis and the number of projects funded. Together, the agencies and organizations funded 1,227 projects in 2011, representing an overall investment of $299.9 million.
WHAT WAS THE BREAKDOWN OF FUNDING IN 2012?

Each of the 20 stakeholders that participated in the 2011-2012 Portfolio Analysis had ASD research projects that were active in 2012. In all, 1,312 projects were funded in 2012, totaling $331,949,933 (Table 4).

The top three Federal funders of ASD research in 2012 remained the same as 2011. The National Institutes of Health (NIH) was the leading Federal (and overall) contributor of funding for ASD research in 2012 with a total of $190.6 million funding 452 projects, representing an increase from the 2011 funding level of $169.2 million. The next largest Federal funder was the Department of Education (ED) with $29.6 million, followed by the Centers for Disease Control and Prevention (CDC), with $17.2 million. As in previous years, the Simons Foundation and Autism Speaks were the largest private funders of ASD research in 2012, with investments of $56.5 million and $13.0 million, respectively.
### 2012 ASD Research Funding by Agency/Organization

<table>
<thead>
<tr>
<th>FUNDING AGENCY/ORGANIZATION</th>
<th>PROJECT COUNT</th>
<th>2012 FUNDING</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Institutes of Health (NIH)</td>
<td>452*</td>
<td>$190,598,854</td>
</tr>
<tr>
<td>Simons Foundation (SF)</td>
<td>247</td>
<td>$56,494,115</td>
</tr>
<tr>
<td>Department of Education (ED)</td>
<td>142</td>
<td>$29,628,108</td>
</tr>
<tr>
<td>Centers for Disease Control and Prevention (CDC)</td>
<td>27</td>
<td>$17,214,124</td>
</tr>
<tr>
<td>Autism Speaks (AS)</td>
<td>185</td>
<td>$12,993,135</td>
</tr>
<tr>
<td>Health Resources and Services Administration (HRSA)</td>
<td>30</td>
<td>$9,400,983**</td>
</tr>
<tr>
<td>National Science Foundation (NSF)</td>
<td>44</td>
<td>$6,539,622</td>
</tr>
<tr>
<td>Department of Defense - Autism Research Program (DoD-ARP)</td>
<td>76</td>
<td>$4,460,138</td>
</tr>
<tr>
<td>Department of Defense - Air Force (DoD-AF)</td>
<td>2</td>
<td>$903,888</td>
</tr>
<tr>
<td>Center for Autism and Related Disorders (CARD)</td>
<td>17</td>
<td>$583,940</td>
</tr>
<tr>
<td>Brain &amp; Behavior Research Foundation (BBRF)</td>
<td>31</td>
<td>$569,427</td>
</tr>
<tr>
<td>Agency for Healthcare Research and Quality (AHRQ)</td>
<td>3</td>
<td>$490,038**</td>
</tr>
<tr>
<td>Substance Abuse and Mental Health Services Administration (SAMHSA)</td>
<td>1</td>
<td>$450,000**</td>
</tr>
<tr>
<td>Autism Science Foundation (ASF)**</td>
<td>12</td>
<td>$385,000</td>
</tr>
<tr>
<td>Administration for Community Living (ACL)</td>
<td>1</td>
<td>$350,000</td>
</tr>
<tr>
<td>Southwest Autism Research &amp; Resource Center (SARRC)</td>
<td>6</td>
<td>$300,000</td>
</tr>
<tr>
<td>Organization for Autism Research (OAR)</td>
<td>19</td>
<td>$273,182</td>
</tr>
<tr>
<td>Autism Research Institute (ARI)</td>
<td>14</td>
<td>$215,379</td>
</tr>
<tr>
<td>Administration for Children and Families (ACF)</td>
<td>1</td>
<td>$100,000</td>
</tr>
<tr>
<td>Centers for Medicare &amp; Medicaid Services (CMS)</td>
<td>1</td>
<td>$0</td>
</tr>
<tr>
<td>Environmental Protection Agency (EPA)</td>
<td>1</td>
<td>$0</td>
</tr>
<tr>
<td><strong>GRAND TOTAL</strong></td>
<td><strong>1,312</strong></td>
<td><strong>$331,949,933</strong></td>
</tr>
</tbody>
</table>

*The NIH project number shown reflects unique NIH projects and includes a small number of projects not represented in the NIH RePORT autism category. Projects funded by more than one NIH institute (“co-funds”) were combined and only counted as a single project.

**The annual funding amount for some projects reported by AHRQ, HRSA, and SAMHSA are prorated estimates for the autism-related portion of a larger project.

***In 2011 ASF made a change in the timing of funding of new grant awards. Funding for some of the 2011 grants was awarded early (in late 2010) and some was awarded late (in early 2012). No funding for new awards was released in 2011, and so only ongoing investments are reported this year. However, some funding from both the 2010 and 2012 cycles supported projects that were being conducted in 2011.

Table 4. The table lists the total funding provided by the 20 Federal agencies and private organizations included in the 2012 Portfolio Analysis and the number of projects funded. Together, the agencies and organizations funded 1,312 projects in 2012, representing an overall investment of more than $331.9 million.
SUMMARY

As outlined in this section, numerous Federal and private funders invested in ASD research in 2011 and 2012. These investments span the range of topics outlined in the IACC Strategic Plan as well as each funder’s ASD portfolio aligning with their specific mission. A greater number of both Federal and private funders participated in the 2011-2012 Portfolio Analysis Report compared to previous years, contributing to a more comprehensive representation of U.S. ASD research funding. Funding in the overall autism research portfolio, including both Federal and private funders, increased 10.7% from 2011 to 2012. Over the five-year span from 2008 to 2012, funding increased by 49.4%, suggesting overall growth in support for ASD research.
What types of ASD research were funded?

To better understand what areas of research were funded in 2011 and 2012, projects were aligned with the corresponding questions in the 2011 IACC Strategic Plan. Figures 8 and 9 illustrate the breakdown of the research funding according to the Strategic Plan’s seven questions related to Screening and Diagnosis, Biology, Risk Factors, Treatments and Interventions, Services, Lifespan Issues, and Infrastructure and Surveillance. Identifying how current research investments correspond to the Strategic Plan provides an understanding of how funders have directed investments across each of the priority areas identified by the IACC, as well as an indication of which areas are well supported versus those that may be in need of additional attention or development.

![Image of pie chart showing the distribution of funding across IACC Strategic Plan questions]

**Figure 8.** Topic areas are defined by each question in the IACC Strategic Plan. The seven questions of the Strategic Plan are represented in the clockwise direction, beginning with Screening and Diagnosis (Question 1) and ending with Infrastructure and Surveillance (Question 7).
ASD research funding in 2011 and 2012 supported projects relevant to all seven of the critical questions in the IACC Strategic Plan for ASD Research, and the distribution across the seven questions was similar in both years. As in previous years, the largest portion of funding addressed the underlying biology (Question 2) of ASD (24%, 2011; 30%, 2012). This was followed closely by research aimed at identifying potential causes and risk factors (Question 3) for the disorder (20%, 2011; 17%, 2012). Funding of research into treatments and interventions (Question 4) for ASD, including behavioral therapy, pharmacological treatments, and technology-based interventions, increased from 2010 levels (17%, 2010, 20%, 2011, and 19% in 2012 respectively). Investment in
research infrastructure and surveillance (Question 7) also increased from 2010 levels (12%, 15%, and 14% in 2010, 2011, and 2012 respectively). This investment includes funding for data repositories such as the National Database for Autism Research (NDAR) and the Autism Genetics Resource Exchange (AGRE), as well as surveillance, including studies of ASD prevalence conducted by the Centers for Disease Control and Prevention (CDC).

By comparison, funding of research aimed at improving screening and diagnosis (Question 1) of ASD remained similar to previous years (11%, 10%, and 11% in 2010, 2011, and 2012 respectively). Investment in services research reported in 2011 and 2012 was 9% and 7%, respectively. These figures represent a decrease from the investment reported in 2010 (16% of the overall portfolio), but much of the change can be attributed to the prorated adjustments made in reporting in service-related funding. This proration resulted in a lower level of funding reported for services-related Strategic Plan questions (Questions 5 and 6) in 2011 and 2012 compared to previous years. Funding of research specifically centered on lifespan issues (Question 6) remains the smallest area of investment (2% and 1% in 2011 and 2012 respectively).

When the number of active projects that align with each question, as opposed to the total funding for these projects is considered, the distribution is subtly different due to differences in the relative sizes of projects falling under each of the seven question categories. In 2011, the percentage of total projects aligned with each question were as follows: Question 1 (11%), Question 2 (33%), Question 3 (12%), Question 4 (21%), Question 5 (11%), Question 6 (3%), and Question 7 (9%; See Figure 10). In 2012, the percentage of active projects aligned with each question were as follows: Question 1 (10%), Question 2 (35%), Question 3 (12%), Question 4 (21%), Question 5 (11%), Question 6 (3%), and Question 7 (9%; See Figure 11). It is interesting to note that the number of projects aligning with Question 5 and Question 6 is considerably greater than you might expect based on the proportion of overall funding aligning with these questions (this is also true to a lesser extent for Question 2). This indicates that in order to get a more comprehensive picture of the level of activity in each Strategic Plan question area, it may be helpful to consider both funding as well as number of projects. In contrast, there are fewer projects aligning with Question 3 and Question 7 than you might expect based on the portion of overall ASD research funding included in the Portfolio Analysis. This indicates that the size of the awards for infrastructure development projects (Question 7) and projects related to investigation of ASD risk factors (Question 3) tend to be larger, reflecting the greater cost involved in conducting research in these areas. Research into risk factors often involves large scale genetic and epidemiology studies, which can be costly. Similarly, funding of research infrastructure development and maintenance, such as databases, biobanks, and clinical centers is a considerable investment, but the results benefit multiple research projects.
Figure 10. 2011 Projects aligned to Strategic Plan questions.

Figure 11. 2012 Projects aligned to Strategic Plan questions. Due to rounding, the percentages do not equal 100%.
How did the research projects funded in 2011 and 2012 align with the objectives in the IACC Strategic Plan?

The 78 Strategic Plan objectives were developed by the IACC to set priorities for investment, and they represent areas where the Committee perceived gaps in research that required further research efforts. Thus, areas of research that were already well-established and funded, and research fields that have emerged more recently, are not represented among the IACC Strategic Plan’s objectives. In addition to projects that represent crosscutting or well-established areas of science, some projects did not fit neatly into a Strategic Plan objective category because they lacked particular key aspects of research design required by the objective.

Efforts were made to match all 2011 and 2012 autism research-related projects with the best fitting research objective in the Strategic Plan, though in some cases, projects could only be assigned to a Strategic Plan question, and for the objective category, were assigned to Core/Other. The Core/Other category captures projects that may be related to crosscutting or “core” activities that help support the autism research field, or projects in well-established areas of science that do not fit within the list of specific research objectives outlined in the Strategic Plan. The Core/Other designation was developed by the IACC because the Committee felt it would help readers understand that even though activities in this category fall outside the specific research objectives of the Strategic Plan, they represent projects that are contributing in important ways to the progress of ASD research.

Analysis of the 2011 and 2012 project portfolios to determine the proportion of projects that fit within Strategic Plan objectives versus the proportion that did not fit within Strategic Plan objectives (Figures 14 and 15) showed that in both 2011 and 2012, every question of the Strategic Plan included projects that were not specific to a particular objective (projects coded to Core/Other). These projects represented approximately 30% of the total number of projects in both years (370 projects in 2011 and 395 projects in 2012). When looking at the proportion of funding from across all seven Strategic Plan question areas devoted to projects that were categorized as Core/Other, a similar pattern emerges, with about 25% of the funding in 2011 and 2012 devoted to these projects (Figures 12 and 13).
2011 Project Count: Alignment with IACC Strategic Plan Objectives

- 30% (370 projects)
- 70% (857 projects)

2011 ASD Funding: Alignment with IACC Strategic Plan Objectives

- 24% ($72,858,123)
- 76% ($227,021,022)

Figure 12. Alignment of 2011 Project Count and ASD Funding of Projects with the IACC Strategic Plan.

2012 Project Count: Alignment with IACC Strategic Plan Objectives

- 30% (395 projects)
- 70% (917 projects)

2012 ASD Funding: Alignment with IACC Strategic Plan Objectives

- 25% ($81,959,851)
- 75% ($249,990,082)

Figure 13. Alignment of 2012 Project Count and ASD Funding of Projects with the IACC Strategic Plan.
Of all seven questions of the Strategic Plan, Question 2 contained the largest proportion of funding that did not align with any specific objective (56% of funding in 2011 and 49% in 2012). More detail on the types of research represented by projects that were categorized as Core/Other can be found in subsequent chapters of this report that are focused on each Strategic Plan question.

### 2011 ASD Funding: Alignment with IACC Strategic Plan Objectives

<table>
<thead>
<tr>
<th>Question</th>
<th>Specific</th>
<th>Core/Other</th>
<th>Core/Other (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1. Screening and Diagnosis</td>
<td>$28,444,015</td>
<td>$2,310,877</td>
<td>8%</td>
</tr>
<tr>
<td>Q2. Biology</td>
<td>$32,096,050</td>
<td>$41,127,339</td>
<td>56%</td>
</tr>
<tr>
<td>Q3. Risk Factors</td>
<td>$59,484,858</td>
<td>$724,770</td>
<td>1%</td>
</tr>
<tr>
<td>Q4. Treatments and Interventions</td>
<td>$56,041,771</td>
<td>$4,877,350</td>
<td>8%</td>
</tr>
<tr>
<td>Q5. Services</td>
<td>$14,565,200</td>
<td>$11,553,704</td>
<td>44%</td>
</tr>
<tr>
<td>Q6. Lifespan Issues</td>
<td>$4,847,920</td>
<td>$50,000</td>
<td>1%</td>
</tr>
<tr>
<td>Q7. Infrastructure and Surveillance</td>
<td>$31,541,207</td>
<td>$12,314,084</td>
<td>28%</td>
</tr>
</tbody>
</table>

**Figure 14.** Each question in the Strategic Plan contained projects that were not specific to a particular objective, designated Core/Other. Funding for projects that fall under specific objectives are indicated in blue, and Core/Other projects are indicated in orange. Subcategory analysis provided within the summary for each question of the Strategic Plan provides a description of the research areas addressed by all projects, including those assigned to Core/Other.
Figure 15. Each question in the Strategic Plan contained projects that were not specific to a particular objective, designated Core/Other. Funding for projects that fall under specific objectives are indicated in blue, and Core/Other projects are indicated in orange. Subcategory analysis provided within the summary for each question of the Strategic Plan provides a description of the research areas addressed by all projects, including those assigned to Core Other.
Subcategory Classification

In 2010, OARC introduced the subcategory classification system (Figure 16) to the IACC Portfolio Analysis Report to help the Committee and other readers of this report better understand the types of research encompassed by the projects in the research portfolio – especially those projects that are categorized as outside the objectives of the Strategic Plan but within a question’s research area – projects designated as Core/Other (as described in the previous section). For the subcategory analysis, each project in the 2011 and 2012 Portfolio Analysis was assigned to a subcategory based on the research area it addressed. The application of subcategory coding to projects in the portfolio helped to break the portfolio into easy-to-understand topical areas. For example, within Question 1 (Screening and Diagnosis), the projects were divided into four subcategories: Diagnostic and screening tools, Early signs and biomarkers, Intermediate phenotypes/Subgroups, and Symptomology. When the projects in the 2011 and 2012 portfolios were categorized according to the subcategory system, less than 1% of projects were not aligned with a specific subcategory.

IACC Strategic Plan Questions and Corresponding Research Areas

Question 1. When should I be concerned?

Screening & Diagnosis
- Early signs and biomarkers
- Diagnostic and screening tools
- Intermediate phenotype/subgroups
- Symptomology

Question 2. How can I understand what is happening?

Biology
- Cognitive studies
- Computational science
- Co-occurring conditions
- Developmental trajectory
- Immune/metabolic pathways
- Molecular pathways
- Neural systems
- Neuropathology
- Sensory and motor function
- Subgroups/biosignatures

Question 3. What caused this to happen and can it be prevented?

Risk Factors
- Genetic risk factors
- Environmental risk factors
- Epigenetics
- Gene-environment

Question 4. Which treatments and interventions will help?

Treatments & Interventions
- Technology-based intervention and supports
- Behavioral
- Complementary, dietary, and alternative
- Educational
- Medical/pharmacologic
- Model systems/therapeutic targets
- Occupational, physical, and sensory-based

Question 5. Where can I turn for services?

Services
- Services utilization and access
- Community inclusion programs
- Efficacious and cost-effective service delivery
- Family well-being and safety
- Practitioner training

Question 6. What does the future hold, particularly for adults?

Lifespan Issues

Question 7. What other infrastructure and surveillance needs must be met?

Infrastructure & Surveillance
- Biobanks
- Data tools
- Research infrastructure
- Surveillance and prevalence studies
- Research workforce development
- Research recruitment and clinical care

Figure 16. A subcategory classification system was created to allow an understanding of the autism research portfolio based on simple research topics that are relevant to each of the IACC Strategic Plan questions. Appendix C provides detailed definitions of the subcategory research areas.
Analysis of Progress toward IACC Strategic Plan Objectives

The 78 objectives in the Strategic Plan describe specific research priorities identified by the IACC, each with a goal date for initiation and a professional judgment estimate of the budget that may be required to accomplish the objective. Each ASD project that received funding in 2011 and 2012 was evaluated with respect to the 78 objectives in the 2011 IACC Strategic Plan for ASD Research in order to determine which Strategic Plan question and objective it fulfilled. Analysis of the full portfolio of government and privately funded projects aligned with the IACC Strategic Plan objectives yielded information about the progress that has been made toward completion of the objectives in the 2011 Strategic Plan. In 2011, this analysis indicated that of the 78 objectives in the IACC Strategic Plan, 87% (68 objectives) were underway or completed, and in 2012, 90% (70 objectives) were underway or completed (green or yellow in the stoplight figure as explained below) (See Figure 17). Further discussion of the progress toward achievement of individual Strategic Plan objectives is found in subsequent chapters of this report. The analysis also enabled assessment of areas of research where more work may be needed to achieve Strategic Plan objectives.

---

1Professional judgment budget estimates for each of the IACC Strategic Plan objectives were formulated by scientific and program experts in the field and provide an estimate of what it may cost to conduct each of the projects described. The IACC provided these budget recommendations as guidance to Federal agencies and partner organizations on the potential cost of conducting the recommended research. The IACC’s role in research is advisory, and the Committee does not have its own research budget to conduct or support research.

2The 2011 IACC Strategic Plan is the most recent update of the Strategic Plan where new objectives were added. The subsequent 2012 and 2013 updates of the Strategic Plan did not include any edits to the objectives, therefore the objectives as described in the 2011 IACC Strategic Plan were used to code the 2011 and 2012 projects to specific objectives.
Research Progress on IACC Strategic Plan Objectives 2011-2012

* The 2011 IACC Strategic Plan has 78 total research funding objectives

Figure 17. This figure provides the percentage of the total number of IACC Strategic Plan objectives that have been completed to date, based on an analysis of funded projects assigned to each of the Strategic Plan’s 78 objectives. As of 2012, 90% of objectives were either complete or partially complete (had all or some of the required funded projects), with 10% of objectives having no activity/assigned projects.

Upcoming chapters in this report give an overview of the progress on completing objectives in each question of the Strategic Plan in 2011 and 2012. The overall progress for each question is denoted by a stoplight figure for each year at the beginning of each chapter. Within each stoplight figure, the number in the green light indicates the number of objectives that have been considered completed, the number in the yellow light indicates the number of objectives partially completed, and the number of objectives in the red light indicates the number of objectives where no progress has been documented through the portfolio analysis. Each of the chapters describing the progress in the seven Strategic Plan question areas also contains a table that provides information about the progress made toward completion of the Strategic Plan objectives over a five-year period from 2008 through 2012.
QUESTION 1: SCREENING AND DIAGNOSIS

Aspirational Goal: Children at risk for ASD will be identified through reliable methods before ASD behavioral characteristics fully manifest.

Research Focus of Question 1

Question 1 of the IACC Strategic Plan ("When should I be concerned?") pertains to the issues surrounding screening for and diagnosis of ASD, with a focus on early identification of children showing signs of ASD so that they have the opportunity to receive interventions and supports that will lead to improved outcomes. The objectives within this chapter of the Strategic Plan include research to develop biomarkers, screening tools, and diagnostic instruments to aid in early identification. Question 1 also includes research to better understand and overcome barriers to early identification, including efforts to increase access to health services, and to develop or adapt screening and diagnostic tools for use in a wide variety of community settings, at low cost, and in diverse populations. The Committee also prioritized the need for screening and diagnostic tools for use in adolescents and adults and for improved measures that can be used to assess intervention and service needs. Projects addressing issues related to adult screening and diagnosis may be captured either within Question 1 or Question 6 of the Strategic Plan (Question 6 focuses on issues relevant to transitioning youth and adults on the autism spectrum).

Analysis of Question 1 Portfolio 2011-2012

When analyzing the distribution of research dollars across the seven question areas described in the IACC Strategic Plan, projects assigned to Question 1 of the Strategic Plan comprised 10% ($30.8 million) of the total ASD research supported by Federal and private funders in 2011, and 11% ($36.9 million) of total funding for ASD research in 2012. The number of projects assigned to Question 1 totaled 137 (11% of all projects) in 2011, and 135 (10% of all projects) in 2012. A list of the agencies funding research pertaining to Question 1 can be found in Figures 19 and 20. The largest funders of research pertaining to Question 1 (Screening and Diagnosis) are the National Institutes of Health ($25.2 million), the Simons Foundation ($4.2 million), and the National Science Foundation ($4.1 million).

Progress made in 2011 and 2012 toward completion of the nine objectives in Question 1 is indicated by the two stoplight icons at the beginning of this chapter and is described in detail in the table at the end of this chapter (Table 5). To summarize progress, in 2011, two Question 1 objectives were considered completed in terms of the number and types of projects funded and the amount of funding invested. Partial progress was made on six
objectives, while no progress was documented through the portfolio analysis data collection toward one objective. In 2012, one additional objective moved from the “partially completed” to the “completed” category, bringing that number to three, with partial progress on five objectives, and no documented progress on one objective.

The Question 1 objective receiving the most funding (1.L.A) in 2011 and 2012 focuses on research geared toward discovering biomarkers for ASD; it received 41% ($12.4 million) and 35% ($12.9 million) of the Question 1 funding in 2011 and 2012 respectively. This was followed by Objective 1.L.B, which supports studies investigating the use of biological signatures for diagnosis, risk assessment, and intervention for ASD, which accounted for 31% ($9.4 million) of Question 1 overall funding in 2011 and 34% ($12.8 million) in 2012. All other objectives received less than 10% of Question 1 funding in both 2011 and 2012. In 2011, 8% ($2.3 million) of funding for Question 1 went to projects categorized as Core/Other, or not specific to Question 1 objectives (Figure 18). In 2012, 6% ($2.2 million) of funding for Question 1 went to Core/Other projects (Figure 18). Table 5 lists all the objectives and key details of their progress to date.

As in 2010, Objective 1.S.D, which calls for studies to understand the impact of early diagnosis on choice of intervention and outcomes, did not have any projects assigned to it in 2011 and 2012 (Table 5). As described in the IACC Strategic Plan 2013 Update and Table 5, when examining reasons why this objective has no assigned projects, the Committee felt that the lack of progress may be due to unclear wording of the objective, partial overlap with other objectives, and advances in research that have made some aspects of the objective less relevant. At the time the objective was written, early intervention was not in widespread use, so part of the original intent of the objective may have been to determine whether early diagnosis influences families to choose early interventions. Since 2008, the evidence base for early intervention has strengthened, and early interventions are now widely used following early diagnosis, so the question of whether families would choose early intervention may not be as relevant as it may have been previously. Due to all of the issues mentioned above, the Committee decided to revisit this objective in the future for possible revision or elimination.

For Objective 1.S.C, in 2010 there were no studies aimed at identifying reasons for health disparities in accessing early screening and diagnosis services, but in 2011 and 2012 new research projects were funded in this area, moving this objective from a red light to a yellow light status. With regard to Objective 1.S.F, NIH held a workshop in 2011 to address the ethical, legal, and social issues and implications (ELSI) of ASD research, and the Autistic Self Advocacy Network and Autism Speaks each also held workshops addressing this topic. Thus, Objective 1.S.F was completed, moving it from a red light to a green light status.
Examples of Topics addressed by Projects in Core/Other:
Research on early signs of autism, including sensory, motor, social, and linguistic development
Development of technologies that can be applied to screening and diagnosis of ASD
Evaluation of how changes in diagnostic criteria may impact community practice and ASD surveillance activities

Figure 18. Most ASD research projects in Question 1 were coded to specific objectives; projects on topics not covered by the IACC Strategic Plan objectives were coded as Core/Other. Examples of the topics addressed by projects in Core/Other are listed above.
Question 1 Subcategory Analysis

With the development of the subcategory categorization scheme for the IACC ASD Research Portfolio Analysis Report, all projects can be categorized into broad research-related topic areas or themes, including projects that did not fit within the specific research objectives laid out in the Strategic Plan. This enables a more comprehensive understanding of the distribution of all projects across the general research areas aligning with Question 1. Overall, projects in Question 1 neared $31 million in 2011 and $37 million in 2012 and were divided into four subcategories:

Diagnostic and screening tools; Early signs and biomarkers; Intermediate phenotypes/Subgroups; and Symptomology (Figures 19 and 20). There were 137 (in 2011) and 135 (in 2012) projects that fell within Question 1. Of these, the largest portion of funding (56% in 2011 and 43% in 2012) was focused on research to identify Early signs and biomarkers of ASD (especially those that can be used for screening/diagnosis or to measure progress or treatment response). Both biological indicators (including genetic, metabolic, and brain structure/connectivity) and behavioral biomarkers were included in this subcategory. Studies in this subcategory included eye-tracking, measures of infant and toddler development (often comparing children with ASD to their unaffected siblings or to typically developing children), and methods for identifying social or behavioral differences. Research evaluating and defining the Symptomology of ASD was the second largest research investment in Question 1 (18% in 2011 and 27% in 2012). Research in this category included projects that investigate differences in development of social communication and language in those with ASD, and how neurocognitive impairments might contribute to core ASD symptoms. The development of Diagnostic and screening tools accounted for 14% and 18% of Question 1 funding in 2011 and 2012 respectively. The smallest Question 1 subcategory includes research on ASD Intermediate phenotypes/Subgroups (11% in 2011 and 11% in 2012). Only one project assigned to Question 1 did not align well with the subcategories (funding for the ELSI workshop in 2011) and is therefore represented as “Other” in Figure 19. The figure also lists Federal and private funders of research that fits within the Strategic Plan Question 1 category.
Of the four subcategories related to Question 1 (Screening and Diagnosis), in 2011 the largest proportion of funding was devoted to identifying Early signs and biomarkers for ASD (56%). This was followed by characterizing Symptomology (18%), developing Diagnostic and screening tools (14%), and identifying/characterizing Intermediate phenotypes/Subgroups of people with ASD (11%). Lastly, in the subcategory analysis, a workshop focused on the ethics of autism research was categorized as Other (<1%) because it does not fall under one of the four Question 1 subcategories. Federal and private funders of research fitting within Strategic Plan Question 1 are indicated at the bottom of the figure.
QUESTION 1: SCREENING AND DIAGNOSIS – Funding by Subcategories

Total Funding: $36,856,119
Number of Projects: 135

Symptomology
27% ($10,025,605)
31 projects

Diagnostic and Screening Tools
18% ($6,756,747)
31 projects

Early Signs and Biomarkers
43% ($15,903,032)
61 projects

Phenotypes/Subgroups
11% ($4,170,735)
12 projects

Federal Funders
Administration for Children and Families
Agency for Healthcare Research and Quality
Department of Defense-Autism Research Program
Department of Education
Health Resources and Services Administration
National Institutes of Health
National Science Foundation
Substance Abuse and Mental Health Services Administration

Private Funders
Autism Science Foundation
Autism Speaks
Brain & Behavior Research Foundation
Organization for Autism Research
Simons Foundation
Southwest Autism Research & Resource Center

Figure 20. In 2012, funding across the four subcategories for research related to Question 1 (Screening and Diagnosis) was distributed similarly to 2011. Identifying Early signs and biomarkers for ASD represented the largest portion of funding in this question (43%), followed by characterizing Symptomology (27%), developing Diagnostic and screening tools (18%), and finally identifying Intermediate phenotypes/Subgroups of people with ASD (11%). Federal and private funders of research fitting within Strategic Plan Question 1 are indicated at the bottom of the figure.
Progress Made on Question 1 from 2008-2012

Table 5 provides a snapshot of progress made on all nine of the research objectives within Question 1 over the five-year period from 2008-2012, with green, yellow, and red highlighting to indicate the level of budgetary progress of each objective in each year. The table also provides details regarding the status of funding for projects that address each objective, the status of research/scientific progress in each objective area, and information about remaining gaps, needs, and opportunities in each research area. Figure 21 shows the trend in Question 1 funding over time. Funding for Question 1 peaked in 2009 and 2010, coincident with the increase in federal funding for autism research that year due to the American Recovery and Reinvestment Act (ARRA). Question 1 funding in 2012 was slightly below the level reported in 2008. Overall, aside from the slight rise in 2009 and 2010, the funding level was moderate and stayed relatively flat during the five-year period.

Overall, progress has been made in funding projects to address the research needs described in eight of the nine Question 1 objectives (Table 5 – progress level indicated in the “Total” column with yellow or green highlighting). No projects were reported from 2008-2012 for Objective 1.S.D, “Conduct at least two studies to understand the impact of early diagnosis on choice of intervention and outcomes by 2015.” While there may be projects that were coded to Question 4 that may partially address Objective 1.S.D., as mentioned previously, the Committee felt overall that the objective was unclear in its wording, less relevant based on the current state of the science than at the time of its establishment in 2008, and potentially warranted revision or elimination in future iterations of the Strategic Plan.
Figure 21. Question 1 ASD Research Funding from 2008-2012. Funding for Question 1 was moderate and stayed relatively flat over the five-year span.
## Question 1 Multiyear Funding Table

### IACC Strategic Plan Objectives

<table>
<thead>
<tr>
<th>Year</th>
<th>Objective</th>
<th>Funding</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>1.1</td>
<td>$75,000</td>
<td>$14,368,811</td>
</tr>
<tr>
<td>2009</td>
<td>1.1</td>
<td>$4,728,120</td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>1.1</td>
<td>$4,963,192</td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>1.1</td>
<td>$2,387,955</td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>1.1</td>
<td>$2,214,544</td>
<td></td>
</tr>
</tbody>
</table>

### 1.1 Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.

### Progress: Though several projects are underway to develop efficient screeners and diagnostic tools, the overarching aim of this objective has not yet been achieved.

### Remaining Gaps, Needs, and Opportunities: In addition to efficiency, emphasis should be placed on developing cost-effective, performance-based tools, and on validating these across diverse populations. Recent RFAs issued by NIMH and Autism Speaks that focus on parental engagement and early access to care could result in projects that address this objective. Currently, many screening tools exist, and these tools in many cases can be adapted for broader uses, but improved diagnostic tools remain an outstanding need.

<table>
<thead>
<tr>
<th>Year</th>
<th>Objective</th>
<th>Funding</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>1.2</td>
<td>$1,246,922</td>
<td>$11,039,574</td>
</tr>
<tr>
<td>2009</td>
<td>1.2</td>
<td>$3,973,711</td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>1.2</td>
<td>$2,443,557</td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>1.2</td>
<td>$1,120,246</td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>1.2</td>
<td>$2,255,138</td>
<td></td>
</tr>
</tbody>
</table>

### 1.2 Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.

### Progress: Efforts to validate screening tools in diverse populations have begun, including ACF and CDC-funded work with a general developmental screener in Native American populations. More efforts are needed, however, to cover other diverse populations.

### Remaining Gaps, Needs, and Opportunities: There is a need for more comparative studies between general developmental screeners and autism-specific tools. Remaining needs in this area are promotion of family engagement and follow-through, training of intervention and primary care providers and family members, and development of free and validated diagnostic tools for international communities.

<table>
<thead>
<tr>
<th>Year</th>
<th>Objective</th>
<th>Funding</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>N/A</td>
<td>$1,139,072</td>
<td>$796,593</td>
</tr>
<tr>
<td>2009</td>
<td>N/A</td>
<td>$28,000</td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>N/A</td>
<td>$629,521</td>
<td></td>
</tr>
</tbody>
</table>

### N/A Funding: The recommended budget was partially met.

### Progress: The projects supported are only a beginning and more needs to be done to address this objective.

### Remaining Gaps, Needs, and Opportunities: The studies coded to this objective do not focus on identifying reasons for early screening and diagnosis disparities; instead, they are aimed at developing tools to address these disparities. The progress in this area is poor for autism relative to other disease fields, and the more sophisticated approaches employed in fields such as AIDS prevention should be applied to autism. More work should be done to identify the reasons for disparities and to validate the tools that are being developed. A barrier to progress is the need for qualitative studies and the difficulty in securing funding for such studies.

---

*Question 1 Multiyear Funding Table, see appendix for a color-coding key and further details.*
### Question 1 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2008</td>
</tr>
<tr>
<td>Conduct at least two studies to understand the impact of early diagnosis on choice of intervention and outcomes by 2015.</td>
<td>N/A</td>
</tr>
<tr>
<td>IACC Recommended Budget: $6,000,000 over 5 years</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>1.S.D. Funding:</strong> There has been no specific funding for this objective.</td>
<td><strong>Progress:</strong> No projects that are specifically targeted to this area have been initiated, though there are some projects coded to Question 4 that represent progress on this objective (e.g., Early Start Denver Model studies that study children who were diagnosed early and some of their outcomes following treatment, and studies coded to 4.S.F that investigate early interventions for toddlers with ASD).</td>
</tr>
<tr>
<td>Conduct at least one study to determine the positive predictive value and clinical utility (e.g., prediction of co-occurring conditions, family planning) of chromosomal microarray genetic testing for detecting genetic diagnoses for ASD in a clinical setting by 2012.</td>
<td>N/A</td>
</tr>
<tr>
<td>IACC Recommended Budget: $9,600,000 over 5 years</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>1.S.E. Funding:</strong> The recommended budget for this objective was partially met.</td>
<td><strong>Progress:</strong> Microarray testing is now recommended in AAP guidelines. The utility of this testing is more clear in cases where there is already a concern than for diagnostic use in the general population.</td>
</tr>
<tr>
<td>Convene a workshop to examine the ethical, legal, and social implications of ASD research by 2011. The workshop should define possible approaches for conducting future studies of ethical, legal, and social implications of ASD research, taking into consideration how these types of issues have been approached in related medical conditions.</td>
<td>N/A</td>
</tr>
<tr>
<td>IACC Recommended Budget: $35,000 over 1 year</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>1.S.F. Funding:</strong> The recommended budget for this objective was met.</td>
<td><strong>Progress:</strong> The objective was accomplished as the committee intended. NIH held a workshop, “The Ethical, Legal and Social Implications of Autism Spectrum Disorder Research,” ASAN held a symposium of the same title on this topic, and Autism Speaks held a related conference, “Ethics of Communicating Scientific Findings of Autism Risk.”</td>
</tr>
</tbody>
</table>

Question 1 Multiyear Funding Table, see appendix for a color-coding key and further details.
## IACC Strategic Plan Objectives

### Identify behavioral and biological markers that separately, or in combination, accurately identify, before age 2, one or more subtypes of children at risk for developing ASD, and evaluate whether these risk markers or profiles can improve early identification through heightened developmental monitoring and screening by 2014.

**IACC Recommended Budget: $33,300,000 over 5 years**

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$2,885,940</td>
<td>$16,465,034</td>
<td>$13,270,045</td>
<td>$12,416,466</td>
<td>$12,894,621</td>
<td>$57,932,106</td>
</tr>
<tr>
<td></td>
<td>14 projects</td>
<td>43 projects</td>
<td>45 projects</td>
<td>43 projects</td>
<td>40 projects</td>
<td></td>
</tr>
</tbody>
</table>

**1.L.A. Funding:** The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.

**Progress:** More than 40 projects have been supported in this area, but most projects are still in the discovery phase. Identifying reliable early biomarkers has been challenging, but some progress has been made. More work is needed to achieve the full intent of the objective.

**Remaining Gaps, Needs, and Opportunities:** Remaining research needs include continued discovery of biomarkers, linking biomarkers to treatment response, validation of biomarkers discovered in high risk populations for applicability in the general population, and evaluation of whether these biomarkers translate to improvement in screening and diagnosis real-world settings. There is also a need for biomarkers that are cost-effective.

### Develop at least five measures of behavioral and/or biological heterogeneity in children or adults with ASD, beyond variation in intellectual disability, that clearly relate to etiology and risk, treatment response and/or outcome by 2015.

**IACC Recommended Budget: $71,100,000 over 5 years**

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$5,773,203</td>
<td>$8,760,010</td>
<td>$15,228,060</td>
<td>$9,376,400</td>
<td>$12,813,396</td>
<td>$51,951,069</td>
</tr>
<tr>
<td></td>
<td>18 projects</td>
<td>34 projects</td>
<td>52 projects</td>
<td>42 projects</td>
<td>39 projects</td>
<td></td>
</tr>
</tbody>
</table>

**1.L.B. Funding:** The recommended budget was partially met.

**Progress:** Over 50 projects were supported in this area. While behavioral and/or biological heterogeneity are well covered by existing projects, gaps still exist in relating these measures to etiology and risk, treatment response, and/or outcomes.

**Remaining Gaps, Needs, and Opportunities:** There was a discussion of whether this objective should be expanded to be compatible with the Research Domain Criteria (RDoC) now being used by NIMH, which focus on functional domains rather than disorder-specific characteristics.

### Identify and develop measures to assess at least three “continuous dimensions” (i.e., social reciprocity, communication disorders, and repetitive/restrictive behaviors) of ASD symptoms and severity that can be used by practitioners and/or families to assess response to intervention for people with ASD across the lifespan by 2016.

**IACC Recommended Budget: $18,500,000 over 5 years**

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$912,159</td>
<td>$861,069</td>
<td>$3,893,622</td>
<td>$2,353,440</td>
<td>$2,600,028</td>
<td>$10,620,318</td>
</tr>
<tr>
<td></td>
<td>2 projects</td>
<td>6 projects</td>
<td>22 projects</td>
<td>15 projects</td>
<td>15 projects</td>
<td></td>
</tr>
</tbody>
</table>

**1.L.C. Funding:** The recommended budget was partially met.

**Progress:** Basic science and clinical aspects of the research are underway, but more work is needed for the studies to be applied for use by practitioners and/or families.

**Remaining Gaps, Needs, and Opportunities:** There is a need for finer ways to quantify social behavior and detect change in response to successful treatment. There is a need to move toward performance-based measures and away from the checklist approach.

---

Question 1 Multiyear Funding Table, see appendix for a color-coding key and further details.
### Question 1 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2008</td>
</tr>
<tr>
<td>Not specific to any objective</td>
<td></td>
</tr>
<tr>
<td>(Core/Other Activities)</td>
<td>$18,229,985</td>
</tr>
<tr>
<td></td>
<td>63 projects</td>
</tr>
<tr>
<td>Total funding for Question 1</td>
<td>$29,123,209</td>
</tr>
<tr>
<td></td>
<td>107 projects</td>
</tr>
</tbody>
</table>

*Table 5. Multiyear Funding Table for Question 1.*

4 The qualitative information provided about the status of each objective within the multiyear funding chart was gathered through the IACC’s consultation with subject matter experts and community stakeholders. For more information about the participants and results of this consultative process, please see the final report, the IACC Strategic Plan for Autism Spectrum Disorder Research - 2013 Update and the IACC website.

5 The numbers in this table have been updated since the 2013 IACC Strategic Plan has been published.
QUESTION 2: BIOLOGY

Aspirational Goal: Discover how ASD affects development, which will lead to targeted and personalized interventions.

Research Focus of Question 2

Question 2 (“How can I understand what is happening?”) addresses the underlying biology of ASD. Research in this field focuses on identifying the biological differences and mechanisms in early development and throughout life that contribute to ASD, as well as the characterization of the behavioral and cognitive aspects of ASD. Projects range from basic neuroscience using cellular and animal models to clinical studies. Taken together, the aim of the research represented by Question 2 is to understand the biological processes underlying ASD from the molecular level to sensory, motor, behavioral, and cognitive development and functioning.

Analysis of Question 2 Portfolio 2011-2012

When analyzing the distribution of research dollars across the seven question areas described in the IACC Strategic Plan, research on the biology of ASD (Question 2) accounted for the largest portion of ASD research funding in both 2011 ($73.2 million; 24% of total ASD research funding) and 2012 ($100.3 million; 30% of total ASD research funding). As in previous years, more projects corresponded to Question 2 than any other question in the Strategic Plan, comprising 399 projects (32% of all projects) in 2011, and 461 projects (35% of all projects) in 2012.

Progress was made for each of the nine objectives under Question 2. In 2011, three objectives were considered completed in terms of meeting the budget recommendations in their respective research areas, while six of the objectives were partially completed. In 2012, the number of objectives completed increased to five, while four of the objectives were partially completed. A full list of Question 2 objectives and details of their progress can be found in Table 6.

Although all objectives in Question 2 showed some progress in terms of funded research, the majority of research projects that were categorized under this question did not fit into any of the specific Question 2 research objectives and were categorized as Core/Other. In 2011, 56% ($41.1 million) of funding for Question 2 went to projects that were not specific to Question 2 objectives (Figure 22). In 2012, 49% ($48.9 million) of funding went to projects that were not specific to Question 2 objectives (Figure 22). This is similar to levels observed in previous
IACC autism research portfolio analyses. Question 2 encompasses a very broad range of basic research on ASD, some of which is not captured in the question’s nine research objectives, which focus on gap areas prioritized by the Committee. The Question 2 projects designated as Core/Other correspond to research areas that were already established and/or well-funded at the time the Strategic Plan was developed, as well as areas of emerging science that may not have been captured in the Strategic Plan objectives. This is in large part due to several areas of established, ongoing research that fit within this Question, including basic research on autism that involves the molecular neuroscience, brain structure and function, and behavioral and cognitive neuroscience fields. Figure 22 provides a snapshot of the range of research included in the group of Question 2 projects that were designated as Core/Other.

The two objectives receiving the largest portion of Question 2 funding (2.S.D and 2.S.G) have remained consistent across portfolio analyses since 2009. Almost a fifth of funding associated with Question 2 in both 2011 (17%; $12.4 million) and 2012 (18%; $18.5 million) was devoted to understanding the underlying biology of genetic conditions related to ASD, including Rett syndrome, fragile X syndrome, and tuberous sclerosis complex (2.S.D). Projects investigating a link between specific genotypes and functional or structural phenotypes (2.S.G) received 15% ($11.1 million) of funding in 2011 and 16% ($15.6 million) of funding in 2012. This research includes studies examining genotypes and phenotypes, alterations in language function and development, or specific regional differences in brain structure compared to those who have other genotypes.

While the IACC Portfolio Analysis attempts to capture all activity categorized under the various objectives of the Strategic Plan, in some cases it is difficult to do so. For example, samples collected by the National Institute of Child Health and Human Development (NICHD) Brain and Tissue Bank for Developmental Disorders are an important resource for ASD research. However, because the tissue bank is not ASD-specific, funding of this initiative—which includes outreach with the aim of increasing tissue donation, which would fall under Objective 2.S.C— is not included in the Portfolio Analysis. Thus, though this project contributes to Objective 2.S.C., its funding is not counted toward the total, and this in turn reduces the extent to which objectives such as 2.S.C appear completed.
2011: Proportion of Projects Corresponding to IACC Strategic Plan Question 2 Objectives

- 56% ($41,127,339)
- 44% ($32,096,050)

2012: Proportion of Projects Corresponding to IACC Strategic Plan Question 2 Objectives

- 49% ($48,851,715)
- 51% ($51,402,699)

Examples of Topics addressed by Projects in Core/Other:
- Role of genes and molecular pathways in ASD
- Structure, development, and function of brain regions in aspects of ASD
- Neural circuitry underlying ASD
- Cognition, learning, sensory perception and social behaviors in ASD

Figure 22. Roughly half of ASD research projects in Question 2 were coded to specific objectives; those that did not fit within the IACC Strategic Plan objectives were coded as Core/Other. Examples of topics addressed by projects in Core/Other are listed above.
Question 2 Subcategory Analysis

Due to the large proportion of research in Question 2 that could not be assigned to a particular objective, the subcategory analysis was particularly useful in understanding the distribution of research on the underlying mechanisms of ASD. Research in this area covers a broad array of science, and therefore Question 2, which was approximately $73.2 million of total funding in 2011 and 100.3 million in 2012, was divided into several subcategories. These include: Cognitive studies; Computational science; Co-occurring conditions; Developmental trajectory; Immune/Metabolic pathways; Molecular pathways; Neural systems; Neuropathology; Sensory and motor function; and Subgroups/Biosignatures (Figures 23 and 24).

The largest portion of Question 2 funding in 2011 (32%) and 2012 (35%) was devoted to research on Molecular pathways (systems of genes, proteins, and other molecules) involved in ASD and related disorders (such as fragile X, Rett syndrome, etc.), including projects that explore these pathways using animal model systems that mimic various aspects of ASD. Research exploring the Neural systems involved in ASD was the second largest research investment with 18% of funding in both 2011 and 2012. These studies typically use imaging techniques such as MRI (magnetic resonance imaging) and EEG (electroencephalography) to look at differences in brain structure, neural circuitry, and regional activation associated with ASD. Projects aiming to identify ASD Subgroups/Biosignatures accounted for 15% of Question 2 funding in 2011 and 2012. Research into the Developmental trajectory of ASD, which includes longitudinal studies that follow social, behavioral, and physical development over time, accounted for 7% and 10% of research funding in 2011 and 2012 respectively. Projects investigating Sensory and motor function in ASD accounted for 7% in 2011 and 5% in 2012 of research funding. Studies focusing on Co-occurring conditions, such as sleep disorders, epilepsy, and gastrointestinal disruption, represented 6% and 3% of funding in 2011 and 2012 respectively. In 2011, Cognitive studies accounted for 5% of ASD research funding, and Computational science projects accounted for 4%; in 2012, each accounted for 4% of ASD research. Research into Immune/Metabolic pathways disruptions associated with ASD corresponded to 3% of funding in 2011 and 2012. Finally, Neuropathology studies using postmortem brain tissue accounted for 2% of funding in both 2011 and 2012. Figures 23 and 24 also list Federal and private funders of research that fit within the Strategic Plan Question 2 category.
Figure 23. In order to adequately describe the breadth of research represented by Question 2 (Biology), a large number of subcategories were used when grouping projects. In 2011, the subcategory with the largest portion of funding was Molecular pathways (32%), followed by Neural systems (18%), Subgroups/Biosignatures (15%), Developmental trajectories and Sensory and motor function (both 7%), Co-occurring conditions (6%), Cognitive studies (5%) and Computational science (4%) Immune/Metabolic pathways (3%), and finally Neuropathology (2%). Federal and private funders of research fitting within Strategic Plan Question 2 are indicated at the bottom of the figure.
2012
QUESTION 2: BIOLOGY – Funding by Subcategories
Total Funding: $100,254,414
Number of Projects: 461

Cognitive Studies
4% ($3,977,731)
30 projects

Computational Science
4% ($4,254,038)
16 projects

Co-occurring Conditions
3% ($3,218,960)
19 projects

Developmental Trajectories
10% ($10,392,607)
25 projects

Immune/Metabolic Pathways
3% ($3,179,954)
29 projects

Molecular Pathways
35% ($34,795,621)
170 projects

Neural Systems
18% ($17,833,908)
80 projects

Neuropathology
2% ($1,958,447)
15 projects

Sensory and Motor Function
5% ($5,450,190)
23 projects

Subgroups/Biosignatures
15% ($15,192,958)
54 projects

Figure 24. In 2012, the subcategory with the largest portion of funding was Molecular pathways (35%), followed by Neural systems (18%), Subgroups/Biosignatures (15%), Developmental trajectories (10%), Sensory and motor function (5%), Cognitive studies and Computational science (both 4%), Co-occurring conditions and Immune/Metabolic pathways (both 3%) and lastly Neuropathology (2%). Federal and private funders of research fitting within Strategic Plan Question 2 are indicated at the bottom of the figure.
Progress Made on Question 2 from 2008-2012

Table 6 describes the progress made on the nine research objectives within Question 2 over the five-year period from 2008-2012. The table also provides details regarding the status of funding for each objective, the status of research/scientific progress in each objective area, and information about remaining gaps, needs, and opportunities in each research area. Figure 25 shows the trend in Question 2 funding over time. Overall, funding for research projects related to Question 2 was relatively higher than most other areas. Projects corresponding to Question 2 comprised the largest proportion of overall ASD research funding in 2010-2012 and showed a steady increase overall from 2008-2012.

In summary, progress has been made in funding projects to address the research needs described in all nine of the Question 2 objectives. While nearly half of funding was assigned to projects that correspond to the Question 2 objectives, the other half was not specific to any objective and was invested in Core/Other research activities, which encompass long-standing investments in research toward understanding the biology of autism as well as research in newly emerging areas of science.

Figure 25. Question 2 ASD Research Funding from 2008-2012. Overall, funding for Question 2 increased over the five-year span.
<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Funding</th>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2.2</strong> Support at least four research projects to identify mechanisms of fever, metabolic and/or immune system interactions with the central nervous system that may influence ASD during prenatal-postnatal life by 2010 (Fever studies to be started by 2012).</td>
<td><strong>IACC Recommended Budget: $9,800,000 over 4 years</strong></td>
<td></td>
<td>$3,377,568</td>
<td>$3,584,634</td>
<td>$4,972,407</td>
<td>$2,013,417</td>
<td>$3,049,827</td>
<td><strong>$16,997,853</strong></td>
</tr>
<tr>
<td><strong>2.5.A</strong></td>
<td><strong>Funding:</strong> The recommended budget for this objective was met.</td>
<td><strong>Progress:</strong> Many projects were funded in this area (approximately 20-30 per year), but the field is still developing, and emphasis on this objective should continue in the future. Scientific advances have been made in linking maternal innate immune function and immune-system challenge to aspects of ASD. Methodological advances in the field include the development of animal models for study of the role of the immune system in ASD and PET ligands for imaging microglial activation.</td>
<td><strong>Remaining Gaps, Needs, and Opportunities:</strong> There is a need for a well-designed, multi-site clinical study of clinical effects of fever and to develop standard measures of fever and behavioral/cognitive outcomes. Questions about fever could be integrated into funded epidemiological studies. There is also interest in further work on metabolic and mitochondrial issues, but in order for this work to be done, there is a need for validation and standardization of measures for assessment of oxidative stress and mitochondrial function. More guidance is needed on the key questions for this field to answer – a workshop to define these methodologies may be helpful. One of the key questions is to determine whether it is the body temperature associated with fever or some consequence of immune activation and production of the febrile state that leads to amelioration of cognitive function.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>2.3</strong> Launch three studies that specifically focus on the neurodevelopment of females with ASD, spanning basic to clinical research on sex differences by 2011.</td>
<td><strong>IACC Recommended Budget: $8,900,000 over 5 years</strong></td>
<td></td>
<td>$0</td>
<td>$1,370,107</td>
<td>$1,096,678</td>
<td>$150,000</td>
<td>$3,239,998</td>
<td><strong>$5,856,783</strong></td>
</tr>
<tr>
<td><strong>2.5.B</strong></td>
<td><strong>Funding:</strong> The recommended budget was partially met.</td>
<td><strong>Progress:</strong> More than the minimum three studies recommended were launched, but further work is needed in this area. Studies have found that females with ASD often have a higher burden of ASD genetic risk mutations than males, suggesting a gender-associated protective effect in females. Research on factors protecting females from developing ASD symptoms even when challenged with genetic mutations that lead to ASD in boys may help to identify approaches to prevent development of ASD symptoms in both genders.</td>
<td><strong>Remaining Gaps, Needs, and Opportunities:</strong> Studies of protective and compensatory effects in females and differential response to treatment based on gender are promising areas that could help with future prevention and effective, personalized treatment efforts. Beyond genetic differences, it is important to determine whether other biological features, such as differences in neuropathology, are found in the two sexes.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Question 2 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Identify ways to increase awareness among the autism spectrum community of the potential value of brain and tissue donation to further basic research by 2011.</td>
<td>2.A</td>
<td>0 projects</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IACC Recommended Budget: $1,400,000 over 2 years</td>
<td>2.S.C</td>
<td>$726,911</td>
<td>2 projects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.S.C. Funding: The recommended budget was partially met.</td>
<td>2.S.C</td>
<td>$17,000</td>
<td>1 project</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Progress: Loss of autism brain samples due to a freezer malfunction at a major brain bank in 2012 has caused a loss of progress in ASD research. Thus, there is a need for new samples to replace those that were lost and to begin expanding the amount of brain tissue available for ASD research. The Autism BrainNet initiative is a multi-site, privately funded effort that will target autism specifically and will include an autism-specific brain donation outreach campaign that addresses this objective. NIH launched the NIH Neurobiobank ($5 million), which includes samples for research on autism as well as other brain disorders, and has an associated online publication &quot;Why Brain Donation? A Legacy of Hope&quot; to increase awareness about brain donation. Both of these initiatives are not yet reflected in the Portfolio Analysis, because they began in 2013. In addition to these new brain banking efforts, the NICHD Brain and Tissue Bank produced a video for their website to generally increase awareness the potential value of brain and tissue donation to further basic research on neurodevelopmental and pediatric conditions. Since the effort is not autism-specific, it was not captured in the portfolio analysis.</td>
<td>2.S.C</td>
<td>$22,000</td>
<td>1 project</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remaining Gaps, Needs, and Opportunities: There is an ongoing and urgent need to raise awareness of the importance of brain and tissue donation for research, to standardize the methodology of collection and to increase the supply of such tissues. Autism BrainNet, a private outreach and postmortem brain donation program dedicated to research on autism and related disorders will integrate the Autism Tissue Program (ATP) with collection sites at Mount Sinai School of Medicine, the University of Texas Southwestern Medical School, and the University of California, Davis MIND Institute.</td>
<td>2.S.C</td>
<td>$90,120</td>
<td>1 project</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$856,031</td>
</tr>
<tr>
<td>Launch three studies that target improved understanding of the underlying biological pathways of genetic conditions related to autism (e.g., Fragile X, Rett syndrome, tuberous sclerosis complex) and how these conditions inform risk assessment and individualized intervention by 2012.</td>
<td>N/A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IACC Recommended Budget: $9,000,000 over 5 years</td>
<td>2.S.D</td>
<td>$9,171,542</td>
<td>48 projects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.S.D. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.</td>
<td>2.S.D</td>
<td>$13,162,905</td>
<td>57 projects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Progress: A large number of projects were funded that address this objective. Investment in this area has doubled since 2009, and in 2013, NIH began funding an ACE center focused on tuberous sclerosis. Much is being learned about conditions related to autism that can be applied to autism. This objective is on track.</td>
<td>2.S.D</td>
<td>$12,360,956</td>
<td>64 projects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remaining Gaps, Needs, and Opportunities: The next step will be to translate findings in this area into clinically useful therapies.</td>
<td>2.S.D</td>
<td>$18,452,242</td>
<td>83 projects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$53,147,645</td>
</tr>
</tbody>
</table>

Question 2 Multiyear Funding Table, see appendix for a color-coding key and further details.
# Question 2 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year</strong></td>
<td><strong>2008</strong></td>
</tr>
<tr>
<td>Launch three studies that target the underlying biological mechanisms of co-occurring conditions with autism, including seizures/epilepsy, sleep disorders, wandering/elopement behavior, and familial autoimmune disorders, by 2012. <strong>IACC Recommended Budget:</strong> $9,000,000 over 5 years</td>
<td></td>
</tr>
<tr>
<td>Year 2008 2009 2010 2011 2012 Total</td>
<td>N/A</td>
</tr>
<tr>
<td>Launch two studies that focus on prospective characterization of children with reported regression to investigate potential risk factors by 2012. <strong>IACC Recommended Budget:</strong> $4,500,000 over 5 years</td>
<td></td>
</tr>
<tr>
<td>Year 2008 2009 2010 2011 2012 Total</td>
<td>N/A</td>
</tr>
<tr>
<td>Support five studies that associate specific genotypes with functional or structural phenotypes, including behavioral and medical phenotypes (e.g., nonverbal individuals with ASD and those with cognitive impairments) by 2015. <strong>IACC Recommended Budget:</strong> $22,600,000 over 5 years</td>
<td></td>
</tr>
</tbody>
</table>

**2.5.E. Funding:** The recommended budget for this objective was met.  
**Progress:** More than twenty projects were funded that were specific to this objective. Scientific advances in this area include mechanistic and mutation linkages of epilepsy and ASD-like behaviors, as well as circadian rhythm disruptions downstream of ASD-associated mutations.  
**Remaining Gaps, Needs, and Opportunities:** While studies on co-occurring conditions have been initiated, a greater depth of understanding is needed. Further efforts are needed, especially on wandering, metabolic and immune conditions related to ASD, as well as a systems-biology approach to understand how these co-occurring conditions are related to ASD. In order to more accurately assess progress, wandering/elopement should be considered separately from seizures/epilepsy/sleep. Familial autoimmune disorders could be moved to 2.S.A to be grouped with other immune-related issues.

**2.5.F. Funding:** The recommended budget was partially met.  
**Progress:** The number of recommended projects has been met and progress is being made, but further work is needed to understand how autism develops. Some recent data suggest that regression may be more of a continuum than a distinct type of autism, and several studies have provided new descriptions of ASD developmental trajectories. However, other studies have found some differences between children with reported regression vs. children without reported regression.  
**Remaining Gaps, Needs, and Opportunities:** Further work is needed to better understand subtypes and potential biomarkers. High-risk siblings may present an opportunity for studying regression prospectively.

**2.5.G. Funding:** The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.  
**Progress:** Over 40 projects have been funded in this area, and the projects cover the areas described, so the objective appears to be on track.  
**Remaining Gaps, Needs, and Opportunities:** With so many studies initiated, the next step is to encourage multi-site collaboration in order to achieve the large number of subjects required for meaningful data interpretation.
## Question 2 Multiyear Funding Table

### IACC Strategic Plan Objectives

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Complete a large-scale, multidisciplinary, collaborative project that longitudinally and comprehensively examines how the biological, clinical, and developmental profiles of individuals, with a special emphasis on females, youths, and adults with ASD, change over time as compared to typically developing people by 2020.</strong>&lt;br&gt;<strong>IACC Recommended Budget:</strong> $126,200,000 over 12 years</td>
<td>2.5</td>
<td>2.L.A</td>
<td>2.L.A</td>
<td>2.L.A</td>
<td>2.L.A</td>
<td>$20,661,641</td>
</tr>
<tr>
<td><strong>Launch at least three studies that evaluate the applicability of ASD phenotype and/or biological signature findings for performing diagnosis, risk assessment, or clinical intervention by 2015.</strong>&lt;br&gt;<strong>IACC Recommended Budget:</strong> $7,200,000 over 5 years</td>
<td>N/A</td>
<td>2.L.B</td>
<td>2.L.B</td>
<td>2.L.B</td>
<td>2.L.B</td>
<td>$3,628,406</td>
</tr>
<tr>
<td><strong>Not specific to any objective (Core/Other Activities)</strong></td>
<td>2. Core/Other Activities</td>
<td>2. Core/Other Activities</td>
<td>2. Core/Other Activities</td>
<td>2. Core/Other Activities</td>
<td>2. Core/Other Activities</td>
<td>$203,144,324</td>
</tr>
<tr>
<td><strong>Total funding for Question 2</strong>&lt;br&gt;<strong>$368,612,503</strong></td>
<td>$40,621,403</td>
<td>$63,252,949</td>
<td>$91,260,349</td>
<td>$73,223,388</td>
<td>$100,254,414</td>
<td>$368,612,503*</td>
</tr>
</tbody>
</table>

### 2.5 Funding: The recommended budget was partially met.  
**Progress:** Several projects have been funded in this area, and the ACE Network continues to collect data relevant to this objective.  
**Remaining Gaps, Needs, and Opportunities:** Though this research is underway, more clinical studies are needed over a longer trajectory to identify issues faced as people with ASD age, especially with regard to risk factors for other medical conditions. Another remaining need is that of standardization of data collection and analysis methods.

### 2.L.A Funding: The recommended budget was partially met.  
**Progress:** Imaging studies have developed activity signatures of the ASD brain. While more than 3 studies were launched, more funding and work in this area are needed.  
**Remaining Gaps, Needs, and Opportunities:** This objective also requires standardization of data collection and analysis methods, as well as collaboration among investigators to pool data. Increased emphasis must be placed on conducting biological evaluations of very young children at risk for ASD and on collecting biological samples from these young children, to enable research into the establishment of biomarkers or risk markers in this population.

### Table 6. Multiyear Funding Table for Question 2.

*The numbers in this table have been updated since the 2013 IACC Strategic Plan has been published.*
QUESTION 3: RISK FACTORS

Aspirational Goal: Causes of ASD will be discovered that inform prognosis and treatments and lead to prevention/preemption of the challenges and disabilities of ASD.

Research Focus of Question 3

Question 3 (“What caused this to happen and can it be prevented?”) focuses on the risk factors associated with the development of ASD. Research related to Question 3 looks at the role of genetics, epigenetics, and the environment in the development of ASD, as well as the interactions between risk factors. Question 3 objectives address topics such as the need to develop improved approaches to study environmental exposures and gene-environment interactions, and to explore the potential roles of the microbiome and epigenetics on etiology. Also included are studies of risk factors and protective factors (factors that may protect an individual from developing ASD, even in the presence of other risk factors).

Analysis of Question 3 Portfolio 2011-2012

Research on risk factors associated with ASD (Question 3) accounted for 20% ($60.2 million) and 17% ($56.5 million) of the total funding in 2011 and 2012 respectively. In 2011, Question 3 contained 148 projects (12.1% of all projects), and in 2012 it had 162 projects (12.3% of all projects).

In 2011, progress was made on all but two of the 15 Question 3 objectives. Seven objectives were considered completed, while six objectives were partially completed. In 2012, six objectives were completed, and eight were partially completed. One objective in Question 3 did not have any active projects throughout 2011 and 2012. A full list of objectives and their progress can be found in Table 7.

Nearly all projects in Question 3 were assigned to a particular objective. In 2011, only 1% ($0.7 million) of the Question 3 funding was distributed to projects that were Core/Other (Figure 26). Similarly, in 2012, 1% ($0.3 million) of the Question 3 funding was distributed to projects that were categorized to Core/Other (Figure 26).
As in previous years, the Question 3 objective that received the largest proportion of funding in 2011 (42%, $25.4 million) and 2012 (41%, $23.0 million) focused on identifying genetic risk factors for ASD (3.L.B). This was followed by funding for surveillance and epidemiological studies to collect data on environmental factors during preconception and prenatal and early postnatal development, as well as genetic data (3.L.D). This objective accounted for 19% ($11.6 million) of the overall funding for Question 3 in 2011 and 24% ($13.5 million) in 2012.

Research on epigenetics (3.S.I) received 9% ($5.3 million) of the funding in 2011 and 11% ($6.1 million) in 2012, and projects focusing on gene-environment interactions (3.S.C) received 9% ($5.7 million) and 6% ($3.6 million) in 2011 and 2012 respectively. Research on special populations with the aim of understanding environmental risk factors (3.S.H) accounted for 8% ($4.7 million) of funding in 2011 and 7% ($4.1 million) in 2012; prospective studies of the pregnancies of mothers who already have one child with ASD (3.L.A) received 5% ($2.9 million) in both 2011 and 2012. Genome-wide association studies to find candidate genes for autism (3.S.A) received 4% ($2.2 million) and 3% ($1.7 million) in 2011 and 2012 respectively. The investigation of possible links between environmental factors and ASD subtypes (3.L.C), research to identify subpopulations susceptible to different environmental factors (3.S.E), studies on environmental factors identified in the 2007 IOM report (3.S.F), investigation of the microbiome (3.S.I), and the development of model systems to explore environmental risks (3.S.K), each received approximately 1% or less of the funding for Question 3 in 2011 and 2012. In 2011, a workshop hosted by the National Institute of Environmental Health Sciences (NIEHS) was convened to explore bioinformatics approaches to identify environmental risks; thus, Objective 3.S.G. was completed. The workshop reflected less than 1% of the overall funding for Question 3.

In 2011, two of the Question 3 objectives did not have assigned activities. One of these objectives calls for development of measures to identify markers of environmental exposure in biospecimens (3.S.B), and another calls for efforts to ensure that studies of environmental exposures and ASD include racially and ethnically diverse populations (3.S.D). In 2012, Objective 3.S.D remained inactive; however, with the presence of one new project, Objective 3.S.B became active for the first time since 2008. For Objective 3.S.D, there are projects coded to other objectives in the portfolio that may partially meet the requirements, but because projects can only be coded to one objective, that funding is not reflected in the 3.S.D total. Even if that funding were to be considered, the objective would still be unmet.
2011: Proportion of Projects Corresponding to IACC Strategic Plan Question 3 Objectives

- 1% (724,770)
- 99% (59,484,858)

2012: Proportion of Projects Corresponding to IACC Strategic Plan Question 3 Objectives

- 1% (315,607)
- 99% (56,171,418)

Examples of Topics Addressed by Projects in Core/Other:
Studies of genetic risk for ASD using epidemiologic approaches or postmortem brain tissue

Figure 26. Most ASD research projects in Question 3 were coded to specific objectives; those that did not fit within the IACC Strategic Plan objectives were coded as Core/Other. Examples of topics addressed by projects in Core/Other are listed above.
Question 3 Subcategory Analysis

Projects in Question 3, which made up nearly $60.2 million of total funding in 2011 and $56.5 million in 2012, were divided into four subcategories to understand the funding distribution across the research areas relating to understanding and identifying risk factors for ASD. These subcategories include: Environmental risk factors; Epigenetics; Gene-Environment studies; and Genetic risk factors (Figures 27 and 28).

The largest portion of Question 3 funding was devoted to research into Genetic risk factors in both 2011 (46%) and in 2012 (43%). The second largest research investment was investigating the role of environmental risk factors in the presence of genetic susceptibility (Gene-Environment) which accounted for 34% in 2011 and 37% in 2012. Projects that considered only environmental risk factors (Environmental risk factors) accounted for 11% and 9% of Question 3 funding in 2011 and 2012 respectively. Projects on Epigenetics, which include studies of DNA modifications such as methylation that do not affect amino acid sequence (i.e., not genetic mutations), received 10% in 2011 and 11% in 2012 of the funding. It is thought that epigenetic changes are one way the environment may influence gene expression to increase or decrease the chances of developing ASD. When considered together, the three subcategories that take environmental factors into account (Environment risk factors, Gene-Environment, and Epigenetics) accounted for over half (55% and 57% in 2011 and 2012 respectively) of the funding associated with Question 3. Figures 27 and 28 also list Federal and private funders of research that fits within the Strategic Plan Question 3 category.
QUESTION 3: RISK FACTORS – Funding by Subcategories

Total Funding: $60,209,628
Number of Projects: 148

- Environmental Risk Factors: 11% ($6,458,503) 30 projects
- Epigenetics: 10% ($5,805,078) 21 projects
- Gene-Environment: 34% ($20,514,574) 28 projects
- Genetic Risk Factors: 46% ($27,431,472) 69 projects

Federal Funders:
- Centers for Disease Control and Prevention
- Department of Defense-Autism Research Program
- Environmental Protection Agency
- Health Resources and Services Administration
- National Institutes of Health
- National Science Foundation

Private Funders:
- Autism Research Institute
- Autism Speaks
- Brain & Behavior Research Foundation
- Simons Foundation

Figure 27. Projects aligning with Question 3 (Risk Factors) were divided into four subcategories. In 2011, Genetic risk factors accounted for the majority of research funding (46%), followed by studies focused on Gene-Environment interactions (34%). Studies on Environmental risk factors received 11% of the funding for projects within Question 3, and Epigenetics studies received 10%. Federal and private funders of research fitting within Strategic Plan Question 3 are indicated at the bottom of the figure.
QUESTION 3: RISK FACTORS – Funding by Subcategories

2012

Total Funding: $56,487,025
Number of Projects: 162

Environmental Risk Factors
9% ($4,958,062)
29 projects

Epigenetics
11% ($6,122,724)
22 projects

Gene-Environment
37% ($21,060,276)
29 projects

Genetic Risk Factors
43% ($24,345,963)
82 projects

Federal Funders
- Centers for Disease Control and Prevention
- Department of Defense-Autism Research Program
- Environmental Protection Agency
- Health Resources and Services Administration
- National Institutes of Health
- National Science Foundation

Private Funders
- Autism Research Institute
- Autism Science Foundation
- Autism Speaks
- Brain & Behavior Research Foundation
- Simons Foundation

Figure 28. In 2012, research on Genetic risk factors (43%) and Gene-Environment interactions (37%) received the greatest portion of research funding among projects assigned to Question 3 (Risk Factors). This was followed by Epigenetics studies (11%), and studies on Environmental risk factors (9%). Federal and private funders of research fitting within Strategic Plan Question 3 are indicated at the bottom of the figure.
Progress Made on Question 3 from 2008-2012

Table 7 describes the progress made on the 15 research objectives within Question 3 over the five-year period from 2008-2012. The table also provides details regarding the status of funding for each objective, the status of research/scientific progress in each objective area, and information about remaining gaps, needs, and opportunities in each research area. Figure 29 shows the trend in Question 3 funding over time. In 2008, research relating to Question 3 was the highest funded area, but over the five years studied, funding levels decreased to below that of Question 2 and 4.

While research on risk factors has been funded at a higher level than some other areas of research (it was the most highly funded area in 2008-2009), there has been a significant overall decrease in funding in the five-year period from 2008-2012 (Figure 29). All 15 Question 3 objectives have had some funded research projects from 2008-2012. Nine out of 15 objectives showed a decrease in number of projects over the five period, three objectives showed an increase, and three objectives were flat or only required a single project (Table 7).

Figure 29. Question 3 ASD Research Funding from 2008-2012. Though there was a peak in funding in 2009, overall funding for Question 3 decreased over the five-year span.
<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Year</th>
<th>Funding</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2008</td>
<td>2009</td>
<td>2010</td>
</tr>
<tr>
<td>Coordinate and implement the inclusion of approximately 20,000 subjects for genome-wide association studies, as well as a sample of 1,200 for sequencing studies to examine more than 50 candidate genes by 2011. Studies should investigate factors contributing to phenotypic variation across individuals who share an identified genetic variant and stratify subjects according to behavioral, cognitive, and clinical features. <strong>IACC Recommended Budget: $43,700,000 over 4 years</strong></td>
<td>3.2</td>
<td>$4,065,392</td>
<td>$13,926,663</td>
</tr>
<tr>
<td><strong>3.2. Funding:</strong> The recommended budget was partially met, and is approaching the recommended budget. <strong>Progress:</strong> Progress has been made on this objective through the funding of several GWAS and sequencing projects. The current number of 6,000 GWAS subjects falls short of the goal of 20,000, but the number of whole exome sequences far exceeds 1,200, and could also reach 6,000 in the next year. Whole exome sequencing has identified 7-10 candidate genes, and promises to move closer to the goal of 50 in the future. Progress is being made in CNV studies. Overall, the work is on target.</td>
<td><strong>Remaining Gaps, Needs, and Opportunities:</strong> More subtyping and genotype-phenotype work outside of syndromic forms of autism, as well as natural history studies, are needed.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within the highest-priority categories of exposures for ASD, identify and standardize at least three measures for identifying markers of environmental exposure in biospecimens by 2011. <strong>IACC Recommended Budget: $3,500,000 over 3 years</strong></td>
<td>3.3</td>
<td>$713,227</td>
<td>$0</td>
</tr>
<tr>
<td><strong>3.3. Funding:</strong> The recommended budget was not met; the funding allocated to projects specific to this objective falls far short of the recommendation. <strong>Progress:</strong> There has been progress on the understanding of exposures, but more work needs to be done to apply this directly to autism research. Progress has made through methodological advances embedded in epidemiological studies funded by NIEHS, but those projects are not captured by the Portfolio Analysis because they are not specific to autism. <strong>Remaining Gaps, Needs, and Opportunities:</strong> The primary obstacle to completion of this objective has been availability of funding to identify and validate exposure markers. There is a need for biomarkers of exposure; exposomics should be a priority area for future research.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initiate efforts to expand existing large case-control and other studies to enhance capabilities for targeted gene-environment research by 2011. <strong>IACC Recommended Budget: $27,800,000 over 5 years</strong></td>
<td>3.4</td>
<td>$4,703,867</td>
<td>$4,824,779</td>
</tr>
<tr>
<td><strong>3.4. Funding:</strong> The recommended budget was nearly met, but work still needs to continue on this objective. <strong>Progress:</strong> The funding allocated to this area so far has primarily supported building infrastructure that can now be expanded to include more subjects, more data, and more analytical projects. Studies such as the MARBLES (Markers of Autism Risk in Babies Learning Early Signs) cohort study and the CHARGE (Childhood Autism Risks from Genetics and the Environment) study are included under this objective. <strong>Remaining Gaps, Needs, and Opportunities:</strong> Continued benefit will be derived from past investments as these resources are expanded and pooled.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Question 3 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year</strong></td>
<td>2008</td>
</tr>
<tr>
<td><strong>Enhance existing case-control studies to enroll racially and ethnically diverse populations affected by ASD by 2011.</strong></td>
<td><strong>3.S</strong></td>
</tr>
<tr>
<td>IACC Recommended Budget: $3,300,000 over 5 years</td>
<td>$84,628</td>
</tr>
<tr>
<td>2 projects</td>
<td>3 projects</td>
</tr>
<tr>
<td><strong>3.S.D. Funding:</strong> The recommended budget was not met; the funding allocated to projects specific to this objective falls far short of the recommendation.</td>
<td><strong>Progress:</strong> The UCLA ACE center coded to 3.L.B. reflects some progress on this objective. CADDRE also includes racially diverse participants from multiple urban centers. Overall, however, both funding and outcomes related to this objective are far below the goal.</td>
</tr>
<tr>
<td><strong>Support at least two studies to determine if there are subpopulations that are more susceptible to environmental exposures (e.g., immune challenges related to infections, vaccinations, or underlying autoimmune problems) by 2012.</strong></td>
<td><strong>3.S.E</strong></td>
</tr>
<tr>
<td>IACC Recommended Budget: $8,000,000 over 2 years</td>
<td>N/A</td>
</tr>
<tr>
<td>13 projects</td>
<td>10 projects</td>
</tr>
<tr>
<td><strong>3.S.E. Funding:</strong> The recommended budget was partially met</td>
<td><strong>Progress:</strong> Several projects were funded in this area, going beyond the minimum recommended by the committee, but the projects have been smaller than what was expected. However, even with smaller studies, a large amount of data has been collected relating to immunological conditions in children and mothers.</td>
</tr>
<tr>
<td>IACC Recommended Budget: $56,000,000 over 2 years (revised in 2010)</td>
<td>$7,600,673</td>
</tr>
<tr>
<td>19 projects</td>
<td>14 projects</td>
</tr>
<tr>
<td><strong>3.S.F. Funding:</strong> The recommended budget was partially met</td>
<td><strong>Progress:</strong> There has been a significant decrease in the number of studies related to this objective.</td>
</tr>
</tbody>
</table>

*Question 3 Multiyear Funding Table, see appendix for a color-coding key and further details.*
## Question 3 Multiyear Funding Table

### IACC Strategic Plan Objectives

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td>3.S.G</td>
<td>3.S.G</td>
<td>3.S.G</td>
<td>$46,991</td>
</tr>
<tr>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td>0 projects</td>
<td>1 project</td>
<td>0 projects</td>
<td></td>
</tr>
</tbody>
</table>

**3.S.G. Funding:** The workshop identified in this objective was funded and held by NIEHS in 2011.

**Progress:** A workshop on this topic, *Autism and the Environment: New Ideas for Advancing the Science*, was convened by the National Institute of Environmental Health Sciences (NIEHS) in 2010. ([Meeting report](#) available). Therefore, this objective has been completed.

**Remaining Gaps, Needs, and Opportunities:**

Next steps for this area include the need to develop an exposome. A forum for the sharing of new technologies and standardized assessments would also be useful in moving this field forward.

### Support at least three studies of special populations or use existing databases to inform our understanding of environmental risk factors for ASD in pregnancy and the early postnatal period by 2012. Such studies could include:

- Comparisons of populations differing in geography, gender, ethnic background, exposure history (e.g., prematurity, maternal infection, nutritional deficiencies, toxins), and migration patterns; and
- Comparisons of phenotype (e.g., cytokine profiles), in children with and without a history of autistic regression, adverse events following immunization (such as fever and seizures), and mitochondrial impairment. These studies may also include comparisons of phenotype between children with regressive ASD and their siblings.

**Emphasis on environmental factors that influence prenatal and early postnatal development is particularly of high priority. Epidemiological studies should pay special attention to include racially and ethnically diverse populations.**

**IACC Recommended Budget:** $12,000,000 over 5 years

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td>3.S.H</td>
<td>3.S.H</td>
<td>3.S.H</td>
<td>$10,281,278</td>
</tr>
<tr>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td>$1,527,866</td>
<td>$4,657,095</td>
<td>$4,096,317</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13 projects</td>
<td>16 projects</td>
<td>13 projects</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**3.S.H. Funding:** The recommended budget was partially met, and is approaching the recommended budget.

**Progress:** The funded projects cover the objective well; there are 32 projects that are related to this objective, though more projects focus on use of databases than on special populations. A positive element of progress for this objective is the existence of large monitoring databases and projects that capitalize on those resources, such as iCARE and MINERVIA.

**Remaining Gaps, Needs, and Opportunities:** While progress is being made in this area, and it must be maintained in order to achieve this objective.

---

*Question 3 Multiyear Funding Table, see appendix for a color-coding key and further details.*
### Question 3 Multiyear Funding Table

**IACC Strategic Plan Objectives**

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Support at least two studies that examine potential differences in the microbiome of individuals with ASD versus comparison groups by 2012.</strong>&lt;br&gt;<strong>IACC Recommended Budget:</strong> $1,000,000 over 2 years</td>
<td>N/A</td>
<td>N/A</td>
<td>3.S.I $53,960</td>
<td>3 projects</td>
<td>3.S.I $439,971</td>
<td>4 projects</td>
</tr>
</tbody>
</table>

**3.S.I. Funding:** The recommended budget was partially met.<br><br>**Progress:** The number of projects in this area has been growing, with 6 projects in 2012. The number of funded projects is large relative to the amount of funding, indicating that each of the projects is small, which suggests that these projects will not be sufficient in scope to complete this objective.<br><br>**Remaining Gaps, Needs, and Opportunities:** The high cost of required technology could be a barrier to the completion of this objective. These smaller pilot studies are potentially underpowered. The question of sample availability is important for this objective, along with raising researcher awareness of sample repositories.

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Support at least three studies that focus on the role of epigenetics in the etiology of ASD, including studies that include assays to measure DNA methylations and histone modifications and those exploring how exposures may act on maternal or paternal genomes via epigenetic mechanisms to alter gene expression, by 2012.</strong>&lt;br&gt;<strong>IACC Recommended Budget:</strong> $20,000,000 over 5 years</td>
<td>N/A</td>
<td>N/A</td>
<td>3.S.J $5,072,389</td>
<td>15 projects</td>
<td>3.S.J $5,341,237</td>
<td>19 projects</td>
</tr>
</tbody>
</table>

**3.S.J. Funding:** The recommended budget was partially met, and the annualized recommended budget targets were met for all 3 years since the objective was introduced; therefore, the funding for this objective is on track. If this funding trend continues, the objective’s recommended budget will be met within the recommended 5 year timeframe.<br><br>**Progress:** More than the recommended number of projects have been funded, with 22 projects supported in 2012. This is a growing area of research, and the current momentum in this area should be maintained.<br><br>**Remaining Gaps, Needs, and Opportunities:** An important technological need for this objective is the development of robust epigenetic measurements for small biological samples, such as blood spots. A possible barrier to research in this area is the availability and preservation quality of these samples. Large funded studies such as MARBLES might provide an opportunity to collect samples. If samples are made available, that may catalyze research in this area.

---

**Question 3 Multiyear Funding Table, see appendix for a color-coding key and further details.**
<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Support two studies and a workshop that facilitate the development of vertebrate and invertebrate model systems for the exploration of environmental risks and their interaction with gender and genetic susceptibilities for ASD by 2012. <strong>IACC Recommended Budget: $1,535,000 over 3 years</strong></td>
<td>2008</td>
<td>N/A</td>
<td>N/A</td>
<td><strong>3.S.K</strong></td>
<td><strong>$733,922</strong></td>
<td><strong>5 projects</strong></td>
<td><strong>$1,287,763</strong></td>
</tr>
<tr>
<td><strong>3.S.K. Funding:</strong> The recommended budget was partially met. However, the yearly funding decreased significantly from 2010-2012. It should be noted that this objective overlaps partially with 2.S.B., which is focused on research on sex differences in ASD, and 4.S.B., which focuses on development of animal models that can be used for understanding molecular and neural pathways that can be targeted by interventions. Genetic pathways that play a role in gender differences and other molecular and neural pathways may interact with environmental factors, so funding for these objectives could reflect progress on the goals of 3.S.K. <strong>Progress:</strong> Projects by Tychele Turner at Johns Hopkins and Donna Werling at UCLA that are using animal models to investigate sex differences in autism are coded to 2.S.B. The following 2010 workshop sponsored by NIEHS, <em>Autism and the Environment: Advancing the Science</em>, touched on this topic, but it was not the main focus of the workshop. <strong>Remaining Gaps, Needs, and Opportunities:</strong> The development of animal models for more broad ASD research is coded to question 4, and the use of such models to answer environmental exposure questions is a next step for this objective.</td>
<td>2009</td>
<td>N/A</td>
<td><strong>3.S.K</strong></td>
<td><strong>$463,841</strong></td>
<td><strong>3 projects</strong></td>
<td><strong>3.S.K</strong></td>
<td><strong>$90,000</strong></td>
</tr>
<tr>
<td>Conduct a multi-site study of the subsequent pregnancies of 1,000 women with a child with ASD to assess the impact of environmental factors in a period most relevant to the progression of ASD by 2014. <strong>IACC Recommended Budget: $11,100,000 over 5 years</strong></td>
<td>2010</td>
<td><strong>3.7</strong></td>
<td><strong>$2,742,999</strong></td>
<td><strong>1 project</strong></td>
<td><strong>3.L.A</strong></td>
<td><strong>$3,740,812</strong></td>
<td><strong>2 projects</strong></td>
</tr>
<tr>
<td><strong>3.7</strong></td>
<td><strong>$2,742,999</strong></td>
<td><strong>1 project</strong></td>
<td><strong>3.L.A</strong></td>
<td><strong>$3,740,812</strong></td>
<td><strong>2 projects</strong></td>
<td><strong>3.L.A</strong></td>
<td><strong>$2,971,093</strong></td>
</tr>
</tbody>
</table>

**3.7 Funding:** The recommended budget for this objective was met, but emphasis on this objective should continue in the future. **Progress:** The Group is concerned about the lack of continued funding for EARLI. More positively, projects analyzing the previously collected EARLI data are in process. Also, the MARBLES project contributes toward the goal of studying the interaction of genetic and environmental factors beginning during pregnancy, but, since it is not a multi-site study, and is also a continuation of an existing study funded as a pilot under a UC Davis Children’s Center grant, funding for MARBLES is coded to 3.S.C., which overlaps somewhat with this objective. **Remaining Gaps, Needs, and Opportunities:** A barrier to this type of work is the extremely high cost of building the necessary infrastructure. With MARBLES and previously with EARLI, there has been some progress on infrastructure. It is important to maintain these cohorts where possible, to collect a wide range of samples, and to use them for multiple studies to capitalize on investments made.
### Question 3 Multiyear Funding Table

#### IACC Strategic Plan Objectives

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
</table>
| **Identify genetic risk factors in at least 50% of people with ASD by 2014.**
**IACC Recommended Budget:** $33,900,000 over 6 years | 3.8 | 3.8B | 3.8B | 3.8B | 3.8B | **$169,806,458** |
| **3.8 Funding:** The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective. | **Progress:** Further work is needed to identify genetic risk factors in at least 50% of people. Currently, whole exome analysis predicts that a genetic risk factor can be identified for 20% of people; inclusion of CNV data might push this toward 30%. | **Remaining Gaps, Needs, and Opportunities:** The initial budget recommendation for this objective was made based on the assumption that GWAS studies would provide risk factor identification, but sequencing has proven more fruitful. Since this technique is more expensive, a higher budget will be required to meet the goal of 50%. |
| **Determine the effect of at least five environmental factors on the risk for subtypes of ASD in the prenatal and early postnatal period of development by 2015.**
**IACC Recommended Budget:** $25,100,000 over 7 years | 3.6 | 3.6C | 3.6C | 3.6C | 3.6C | **$5,349,089** |
| **3.6 Funding:** The recommended budget was partially met, and several projects were funded, but it appears there is a downward trend in funding for these projects over time. This objective partially overlaps with 3.L.A. | **Progress:** Epidemiological studies coded to other objectives (e.g., EARLI) may also represent progress in this area. | **Remaining Gaps, Needs, and Opportunities:** A barrier to the completion of this objective is the undefined nature of ASD subtypes, both phenotypically and etiologically, lack of prenatal samples, and the lack of longitudinal follow-up of at-risk subgroups. This field is still developing and needs support. |
| **Support ancillary studies within one or more large-scale, population-based surveillance and epidemiological studies, including United States populations, to collect data on environmental factors during preconception, and during prenatal and early postnatal development, as well as genetic data, that could be pooled (as needed) to analyze targets for potential gene/environment interactions by 2015.**
**IACC Recommended Budget:** $44,400,000 over 5 years | 3.9 | 3.9D | 3.9D | 3.9D | 3.9D | **$63,013,714** |
| **3.9 Funding:** The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective. | **Progress:** The funds allocated to this objective to date have been used for data collection and the development of infrastructure, with most of the studies coded to this area relating to CDC’s CADDRE program. | **Remaining Gaps, Needs, and Opportunities:** Continued funding will be needed to support data analysis. Both molecular and environmental data are needed. |

*Question 3 Multiyear Funding Table, see appendix for a color-coding key and further details.*
## Question 3 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not specific to any objective</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$17,656,815</td>
</tr>
<tr>
<td>(Core/Other Activities)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Core/Other Activities</td>
<td>$6,791,008</td>
<td>$8,512,980</td>
<td>$1,312,450</td>
<td>$724,770</td>
<td>$315,607</td>
<td>$17,656,815</td>
</tr>
<tr>
<td></td>
<td>52 projects</td>
<td>39 projects</td>
<td>7 projects</td>
<td>5 projects</td>
<td>3 projects</td>
<td></td>
</tr>
<tr>
<td>Total funding for Question 3</td>
<td>$82,846,620</td>
<td>$100,043,216</td>
<td>$81,231,647</td>
<td>$60,209,628</td>
<td>$56,487,025</td>
<td>$380,818,136</td>
</tr>
<tr>
<td></td>
<td>221 projects</td>
<td>192 projects</td>
<td>162 projects</td>
<td>148 projects</td>
<td>162 projects</td>
<td></td>
</tr>
</tbody>
</table>

Question 3 Multiyear Funding Table, see appendix for a color-coding key and further details.

Table 7. Multiyear Funding Table for Question 3.
QUESTION 4: TREATMENTS AND INTERVENTIONS

Aspirational Goal: Interventions will be developed that are effective for reducing both core and associated symptoms, for building adaptive skills, and for maximizing quality of life and health for people with ASD.

Research Focus of Question 4

Question 4 asks “Which treatments and interventions will help?” and covers a range of intervention approaches currently being considered, including pharmacological, behavioral, educational, and alternative/complementary/integrative medicine approaches. Research in this field encompasses the development of new treatments using early stage animal models and small-scale experiments as well as full-scale clinical trials. Question 4 also includes studies to assess the safety and effectiveness of treatments already in use in the community.

Analysis of Question 4 Portfolio 2011-2012

Research assigned to Question 4 received 20% ($60.8 million) of total ASD research funding in 2011, and 19% ($64.1 million) of ASD research funding in 2012. Question 4 included 260 projects in 2011 and 270 projects in 2012, representing 21% of the total number of projects reported in both years.

Progress was made for all of the Question 4 objectives in 2011 and 2012, with four objectives considered completed, and the remaining eight objectives showing progress. The majority of the projects assigned to Question 4 fit into the Question 4 objectives, but in 2011, 8% ($4.8 million) of the funding went to projects designated as Core/Other, and in 2012, 6% (3.9 million) of the funding went to projects designated as Core/Other (Figure 30). A full list of objectives and their progress can be found in Table 8.

As in previous years, the Question 4 objective to develop model systems that replicate features of ASD (4.S.B) continued to receive the highest proportion of funding in both 2011 (36%, $21.6 million) and 2012 (33%, $21.2 million). There has also been progress on the evaluation of early interventions in randomized controlled trials.
(RCTs) (4.S.D), which was 18% ($11.2 million) in 2011 and 14% ($8.8 million) in 2012. Community-based studies assessing the effectiveness of interventions and services in broader community settings (4.L.D) was 10% ($6.3 million) of Question 4 funding in 2011 and 16% ($10.2 million) of funding in 2012. Funding of randomized clinical trials of interventions that include biological signatures and other measures to predict and monitor outcomes (4.S.F) received 9% ($5.4 million) of funding in 2011 and 10% ($6.3 million) of funding in 2012. Progress was also made on an objective to develop interventions for non-verbal individuals with ASD (4.S.G), with funded projects on the development of new techniques for teaching communication skills, including symbols, and augmentative and alternative communication (5%, $2.8 million in 2011 and 8%, $4.8 million in 2012). While this objective was added to the Strategic Plan as a new priority area in 2011, several funded projects addressing this area were already funded in 2011, and by 2012, the full recommended budget was completed (green light). In 2011, projects focusing on the safety and effectiveness of medications commonly used in the treatment of co-occurring condition or specific behavioral conditions in those with ASD (4.L.C) represented 5% ($2.8 million) of Question 4 funding, whereas it had fewer assigned projects in 2012, with less than 1% ($0.3 million) of Question 4 funding. Overall, by 2012 the objective had partially completed the recommended budget, achieving yellow light status.

Several objectives made progress in 2011-2012, but remained short of their recommended budget targets (Table 8). For example, Objective 4.S.E calls for a workshop to advance the understanding of clinical subtypes and treatment personalization. Personalized medicine has gained considerable interest in both the public and medical arena over recent years due to its potential to change how diseases are diagnosed, understood, and treated. A workshop held by AS in 2011 to discuss improvement of outcome measures for use in a clinical trial setting partially addressed Objective 4.S.E, setting the status of this objective as a yellow light for 2011 and 2012. However, a workshop devoted to subtyping and treatment personalization has not taken place to date, possibly because research in this area is still in early stages. Another example, Objective 4.L.A, which focused on randomized controlled trials for medications targeting core symptoms of ASD, showed progress in the number of projects funded (funded more projects than the minimum set in the objective) and progress in the amount of funding, but still fell short of the overall recommended budget.
### 2011: Proportion of Projects Corresponding to IACC Strategic Plan Question 4 Objectives

- **Core/Other**: 8% ($4,777,350)
- **Specific to objectives**: 92% ($56,041,771)

### 2012: Proportion of Projects Corresponding to IACC Strategic Plan Question 4 Objectives

- **Core/Other**: 6% ($3,862,655)
- **Specific to objectives**: 94% ($60,287,245)

---

**Examples of Topics Addressed by Projects in Core/Other:**

- Development of technologies for educational, cognitive, and social skills interventions
- Development of approaches to improve physical health and reduce sensory overstimulation

---

*Figure 30. Most ASD research projects in Question 4 were coded to specific objectives; those that did not fit within the IACC Strategic Plan objectives were coded as Core/Other. Examples of topics addressed by projects in Core/Other are listed above.*
Question 4 Subcategory Analysis

Question 4 represents research on a wide array of different approaches to treatments and interventions for ASD, ranging from medications to alleviate core and co-occurring symptoms, to behavioral therapies and technologies to improve communication, socialization, life skills, and learning. Projects under Question 4 accounted for approximately $60.8 million of total funding in 2011 and $64.1 million in 2012 and were broken down into these subcategories: Behavioral; Complementary, dietary, and alternative; Educational; Medical/Pharmacologic; Model systems/Therapeutic targets; Occupational, physical, and sensory-based; and Technology-based interventions and supports (Figures 31 and 32).

As in 2010, the largest portion of Question 4 funding supported early phases of intervention development (Model systems/Therapeutic targets); specifically, 36% of overall Question 4 funding in 2011 and 33% in 2012. This includes development and validation of animal and cellular models that mimic characteristics found in people with ASD, as well as the use of these models to test experimental autism therapies. Research on Behavioral therapies—including applied behavior analysis (ABA), cognitive behavioral therapy, social skills training, the Lovaas method, and joint attention training—accounted for 27% of Question 4 funding in 2011 and 25% in 2012. This was followed by research on Medical/Pharmacologic interventions, which received 18% of funding in 2011 and 16% in 2012. By comparison, Educational interventions, such as those used in a classroom setting, accounted for 9% and 12% of research funding in 2011 and 2012 respectively. Technology-based interventions and supports—such as augmentative and alternative communication (AAC) and robots to help children with ASD develop social skills—represent an area that has been steadily growing over recent years. These interventions received 8% and 10% of the Question 4 funding in 2011 and 2012 respectively. Occupational, physical, and sensory-based therapies represent 2% in 2011 and 3% in 2012. Complementary, dietary, and alternative treatments were 1% of funding in both 2011 and 2012. The figures also list Federal and private funders of research that fits within the Strategic Plan Question 4 category.
Table 3-1. The subcategories for Question 4 (Treatments and Interventions) illustrate the many approaches to treatments and interventions supported by autism research funders. In 2011, the largest amount of funding supported projects to develop Model systems/Therapeutic targets (36%), followed by research on Behavioral interventions (27%). Medical/Pharmacologic interventions received 18% of funding, Educational (classroom-based) interventions received 9% of funding, and Technology-based interventions and supports received 8% of funding. The subcategories with the smallest amounts of funding included Occupational, physical, and sensory-based (2%) and Complementary, dietary, and alternative (1%). Please note that one project has been categorized as Other as it does not fall under one of the four main research areas of Question 4. However, this project, which evaluates the comparative effectiveness of multiple types of therapies for children with ASD, is not represented on the pie chart as although the project was active in 2011, there was no funding reported. The figure also lists Federal and private funders of research that fits within the Strategic Plan Question 4 category.
**2012**  
**QUESTION 4: TREATMENTS AND INTERVENTIONS – Funding by Subcategories**  
Total Funding: $64,149,900  
Number of Projects: 270

<table>
<thead>
<tr>
<th>Subcategory</th>
<th>Percentage</th>
<th>Funding (in $)</th>
<th>Number of Projects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model Systems/Therapeutic Targets</td>
<td>33%</td>
<td>$21,232,514</td>
<td>94</td>
</tr>
<tr>
<td>Behavioral</td>
<td>25%</td>
<td>$16,049,307</td>
<td>68</td>
</tr>
<tr>
<td>Medical/Pharmacologic</td>
<td>16%</td>
<td>$10,251,776</td>
<td>32</td>
</tr>
<tr>
<td>Occupational, Physical, and Sensory-Based</td>
<td>3%</td>
<td>$1,949,213</td>
<td>14</td>
</tr>
<tr>
<td>Technology-Based Interventions and Supports</td>
<td>10%</td>
<td>$6,308,826</td>
<td>34</td>
</tr>
<tr>
<td>Educational</td>
<td>12%</td>
<td>$7,781,819</td>
<td>22</td>
</tr>
<tr>
<td>Complementary, Dietary, and Alternative</td>
<td>1%</td>
<td>$576,445</td>
<td>6</td>
</tr>
</tbody>
</table>

**Federal Funders**  
- Department of Defense - Autism Research Program  
- Department of Education  
- Health Resources and Services Administration  
- National Institutes of Health  
- National Science Foundation

**Private Funders**  
- Autism Research Institute  
- Autism Science Foundation  
- Autism Speaks  
- Brain & Behavior Research Foundation  
- Center for Autism and Related Disorders  
- Organization for Autism Research  
- Simons Foundation  
- Southwest Autism Research & Resource Center

Figure 32. In 2012, the largest amount of funding for Question 4 (Treatments and Interventions) supported projects to develop Model systems/Therapeutic targets (33%). This was followed by research on Behavioral interventions (25%), Medical/Pharmacologic interventions (16%), Educational (classroom-based) interventions (12%), Technology-based interventions and supports (10%), Occupational, physical, and sensory-based interventions (3%), and finally Complementary, dietary, and alternative interventions (1%). The figure also lists Federal and private funders of research that fits within the Strategic Plan Question 4 category.
Progress Made on Question 4 from 2008-2012

Table 8 describes the progress made on the 12 research objectives within Question 4 over the five-year period from 2008-2012. The table also provides details regarding the status of funding for each objective, the status of research/scientific progress in each objective area, and information about remaining gaps, needs, and opportunities in each research area. Figure 33 shows the trend in Question 4 funding over time. Overall, Question 4 funding maintained a consistently high level. The progress made on the objectives to date suggests that while studies on areas that were prioritized before the Strategic Plan was in place, such as animal model development and randomized controlled trials of behavioral and pharmacological interventions, have received moderate to high funding to date, there are other areas of research that are still emerging. Examples include studies on interventions for high-risk children without a diagnosis (such as siblings of children with ASD) and studies of interventions for secondary health conditions.

Figure 33. Question 4 ASD Research Funding from 2008-2012. Funding for Question 4 remained steady, with a slight increase over the five-year span.
### Question 4 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year</strong></td>
<td><strong>2008</strong></td>
</tr>
<tr>
<td>Support at least three randomized controlled trials that address co-occurring medical conditions associated with ASD by 2010.</td>
<td>4.2</td>
</tr>
<tr>
<td>IACC Recommended Budget: $13,400,000 over 3 years</td>
<td>$4,583,171</td>
</tr>
<tr>
<td>5 projects</td>
<td>6 projects</td>
</tr>
<tr>
<td><strong>4.S.A. Funding:</strong> The recommended budget for this objective was met.</td>
<td></td>
</tr>
<tr>
<td><strong>Progress:</strong> More than three projects were funded, including trials of sleep, anxiety, seizure and gastrointestinal (GI) interventions, meeting the objective. Additional work will be needed in the future to fully address these conditions.</td>
<td></td>
</tr>
<tr>
<td><strong>Remaining Gaps, Needs, and Opportunities:</strong> Sleep issues, anxiety, hyperactivity and GI issues are key co-occurring medical conditions in patients with ASD. Although there is much more known today about sleep initiation than what was understood 5 years ago, there is little understanding of what interventions/treatments are effective for sleep maintenance or night awakening. There is not much known concerning anxiety treatments for those with ASD, and challenges exist regarding the adaptation of anxiety treatments from outside ASD patient groups. Research into interventions for hyperactivity may be transferred from populations outside of those with ASD (i.e., ADHD). Though there has been an increased awareness of gastrointestinal difficulties and common symptoms among people with ASD, little is known about the etiology of autism-related GI issues. More research on the etiology of GI issues will be needed to develop appropriate treatments/interventions.</td>
<td></td>
</tr>
</tbody>
</table>

| Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012. | 4.5 | 4.S.B | 4.S.B | 4.S.B | 4.S.B | $102,110,669 |
| IACC Recommended Budget: $75,000,000 over 5 years | $15,879,827 | $20,162,709 | $23,229,501 | $21,606,118 | $21,232,514 |
| 42 projects | 70 projects | 92 projects | 89 projects | 94 projects | |
| **4.S.B. Funding:** The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective. | |
| **Progress:** More than 90 projects were supported to develop animal models. | |
| **Remaining Gaps, Needs, and Opportunities:** Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built. The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important. | |
Question 4 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2008</td>
</tr>
<tr>
<td>Test safety and efficacy of at least five widely used interventions (e.g., nutrition, medications, assisted technologies, sensory integration, medical procedures) that have not been rigorously studied for use in ASD by 2012.</td>
<td></td>
</tr>
<tr>
<td><strong>IACC Recommended Budget:</strong> $27,800,000 over 5 years</td>
<td><strong>4.6</strong></td>
</tr>
<tr>
<td>$641,285</td>
<td>$3,252,941</td>
</tr>
<tr>
<td>8 projects</td>
<td>29 projects</td>
</tr>
</tbody>
</table>

**4.S.C. Funding:** The recommended budget was partially met.  
**Progress:** Several projects were funded in this area, but more work is needed, as this is an area of significant public interest.  
**Remaining Gaps, Needs, and Opportunities:** Experts discussed the best balance between developing new treatments and testing current treatments that lack evidence, especially when funds are limited and conclusive clinical trials are expensive. The group noted that interventions for minimally verbal children are needed; some projects on assistive communication technologies, robotics and speech processing technology to assist with social communication training are funded, but more are needed. There are other projects related to minimally verbal autism in objective 4.S.G. Small pilot studies on nutritional therapies (i.e., GFCF diet studies) have been conducted with inconclusive outcomes, demonstrating the necessity for further exploration of nutritional interventions. Future emphasis on scientific investment in sensory integration and assisted technologies is needed.

| Complete two multi-site randomized controlled trials of comprehensive early intervention that address core symptoms, family functioning and community involvement by 2013. | **4.7** | **4.S.D** | **4.S.D** | **4.S.D** | **4.S.D** | **42,088,407** |
| IACC Recommended Budget: $16,700,000 over 5 years | $4,236,869 | $7,540,613 | $10,306,148 | $11,356,647 | $8,848,130 | |
| 5 projects | 9 projects | 18 projects | 20 projects | 21 projects | |

**4.S.D. Funding:** The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.  
**Progress:** In 2011 and 2012, ~20 trials were supported, including a mix of trial sizes.  
**Remaining Gaps, Needs, and Opportunities:** There is a need for both small, pilot studies and larger, robustly powered studies in this area. Several larger studies in the past few years (e.g., Early Start Denver Model) have emerged, but most studies in this area are generally smaller than in other fields of medicine and therefore lack the power to be informative if negative or definitive if positive. This objective also cites “family functioning” and “community living,” which may have significant overlap with objectives in Questions 5 and 6 of the Strategic Plan.

Question 4 Multiyear Funding Table, see appendix for a color-coding key and further details.
### Question 4 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2008</td>
</tr>
<tr>
<td>Convene a workshop to advance the understanding of clinical subtypes and treatment personalization (i.e., what are the core symptoms to target for treatment studies) by 2011. <em>This objective was partially completed in 2011.</em></td>
<td>N/A</td>
</tr>
</tbody>
</table>

**4.S.E. Funding:** The recommended budget was partially met, but was not put toward a single dedicated workshop.

**Progress:** Two workshops and other activities that have partially addressed this issue have taken place, but to date there has not been a dedicated workshop on this issue, so this objective is marked “yellow.”

**Remaining Gaps, Needs, and Opportunities:** Autism Speaks held two relevant workshops. The first, that took place on January 2011, “Outcome Measures for Clinical Trials with Individuals with ASD: Challenges and Opportunities,” was focused on developing strategies for advancing clinical trials of medications for ASD core and associated symptoms. The second, “Translational Medicine Research in ASD: Challenges and Opportunities,” that also took place in January 2011 focused on the basic science needed to discover and develop new treatments. Biomarkers and treatment personalization were among the topics discussed in both workshops. The EU-AIMS public-private consortium in Europe is working toward “developing and validating translational approaches for the advancement of novel therapies to treat ASD.” Identification of biomarkers of subtypes of ASD and personalization of interventions are within the consortium’s goals. Joint meetings between EU-AIMS and the Foundation for NIH Biomarkers Consortium, another recently-formed consortium around biomarkers and personalized treatments, are ongoing to determine the opportunities for collaboration on identifying surrogate markers for ASD treatment studies. Thus, while a dedicated workshop on clinical subtypes has not taken place, some of the present activities are discussing and implementing projects related to this topic.

Launch randomized controlled trials of interventions including biological signatures and other measures to predict response, and monitor quality of life and functional outcomes in each of the following groups:

- Five trials in infants and toddlers by 2013. *IACC Recommended Budget: $30,000,000 over 5 years.*
- Three trials in school-aged children and/or adolescents by 2013. *IACC Recommended Budget: $18,000,000 over 5 years (revised in 2010)*
- Three trials in adults by 2014. *IACC Recommended Budget: $18,000,000 over 5 years*

Total IACC Recommended Budget: **$66,000,000 over 5 years**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>$12,109,516</td>
<td>$9,791,270</td>
<td>$7,575,212</td>
<td>$5,445,599</td>
<td>$6,255,438</td>
<td><strong>$41,177,035</strong></td>
</tr>
<tr>
<td>16 projects &amp; 30 projects</td>
<td>42 projects</td>
<td>30 projects</td>
<td>23 projects</td>
<td>21 projects</td>
<td></td>
</tr>
</tbody>
</table>

**4.S.F. Funding:** The recommended budget was partially met.

**Progress:** The investment in projects under this objective is making good progress toward the recommended amount, with more than 20 projects funded in 2011 and 2012.

**Remaining Gaps, Needs, and Opportunities:** Current projects in this area are restricted to small pilot studies, which are essential to establishing a foundation prior to expansion to larger scale work. Thus, increased investment in this area is important. It should be noted that most RCTs in the future will incorporate some aspect of biological signatures (thus potentially presenting a challenge to future coding of projects).

Question 4 Multiyear Funding Table, see appendix for a color-coding key and further details.
### Question 4 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year</td>
<td>2008</td>
</tr>
<tr>
<td>Support at least five studies on interventions for nonverbal individuals with ASD by 2012. Such studies may include:</td>
<td>N/A</td>
</tr>
<tr>
<td>· Projects examining service-provision models that enhance access to augmentative and alternative communication (AAC) supports in both classroom and adult service-provision settings, such as residential service-provision and the impact of such access on quality of life, communication, and behavior;</td>
<td></td>
</tr>
<tr>
<td>· Studies of novel treatment approaches that facilitate communication skills in individuals who are nonverbal, including the components of effective AAC approaches for specific sub-populations of people with ASD; and</td>
<td></td>
</tr>
<tr>
<td>· Studies assessing access and use of AAC for children and adults with ASD who have limited or partially limited speech and the impact on functional outcomes and quality of life.</td>
<td></td>
</tr>
<tr>
<td><strong>IACC Recommended Budget:</strong> $3,000,000 over 2 years</td>
<td><strong>11 projects</strong></td>
</tr>
<tr>
<td><strong>4.S.G. Funding:</strong> The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.</td>
<td></td>
</tr>
<tr>
<td><strong>Progress:</strong> Between 11 and 16 studies were funded annually in the years 2010-2012, but results will not be available for at least two years.</td>
<td></td>
</tr>
<tr>
<td><strong>Remaining Gaps, Needs, and Opportunities:</strong> The field of research on non-verbal patients with ASD is growing, yet still requires significant work and future investment. ASD research has historically concentrated on verbal individuals and adults, which highlights the need for increased research on minimally verbal populations.</td>
<td></td>
</tr>
</tbody>
</table>

| Support at least two studies that focus on research on health promotion and prevention of secondary conditions in people with ASD by 2012. Secondary conditions of interest include weight issues and obesity, injury, and co-occurring psychiatric and medical conditions. | N/A         | N/A         | **4.S.H**  | **4.S.H**  | **4.S.H**  | $1,404,969 |
|ictory include weight issues and obesity, injury, and co-occurring psychiatric and medical conditions. |             |             | $225,877   | $222,265   | $956,827   |             |
| **IACC Recommended Budget:** $5,000,000 over 3 years | **2 projects** | **1 project** | **4 projects** |             |             |             |
| **4.S.H. Funding:** The recommended budget was partially met. |             |             |             |             |             |             |
| **Progress:** A small number of projects, but more than the recommended minimum, were funded, but further work is needed to address some of the specific issues described in the objective. |             |             |             |             |             |             |
| **Remaining Gaps, Needs, and Opportunities:** Overlap in interpretation between “co-occurring” and “secondary” conditions presents a challenge in evaluating this objective. There is likely overlap between projects that may fit this objective and those in 4.S.A. Areas of health promotion and disease prevention should be emphasized in this objective, as those are distinct from issues mentioned in other objectives in this Question. It was noted that 4.S.H’s emphasis on prevention and health promotion may also overlap with 5.S.D and 5.L.D on “health and safety and mortality” issues. |             |             |             |             |             |             |

**Question 4 Multiyear Funding Table, see appendix for a color-coding key and further details.**
## Question 4 Multiyear Funding Table

### IACC Strategic Plan Objectives

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$1,380,376</td>
<td>$1,168,146</td>
<td>$1,924,932</td>
<td>$1,527,858</td>
<td>$3,713,783</td>
<td>$9,715,095</td>
</tr>
<tr>
<td></td>
<td>12 projects</td>
<td>10 projects</td>
<td>11 projects</td>
<td>12 projects</td>
<td>14 projects</td>
<td></td>
</tr>
<tr>
<td><strong>Complete at least three randomized controlled trials on medications targeting core symptoms in people with ASD of all ages by 2014.</strong></td>
<td><strong>IACC Recommended Budget: $22,200,000 over 5 years</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### 4. L.A Funding:
The recommended budget was partially met.

**Progress:** 10-14 studies have been funded, which is more than the minimum recommended, and momentum within the pre-clinical phases of this objective is currently building. It should be noted, however, in that many of these studies are small trials or pilot studies.

**Remaining Gaps, Needs, and Opportunities:** Though there is little evidence that CNS drug development in animals will translate to humans, either in terms of toxicity or efficacy, there is still a need for investment in well-established animal model studies to identify promising molecular, cellular, or systems targets before mounting randomized clinical trials in humans. However, existing drugs for other indications may be adapted to ASD without extensive pre-clinical work, and there is also evidence for proof of concept studies for ASD (particularly those addressing core symptoms). It is also critically important to develop appropriate outcome measures for use in trials.

### Develop interventions for siblings of people with ASD with the goal of reducing the risk of recurrence by at least 30% by 2014.

**IACC Recommended Budget: $6,700,000 over 5 years**

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$14,256</td>
<td>$132,263</td>
<td>$307,349</td>
<td>$14,256</td>
<td>$362,987</td>
<td>$831,111</td>
</tr>
<tr>
<td></td>
<td>1 project</td>
<td>2 projects</td>
<td>3 projects</td>
<td>2 projects</td>
<td>2 projects</td>
<td></td>
</tr>
<tr>
<td><strong>4. L.B Funding:</strong></td>
<td>The recommended budget was not met; the funding allocated to projects specific to this objective falls far short of the recommendation.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Progress:** Only a small number of projects has been funded, and the intent of the objective has not been met to date. Research on siblings is still at an early stage, and the results, just beginning to be published, will inform future progress.

**Remaining Gaps, Needs, and Opportunities:** Results from studies within this objective will emerge in the near future. Greater understanding of the mechanisms underlying sibling development of ASD will be key before any targeted early interventions may be developed for this population.

### Conduct at least one study to evaluate the safety and effectiveness of medications commonly used in the treatment of co-occurring conditions or specific behavioral issues in people with ASD by 2015.

**IACC Recommended Budget: $10,000,000 over 5 years**

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$1,061,222</td>
<td>$2,302,240</td>
<td>$2,834,887</td>
<td>$277,072</td>
<td>$6,475,421</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7 projects</td>
<td>7 projects</td>
<td>8 projects</td>
<td>3 projects</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>4. L.C Funding:</strong></td>
<td>The recommended budget was partially met.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Progress:** A small number (3-7) of studies of pharmacological interventions for co-occurring conditions was funded. There exist many studies examining drugs that are in active use for ADHD that are now being adapted to ADHD-ASD patient groups.

**Remaining Gaps, Needs, and Opportunities:** There currently is much need for greater understanding of drug efficacy in ASD populations.

---

*Question 4 Multiyear Funding Table, see appendix for a color-coding key and further details.*
## IACC Strategic Plan Objectives

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>4.L.D</td>
<td>4.L.D</td>
<td>4.L.D</td>
<td></td>
<td>$25,239,169</td>
</tr>
</tbody>
</table>

4.L.D Funding: The recommended budget was partially met, and the annualized recommended budget targets were met for all 3 years since the objective was introduced. Therefore, the funding for this objective is on track.

Progress: 30-45 studies have been supported, which is greater than the recommended minimum of at least five studies. Considerable work has been done under this objective, but these projects do not cover the full scope of interventions in the community. Comparing the large number of studies to the funding suggests that many small studies are being funded rather than fewer large ones.

Remaining Gaps, Needs, and Opportunities: Emphasis on both the evaluation of interventions in controlled/academic settings prior to community based studies and the translation of interventions to community-based settings is key. Understanding of “Type 2 Translation,” or transfer of research from academic settings to real-world settings is important, considering barriers to transferring academic-based interventions to clinical groups and communities. Investment is still necessary in the academic setting before successful translation to community-based interventions can occur. For successful T2 translation to underserved communities, cost effectiveness and case coordination or case management is often helpful with uptake. This objective also overlaps considerably with objectives in Question 5. It is important to explore which supports are specifically executed at the community level (vs. home, schools, etc.), and to determine how they are best designed.

### Not specific to any objective (Core/Other Activities)

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Core/Other Activities</td>
<td>$14,075,905</td>
<td>$15,560,011</td>
<td>$6,290,633</td>
<td>$4,777,350</td>
<td>$3,862,655</td>
<td>$44,566,554</td>
</tr>
</tbody>
</table>

### Total funding for Question 4†

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Core/Other Activities</td>
<td>$53,968,973</td>
<td>$63,403,014</td>
<td>$68,123,890</td>
<td>$60,819,121</td>
<td>$64,149,900</td>
<td>$310,464,898*</td>
</tr>
</tbody>
</table>

---

Table 8. Multiyear Funding Table for Question 4.

*This total reflects all funding for projects aligned to current objectives in the 2011 IACC Strategic Plan and incorporates funding for projects that may have been coded differently in previous versions of the Plan.

†The totals reflect the funding and projects coded to this Question of the Strategic Plan in the particular year indicated at the top of the column. When reading each column vertically, please note that the projects and funding associated with each objective for 2008 may not add up to the total at the bottom of the column; this is due to revisions of the Strategic Plan that caused some objectives to be shifted to other Questions under the Plan. The projects and funding associated with these reclassified objectives are now reflected under the Question in which they appear in the 2011 Strategic Plan.

The numbers in this table have been updated since the 2013 IACC Strategic Plan has been published.
Aspirational Goal: Communities will access and implement necessary high-quality, evidence-based services and supports that maximize quality of life and health across the lifespan for all people with ASD.

Research Focus of Question 5

Question 5 (“Where can I turn for services?”) focuses on services and supports for people with ASD. Objectives address issues including access to services for both individuals with ASD and their families, impact of self-directed care, coordination among State and local agencies’ community-based supports, and the assessment of the health, safety, and mortality of people with ASD. Question 5 also includes research to develop and evaluate the training of service providers (pediatricians, teachers, social workers, etc.), and improve the efficacy, cost-effectiveness, and dissemination of evidence-based practices.

Analysis of Question 5 Portfolio 2011-2012

Question 5 accounted for 9% ($26.1 million) of the total ASD funding reported in 2011, and the percentage of all projects that fall under Question 5 was 11% (137 projects). In 2012, Question 5 accounted for 7% ($22.8 million) of the total ASD funding and 10% (138 projects) of the total number of projects included in the Portfolio Analysis.

Of the nine objectives in this question, progress was made on eight in both 2011 and 2012. In both years, three objectives reached or exceeded the recommended budget amount, some progress was made on five objectives, and only one objective showed no progress. A full list of objectives and details of their progress can be found in Table 9.

In 2011, 56% of funding was associated with projects assigned to a specific objective, whereas 44% of the funding was associated with projects designated as Core/Other (Figure 34). Similarly in 2012, 60% of the funding was associated with projects assigned to a specific objective, and 40% of the funding was associated with projects designated as Core/Other (Figure 34).

Following an increase in the reporting of funding attributed to projects in Question 5 in 2010 (the figure rose from $8.6 million in 2009 to $64.8 million in 2010), the funding reported in 2011 and 2012 has subsequently decreased. In 2010, the increase was mostly attributed to an addition of some large projects funded by the Health Resources...
and Services Administration (HRSA) to the data set, including their Leadership Education in Neurodevelopmental Disabilities (LEND) program, which supports fellowships to pediatricians to enhance the behavioral, psychosocial, and developmental aspects of general pediatric care, as well as their Developmental-Behavioral Pediatrics (DBP) Training Programs at multiple sites across the U.S. In addition, the Department of Education (ED) provided more comprehensive data for their autism-related portfolio in 2010, including projects which involved training teachers in effective methods to engage students with ASD and other developmental disabilities. In 2011 and 2012, an adjustment was made in reporting budget figures for certain large services projects to account for the fact that some of those projects were only partially focused on autism or only partially focused on research. Funding was prorated to only reflect the ASD-specific portion or the portion related to research. In addition to this adjustment, another contributor to the apparent decrease in funding in 2011 and 2012 was that some projects that had received all of their funding in the first year reported $0 in 2011 and 2012, though the projects were still active. These factors together contributed to what appears to be a significant decrease in funding reported for Question 5 in 2011-2012, though if similar adjustments were made to the 2010 data, the change from 2010 to 2011 would be less significant (Figure 37).

The two objectives receiving the most funding in 2011 and 2012 were 5.L.A and 5.L.C, both of which achieved green light (completed) status. Objective 5.L.A, which supports projects to improve dissemination, implementation, and sustainability of evidenced-based interventions, received 22% ($5.8 million) of the Question 5 funding in 2011, and 32% ($7.2 million) in 2012. Evaluation of new and existing training of service providers (5.L.C) accounted for 23% ($6.0 million) and 16% ($3.7 million) of Question 5 funding in 2011 and 2012 respectively. A significant portion of the projects included in this objective are LEND grants that were prorated, therefore this objective has seen a significant drop in funding from 2010 levels ($36.4 million). Assessment of how access to services affects family functioning in diverse populations (5.S.A) was the third most highly funded Question 5 objective in 2011 and 2012 (assigned a green light both years), accounting for 5% ($1.4 million) and 6% ($1.4 million) of funding in 2011 and 2012 respectively. Objective 5.S.C, which calls for implementation and evaluation of coordination among State and local agencies to provide integrated and comprehensive community-based supports and services for individuals with ASD saw a significant decrease in reported funding from $4.2 million in 2010, to $0.6 million (2.6%) in both 2011 and 2012. The progress on this objective in 2010 was attributed to HRSA’s State ASD Demonstration projects, which were not included in the projects that HRSA reported for the 2011-2012 Portfolio Analysis because they were determined not to be research projects, though their goals are related to implementation and evaluation of models of policy and practice-level coordination among state and local agencies. All other objectives each accounted for 2% or less of the overall funding reported for Question 5 in 2011 and 2012. However, Objective 5.L.B, which calls for testing the efficacy and cost-effectiveness of evidence-based services and supports for people with ASD in community settings, did not have any active projects in 2011 (red light), but now has one active project (yellow light) in 2012, with $0.5 million in funding.
Examples of Topics Addressed by Projects in Core/Other:
- Research on social networks and collaborations involving parents and healthcare and service providers
- Research on family well-being support services
- Projects to develop and evaluate practitioner training programs and special educator preparation
- Research on transition in the early school years for children with autism

Figure 34. More than half of the ASD research projects in Question 5 were coded to specific objectives; projects that did not fit within the IACC Strategic Plan objectives were coded as Core/Other. Examples of topics addressed by projects in Core/Other are listed above.
Question 5 Subcategory Analysis

Projects within Question 5, which accounted for approximately $26.1 million in 2011 and $22.8 million in 2012, have been categorized into five subcategories which reflect the general scope of research on services and supports: Community inclusion programs; Efficacious and cost-effective service delivery; Family well-being and safety; Practitioner training; and Services utilization and access (Figures 35 and 36).

As in 2010, the largest subcategory continued to be Practitioner training research, receiving 74% and 66% of Question 5 funding in 2011 and 2012 respectively. Efficacious and cost-effective service delivery, which covers research projects ranging from those to assess current service delivery models to those focused on developing new and efficient ways of providing services such as web-based approaches, received 10% of the funding in 2011 and 16% in 2012. This was followed by research on Services utilization and access (including disparities and potential barriers to access), which often encompasses survey-based research and accounted for 10% and 12% of the funding in Question 5 in 2011 and 2012 respectively. Family well-being and safety research projects received 5% and 4% of the funding, and research on Community inclusion programs received 1% and 2% in 2011 and 2012 funding respectively. Figures 35 and 36 also list Federal and private funders of research that fits within the Strategic Plan Question 5 category.
Figure 35. Projects aligning with Question 5 (Services) were divided across five subcategories. In 2011, subcategory on Practitioner Training research accounted for 74% of the funding for this question. Research projects related to Services utilization and access followed with 10% of the funding, and Efficacious and cost effective service delivery accounted for 10%. Only 5% of funding was designated for research projects related to Family well-being and safety, and 1% supported Community inclusion programs. The figure also lists Federal and private funders of research that fits within the Strategic Plan Question 5 category.
QUESTION 5: SERVICES – Funding by Subcategories

Total Funding: $22,827,101
Number of Projects: 138

- Practitioner Training: 66% ($14,986,157), 94 projects
- Efficacious and Cost-Effective Service Delivery: 16% ($3,683,791), 21 projects
- Services Utilization and Access: 12% ($2,698,973), 13 projects
- Family Well-Being and Safety: 4% ($958,185), 9 projects
- Community Inclusion Programs: 2% ($499,995), 1 project

Federal Funders:
- Administration for Community Living
- Agency for Healthcare Research and Quality
- Centers for Disease Control and Prevention
- Department of Defense - Autism Research Program
- Department of Education
- Health Resources and Services Administration
- National Institutes of Health
- National Science Foundation

Private Funders:
- Autism Science Foundation
- Autism Speaks
- Center for Autism and Related Disorders
- Organization for Autism Research
- Southwest Autism Research & Resource Center

Figure 36. In 2012, the research on Practitioner training subcategory accounted for two thirds (66%) of the funding for Question 5 (Services). Projects related to research on Efficacious and cost-effective service delivery followed with 16% of the funding, and Services utilization and access accounted for 12%. Family well-being and safety projects received 4% of funding, and projects relating to Community inclusion programs received 2%. The figure also lists Federal and private funders of research that fits within the Strategic Plan Question 5 category.
Progress Made on Question 5 from 2008-2012

Table 9 describes the progress made on the nine research objectives within Question 5 over the five-year period from 2008-2012. The table also provides details regarding the status of funding for each objective, the status of research/scientific progress in each objective area, and information about remaining gaps, needs, and opportunities in each research area. Figure 37 shows the trend in Question 5 funding over time. Research related to Question 5 was funded at relatively low levels in comparison with other areas. Question 5 saw a substantial increase in funding from 2008 to 2010, but after adjustments were made in reporting to only report autism-specific and research-related portions of larger projects, funding appeared to decrease from 2010-2012. In addition, an estimated line for Question 5 funding in 2010 is included in the graph to enable a more accurate comparison among years. To calculate the estimated line for 2010, the same methodology for the prorated rates in 2011 and 2012 was used. When these adjustments are made to the 2010 data set, the change from 2009 to 2010, and 2010 to 2011, appear to be less significant. Overall, when comparing 2008 funding for Question 5 with 2012 funding, the general trend is upward, though Question 5 also gained several new objectives from 2008-2011; this also contributed to the rise.

Among the nine Question 5 objectives, considerable progress was made in each objective. Approximately 60% of the total funding for Question 5 was related to specific objectives, while 40% were in areas covered by the Core/Other category, which may represent areas of ongoing, mainstream efforts or emerging research areas that have not been captured in the IACC Strategic Plan objectives.
Figure 37. Question 5 ASD Research Funding from 2008-2012. Overall, funding for Question 5 was lower than some other areas of the Strategic Plan, but it increased over the five-year span. An estimated line for 2010 was included to depict the same methodology for prorated rates made in 2011 and 2012.
## Question 5 Multiyear Funding Table

### IACC Strategic Plan Objectives

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Support two studies that assess how variations in and access to services affect family functioning in diverse populations, including underserved populations, by 2012.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IACC Recommended Budget:</strong> $1,000,000 over 3 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>5.S.A.</strong></td>
<td>$0</td>
<td>$499,999</td>
<td>$2,061,834</td>
<td>$1,351,793</td>
<td>$1,364,087</td>
<td><strong>$5,277,713</strong></td>
</tr>
<tr>
<td><strong>Funding:</strong></td>
<td>0 projects</td>
<td>1 project</td>
<td>9 projects</td>
<td>8 projects</td>
<td>6 projects</td>
<td><strong>5.S.A.</strong></td>
</tr>
</tbody>
</table>

**5.S.A. Funding:** The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.

**Progress:** The initial target of two studies was met, with 1-9 projects supported per year, but more work is still needed in this area.

**Remaining Gaps, Needs, and Opportunities:** The projects under this objective cover several topics related to family functioning and health disparities, but not the full breadth of the gaps mentioned in the objective. This objective, as written, may be too broad. Work is still needed to understand why underserved populations have poorer outcomes and what can be done to close the gaps. We need to understand what portfolio of services will result in the best outcomes for different populations. To address these questions, a qualitative approach (i.e., needs assessment or survey) may be needed to understand the context of barriers faced by different groups. Research on disparities needs to move beyond observational studies to experimental designs to see what approaches work best in different populations and settings.

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Conduct one study to examine how self-directed community-based services and supports impact children, youth, and adults with ASD across the spectrum by 2014.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IACC Recommended Budget:</strong> $6,000,000 over 3 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>5.S.B.</strong></td>
<td>N/A</td>
<td>$446,340</td>
<td>$291,635</td>
<td>$0</td>
<td>$0</td>
<td><strong>$737,975</strong></td>
</tr>
<tr>
<td><strong>Funding:</strong></td>
<td>6 projects</td>
<td>6 projects</td>
<td>1 project</td>
<td>0 projects</td>
<td>0 projects</td>
<td></td>
</tr>
</tbody>
</table>

**5.S.B. Funding:** The recommended budget was partially met.

**Progress:** More work is needed in this area to achieve the goals set forth by the objective. While more than the number of studies called for have been supported, the area is underfunded (the projects have been small) and the projects do not examine all areas targeted in the objective.

**Remaining Gaps, Needs, and Opportunities:** Several of the funded projects relate to recreational activities, but more projects that focus on issues such as housing, employment, and quality of life (self-direction) are needed. Issues such as housing and employment may not be reflected in the portfolio data because the agencies and organizations included in the analysis may not have these topics as a primary focus, and many housing and employment-related efforts may not be specific to ASD. This area may benefit from a “practice to research” approach where already-operating programs can be evaluated for efficacy and this may help to develop more easily implementable services. Work is also needed to determine what outcome measures are informative and useful. Another issue is the scalability, as many vocational projects are very small and intensive and this is not an effective model for broad implementation. Potential funding mechanisms for these evaluations include the Dept. of Education Institute of Educational Science program for partnering researchers and educators and the NIMH Research Initiative for Scientific Enhancement (RISE) R25 program.

---

*Question 5 Multiyear Funding Table, see appendix for a color-coding key and further details.*
### IACC Strategic Plan Objectives

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implement and evaluate five models of policy and practice-level coordination among State and local agencies to provide integrated and comprehensive community-based supports and services that enhance access to services and supports, self-determination, economic self-sufficiency, and quality of life for people with ASD across the spectrum and their families, (which may include access to augmentative and alternative communication [AAC] technology), with at least one project aimed at the needs of transitioning youth and at least one study to evaluate a model of policy and practice-level coordination among State and local mental health agencies serving people with ASD, by 2015.</td>
<td>N/A</td>
<td>5.S.C</td>
<td>5.S.C</td>
<td>5.S.C</td>
<td>5.S.C</td>
<td>$5,425,315</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>$4,225,315</td>
<td>$600,000</td>
<td>$600,000</td>
<td>2 projects</td>
<td></td>
</tr>
<tr>
<td><strong>5.S.C. Funding:</strong> The recommended budget was partially met.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Progress:</strong> Progress has been made but the objective is not fully achieved, as it is under-funded and the projects do not cover all of the issues mentioned in the objective.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Remaining Gaps, Needs, and Opportunities:</strong> Studying services coordination is very difficult and it is hard to define outcomes. State to state dissemination is very limited and fragmented. Also, state policies often are translated to practice very differently in different areas and counties. State and local services programs also suffer from a lack of knowledge in how to engage and sustain community partnerships. A pairing of existing state and local services programs (including those that may be participating in federally-funded state demonstration programs) with research funding for evaluation would be the most cost-effective way to collect and analyze data about the implementation of models of coordination. For example, building research projects onto existing state demonstration programs and supporting the development of partnerships between academic researchers and state agencies to study models of policy implementation would be ways to advance this type of research.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Support two studies to examine health, safety, and mortality issues for people with ASD by 2012.  
**IACC Recommended Budget:** $4,500,000 over 3 years

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>5.S.D</td>
<td>5.S.D</td>
<td>5.S.D</td>
<td>$164,135</td>
<td></td>
</tr>
<tr>
<td>0 projects</td>
<td>$159,135</td>
<td>$0</td>
<td>3 projects</td>
<td>1 project</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**5.S.D. Funding:** The recommended budget was not met; the funding allocated to projects specific to this objective falls far short of the recommendation.

**Progress:** More work is needed on this objective; studies have been funded in this area (e.g., wandering, victimization), but they are small and they do not address all issues within this objective.

**Remaining Gaps, Needs, and Opportunities:** There may be some projects in other Strategic Plan Questions that are related to this objective (i.e., the Utah epidemiological study coded to Question 7 that examines health risks and causes of mortality). There is ongoing data mining of existing data sets to identify risks, new methods of prevention, methods of recovery, and best practices. Best practices need to be developed to respond to wandering (prevention, response, and search). A “practice to research” model, where data are collected in the process of delivering services, would also be appropriate. One issue that is underrepresented in the portfolio is sexual/reproductive health communication for adolescents and adults with ASD. In general, adult needs are not well-represented in the current research.

---

**Question 5 Multiyear Funding Table, see appendix for a color-coding key and further details.**
Question 5 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Year</td>
</tr>
<tr>
<td>Test four methods to improve dissemination, implementation, and sustainability of evidence-based interventions, services, and supports in diverse community settings by 2013.</td>
<td>5.4</td>
</tr>
<tr>
<td></td>
<td>5.4A</td>
</tr>
<tr>
<td>IACC Recommended Budget: $7,000,000 over 5 years</td>
<td>5.4A</td>
</tr>
<tr>
<td><strong>5.4A. Funding:</strong> The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.</td>
<td></td>
</tr>
<tr>
<td><strong>Progress:</strong> This is a very broad objective, and a lot of research is being supported in this area. More work is needed, however, to cover the range of topics addressed in the objective.</td>
<td></td>
</tr>
<tr>
<td><strong>Remaining Gaps, Needs, and Opportunities:</strong> Specifically, the requirement of projects looking at diverse community settings has not been met. Most of the projects listed are not focused on dissemination or may be using a model that is not well-translated to autism. Dissemination should be part of a grant application and this should be rigorously enforced. An opportunity in this area would be to create and support training institutes within existing networks that are focused on implementation and dissemination.</td>
<td></td>
</tr>
</tbody>
</table>

| Test the efficacy and cost-effectiveness of at least four evidence-based services and supports for people with ASD across the spectrum and of all ages living in community settings by 2015. | 5.3  | 0 projects | 5 projects | 0 projects | 0 projects | 1 project | $603,717 |
| 5.3A | $0 | $103,722 | $0 | $0 | $499,995 |
| IACC Recommended Budget: $16,700,000 over 5 years | 5.3A | 0 projects | 5 projects | 0 projects | 0 projects |
| **5.3A. Funding:** The recommended budget was not met; the funding allocated to projects specific to this objective falls far short of the recommendation. |  |  |  |  |  |  |
| **Progress:** There are ongoing projects under this objective with regard to efficacy but not cost-effectiveness. More work is needed and in general, the intention of this objective has not been achieved. |  |  |  |  |  |  |
| **Remaining Gaps, Needs, and Opportunities:** Cost-effectiveness evaluations have to be paired with randomized controlled trials (RCTs). Efforts should be made to build onto existing efforts by adding cost-effectiveness evaluation to existing RCTs. Administrative supplements may help to achieve those additions. There are not well established autism-specific measures of cost-effectiveness. Some barriers to achieving this objective include the need for a long follow up period, which often is not possible due to the cost of running longer term trials. Also, these projects often do not receive favorable scores during grant review because review favors tightly controlled experimental designs rather than experimentation in real-world conditions. |  |  |  |  |  |  |

Question 5 Multiyear Funding Table, see appendix for a color-coding key and further details.
### Question 5 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Funding</th>
<th></th>
<th></th>
<th></th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year</strong></td>
<td><strong>2008</strong></td>
<td><strong>2009</strong></td>
<td><strong>2010</strong></td>
<td><strong>2011</strong></td>
<td><strong>2012</strong></td>
</tr>
<tr>
<td>Evaluate new and existing pre-service and in-service training to increase skill levels in service providers, including direct support workers, parents and legal guardians, education staff, and public service workers, to benefit the spectrum of people with ASD and to promote interdisciplinary practice by 2015.</td>
<td><strong>6.3</strong></td>
<td><strong>5.L.C</strong></td>
<td><strong>5.L.C</strong></td>
<td><strong>5.L.C</strong></td>
<td><strong>5.L.C</strong></td>
</tr>
<tr>
<td></td>
<td>$30,000</td>
<td>$132,494</td>
<td>$36,433,257</td>
<td>$6,048,734</td>
<td>$3,724,262</td>
</tr>
<tr>
<td></td>
<td>1 project</td>
<td>6 projects</td>
<td>83 projects</td>
<td>30 projects</td>
<td>29 projects</td>
</tr>
<tr>
<td><strong>IACC Recommended Budget:</strong> $8,000,000 over 5 years</td>
<td><strong>5.L.C. Funding:</strong> The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.</td>
<td><strong>Progress:</strong> Many projects have been funded in this area. However, there is an ongoing need for support of efforts in this area.</td>
<td><strong>Remaining Gaps, Needs, and Opportunities:</strong> Significant workforce needs remain, especially with regard to paraprofessionals. With all studies in this objective, there remains an issue of scale. Most training programs are designed for small groups. In order for training to be effective at the community level, it has to be able to scale up for broad dissemination, so training programs need to be evaluated for their potential to be scaled up. Comparative effectiveness studies of training models are needed to illuminate whether or not providers need more training, which populations require which training methods, and which training methods are most effective.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evaluate at least two strategies or programs to increase the health and safety of people with ASD that simultaneously consider principles of self-determination and personal autonomy by 2015.</td>
<td><strong>5.L.D</strong></td>
<td><strong>5.L.D</strong></td>
<td><strong>5.L.D</strong></td>
<td><strong>5.L.D</strong></td>
<td><strong>5.L.D</strong></td>
</tr>
<tr>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td>$296,840</td>
<td>$279,999</td>
<td>$54,999</td>
</tr>
<tr>
<td></td>
<td>5 projects</td>
<td>4 projects</td>
<td>3 projects</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IACC Recommended Budget:</strong> $2,000,000 over 2 years</td>
<td><strong>5.L.D. Funding:</strong> The recommended budget was small yet was partially met.</td>
<td><strong>Progress:</strong> Though more than the two studies recommended as a minimum have been funded in this area, more work is needed. This objective overlaps significantly with 5.S.D and also with 4.S.H. In the future, perhaps these objectives should be collapsed and combined.</td>
<td><strong>Remaining Gaps, Needs, and Opportunities:</strong> Obesity is an important issue related to this objective that is currently not represented to a great extent in the portfolio. It is therefore an area where, moving forward, there should be more focus.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Question 5 Multiyear Funding Table, see appendix for a color-coding key and further details.*
Question 5 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Support three studies of dental health issues for people with ASD by 2015.</strong> This should include:</td>
<td>N/A</td>
<td>N/A</td>
<td>$196,457</td>
<td>$443,860</td>
<td>$307,784</td>
<td>$948,101</td>
</tr>
<tr>
<td>• One study on the cost-benefit of providing comprehensive dental services, including routine, non-emergency medical and surgical dental services, denture coverage, and sedation dentistry to adults with ASD as compared to emergency and/or no treatment.</td>
<td></td>
<td></td>
<td>2 projects</td>
<td>3 projects</td>
<td>2 projects</td>
<td></td>
</tr>
<tr>
<td>• One study focusing on the provision of accessible, person-centered, equitable, effective, safe, and efficient dental services to people with ASD.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• One study evaluating pre-service and in-service training program to increase skill levels in oral health professionals to benefit people with ASD and promote interdisciplinary practice.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IACC Recommended Budget:</strong> $900,000 over 3 years for each sub-objective ($2,700,000 total)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**5.L.E. Funding:** The recommended budget was partially met.

**Progress:** While several important projects have been funded in this area, there is a gap in projects that focus on dental services for adults and training for dentists working with autistic adults.

**Remaining Gaps, Needs, and Opportunities:** While the funded studies focus on behavior management, a more comprehensive health focus is needed to address the dental needs of children and adults with ASD. This objective is very specific, but there are other important primary health care needs for people with ASD that need to be addressed. In the future, perhaps this topic could be collapsed under a broader general objective that addresses primary health care needs (combined with 5.S.D, 5.L.D). If a new objective were to be written, other important primary care issues such as mental health services should be included.

<table>
<thead>
<tr>
<th>Not specific to any objective (Core/Other Activities)</th>
<th>$1,247,714</th>
<th>$2,004,687</th>
<th>$13,436,737</th>
<th>$11,553,704</th>
<th>$9,060,297</th>
<th>$37,303,139</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Core/Other Activities</td>
<td>5 projects</td>
<td>8 projects</td>
<td>66 projects</td>
<td>63 projects</td>
<td>62 projects</td>
<td></td>
</tr>
<tr>
<td>5. Core/Other Activities</td>
<td>$1,247,714</td>
<td>$2,004,687</td>
<td>$13,436,737</td>
<td>$11,553,704</td>
<td>$9,060,297</td>
<td></td>
</tr>
</tbody>
</table>

**Reported funding for Question 5**

<table>
<thead>
<tr>
<th>5, Core/Other Activities</th>
<th>$1,685,222</th>
<th>$8,648,050</th>
<th>$64,849,122</th>
<th>$22,827,101</th>
<th>$124,128,399</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 projects</td>
<td>13 projects</td>
<td>36 projects</td>
<td>211 projects</td>
<td>137 projects</td>
<td>138 projects</td>
</tr>
<tr>
<td>5, Core/Other Activities</td>
<td>$1,685,222</td>
<td>$8,648,050</td>
<td>$64,849,122</td>
<td>$22,827,101</td>
<td></td>
</tr>
</tbody>
</table>

**Adjusted funding for Question 5**

<table>
<thead>
<tr>
<th>5, Core/Other Activities</th>
<th>$3,874,552</th>
<th>$8,648,050</th>
<th>$64,849,122</th>
<th>$22,827,101</th>
<th>$126,317,730</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 projects</td>
<td>36 projects</td>
<td>211 projects</td>
<td>137 projects</td>
<td>138 projects</td>
<td></td>
</tr>
<tr>
<td>5, Core/Other Activities</td>
<td>$3,874,552</td>
<td>$8,648,050</td>
<td>$64,849,122</td>
<td>$22,827,101</td>
<td></td>
</tr>
</tbody>
</table>

Question 5 Multiyear Funding Table, see appendix for a color-coding key and further details.

*The “Reported funding” totals reflect the funding and projects originally coded to this Question of the Strategic Plan, as reported in the Portfolio Analysis Report corresponding to the year indicated at the top of the column. When reading each column of the table vertically, please note that the projects and funding associated with each objective for the years 2008 and 2009 may not add up to the reported funding total at the bottom of the column; this is due to adjustments made to account for revisions in the Strategic Plan, which caused the shifting of some objectives to other Questions under the Plan. The projects and funding associated with these reclassified objectives are now reflected under the Question in which they appear in the 2011 Strategic Plan.*

*The “Adjusted funding” total reflects funding for projects aligned to objectives in the 2011 IACC Strategic Plan (the most recent version in which objectives were revised) and incorporates funding for projects that may have been coded differently under previous versions of the Plan.*

Table 9. Multiyear Funding Table for Question 5.
QUESTION 6: LIFESPAN ISSUES

Aspirational Goal: All people with ASD will have the opportunity to lead self-determined lives in the community of their choice through school, work, community participation, meaningful relationships, and access to necessary and individualized services and supports.

Research Focus of Question 6

With increasing societal awareness of the needs of people on the autism spectrum across the lifespan, Question 6 addresses the question “What does the future hold, particularly for adults?” Question 6 encompasses research to identify and address issues surrounding transition to adulthood, access to services across the lifespan, and quality of life. Some of the research in Question 6 represents projects that assess the long-term outcomes (in terms of measures such as quality of life, health, independence, and employment) for people on the autism spectrum, particularly with respect to interventions and services they might have received. Many projects assigned to Question 6 focus on adolescents transitioning from the education system to employment, as well as vocational/job skills and social skills training for both transitional aged youth and adults.

Analysis of Question 6 Portfolio 2011-2012

Funding allocated to projects on lifespan issues addressed by Question 6 represented the smallest segment of ASD research funding. In 2011 and 2012, projects in Question 6 received 2% ($4.9 million) and 1% ($3.9 million) of overall ASD funding respectively, similar to the investment made in 2010 (2%, $6.6 million). When considering number of projects, Question 6 made up only 3% of the whole ASD portfolio, with 35 projects in 2011 and 34 projects in 2012. However, it is important to note that some projects that address lifespan issues, such as transition programs aimed at adolescents and their families as well as evaluation of practitioner training focused on transition-age youth, were better captured by objectives in other questions, and thus were not categorized into Question 6.

In 2011, progress was made in seven of the eight Question 6 objectives. In 2012, seven objectives had active projects, but overall, most of the objectives in Question 6 were far below recommended funding levels. A full list of objectives and their progress can be found in Table 10.
The majority of the projects assigned to Question 6 fit into the Question 6 objectives. In 2011, 1% ($50,000) of the funding went to projects designated as Core/Other, and in 2012, 22% ($0.8 million) of the funding went to projects designated as Core/Other (Figure 38).

Projects focused on developing community-based interventions for adults (6.L.A) received the largest portion of Question 6 funding in 2011 (44%, $2.2 million). This was followed by Objective 6.L.B, which calls for research to determine how interventions, services, and supports delivered during childhood impact adult health and quality of life outcomes; this objective received $1.3 million (28%) in 2011, meeting the annualized budget target, but only had $0.6 million in funding in 2012, and fell short of the overall recommended budget (yellow light). Research to evaluate existing programs for youth transitioning to adulthood (6.S.B) accounts for 14% ($0.7 million) in 2011, and studies assessing the quality of life of adults as it relates to characteristics of the service delivery system (6.S.A) accounted for 11% ($0.5 million) in 2011. The same four objectives continued to receive the most funding in 2012, and were as follows: 6.S.A (26%, $1.0 million), 6.S.B (18%, $0.7 million), 6.L.B (17%, $0.6 million), and 6.L.A (16%, $0.6 million). The remaining three objectives with active projects received 2% or less of the 2011 and 2012 Question 6 funding.

In 2011 and 2012, only one objective lacked any active projects. This objective (6.L.C) calls for comparative effectiveness research (which includes a cost-effectiveness component) into how community-based interventions, services, and supports improve health outcomes and quality of life for adults. Although there were two projects in this objective in 2010, leading to a yellow light for total funding, comparative effectiveness research in the area of lifespan issues remains quite limited and underfunded.
Examples of Topics Addressed by Projects in Core/Other:
- Studies of social and occupational status, as well as other indicators in the population of adults with ASD
- Comparative effectiveness of interventions for adolescents and young adults
- Research and evaluation of housing needs for adults with ASD
- Evaluation of the experiences and needs of adults with ASD for various types of services
- Transition and support programs to help students with ASD graduate and achieve career goals

Figure 38. Most ASD research projects in Question 6 were coded to specific objectives; those that did not fit within the IACC Strategic Plan objectives were coded as Core/Other. Examples of topics addressed by projects in Core/Other are listed above.
Question 6 Subcategory Analysis

Because Question 6 had so few assigned projects (35 projects in 2011 and 34 projects in 2012) and only $3.9 million of total ASD funding in 2012, and many projects encompassed more than one topic for example, one project explores the role of self-determination, social skills, job search strategies, use of transportation, and rehabilitation services on employment outcomes among transition-age youth, it was difficult to formulate and group the research into subcategories in the same fashion as was done for other questions. However, this will likely change as the research field concerned with ASD across the lifespan grows and matures, allowing the development of subcategories in the future.

Progress Made on Question 6 from 2008-2012

Table 10 describes the progress made on the eight research objectives within Question 6 over the five-year period from 2008-2012. The table also provides details regarding the status of funding for each objective, the status of research/scientific progress in each objective area, and information about remaining gaps, needs, and opportunities in each research area. Figure 39 shows the trend in Question 6 funding over time. Question 6 has received the smallest proportion of overall autism research funding from 2009-2012, in line with the very small number of projects assigned to this question. From 2009 to 2010, there was a small increase in funding, but from 2010 to 2012, funding generally leveled off at a low level. However, several of the objectives in Question 6 overlap with objectives from other questions which may have resulted in projects being assigned to other questions in the Strategic Plan; this may have contributed to this relatively low funding level.

Although total funding for Question 6 is low, all eight objectives have seen progress over the five-year span, though for some, the investment has been very low. Overall, many of the research needs related to adults on the autism spectrum and lifespan issues remain unmet, and more focus on this area is warranted.
Figure 39. Question 6 ASD Research Funding from 2008-2012. Funding for Question 6 stayed relatively low over the five-year span.
### IACC Strategic Plan Objectives

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$60,000</td>
<td>$20,000</td>
<td>$283,837</td>
<td>$542,193</td>
<td>$1,013,356</td>
<td>$1,919,186</td>
</tr>
<tr>
<td></td>
<td>1 project</td>
<td>1 project</td>
<td>2 projects</td>
<td>6 projects</td>
<td>10 projects</td>
<td></td>
</tr>
</tbody>
</table>

**6.2. Funding:** The recommended budget was partially met.  
**Progress:** More than (the recommended minimum of) two projects have been funded in this area, though the end goal of determining best practices has not yet been met. Still, this area is moving in the right direction as funding and projects have increased over time.  
**Remaining Gaps, Needs, and Opportunities:** There is a great need to develop standardized measures for quality of life for people with ASD, across both range of ability and lifespan.

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N/A</td>
<td>$0</td>
<td>$700,000</td>
<td>$700,000</td>
<td>$700,000</td>
<td>$2,100,000</td>
</tr>
<tr>
<td></td>
<td>0 projects</td>
<td>2 projects</td>
<td>2 projects</td>
<td>2 projects</td>
<td>2 projects</td>
<td></td>
</tr>
</tbody>
</table>

**6.S.B. Funding:** The recommended budget was partially met.  
**Progress:** More than (the recommended minimum of) one project was funded, meeting the initial target of this objective.  
**Remaining Gaps, Needs, and Opportunities:** Current projects relate to vocational rehabilitation, as called for in the objective, but no projects address Social Security programs, which remain a need. Also, looking at one model is too limited in scope, and stronger partnerships among programs would be beneficial for this objective. In the future, perhaps this objective could be expanded to include more projects and/or funding to examine other models.

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N/A</td>
<td>$0</td>
<td>$28,000</td>
<td>$28,000</td>
<td>$0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0 projects</td>
<td>1 project</td>
<td>1 project</td>
<td>1 project</td>
<td>1 project</td>
<td>$56,000</td>
</tr>
</tbody>
</table>

**6.S.C. Funding:** The recommended budget was not met; the funding allocated to projects specific to this objective falls far short of the recommendation.  
**Progress:** The objective called for a minimum of one project, and one small project to adapt the ADOS modules 1 and 2 for use in adults has been supported in this area, but most likely multiple projects testing various approaches, followed by intense efforts to refine the instruments, would be needed to develop a set of tools that could be used in different settings to diagnose adults.  
**Remaining Gaps, Needs, and Opportunities:** In addition to developing tools that can be used for screening and diagnosis in adults, it is critical to ensure that diagnosis links to a plan for intervention and/or service provision for diagnosed adults, resulting in improved outcomes.
## Question 6 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Funding</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year</strong></td>
<td><strong>2008</strong></td>
<td><strong>2009</strong></td>
</tr>
<tr>
<td>Conduct at least one study to measure and improve the quality of lifelong supports being</td>
<td>N/A</td>
<td>6.S.D</td>
</tr>
<tr>
<td>delivered in community settings to adults across the spectrum with ASD through provision of</td>
<td></td>
<td>$0</td>
</tr>
<tr>
<td>specialized training for direct care staff, parents, and legal guardians, including assessment</td>
<td></td>
<td>0 projects</td>
</tr>
<tr>
<td>and development of ASD-specific training, if necessary, by 2015.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IACC Recommended Budget:</strong> $7,500,000 over 3 years</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 6.S.D. Funding: The recommended budget was not met; the funding allocated to projects specific to this objective falls far short of the recommendation.

### Progress: While more than one project has been funded, and the objective called for one project at minimum, the current funding and projects for this objective are not likely to meet the intent of the objective. Also, the few projects funded do not address the full range of issues mentioned in this objective.

### Remaining Gaps, Needs, and Opportunities: The projects under this objective focus on secondary students and transition age youth and there are no projects focusing on older adults. No new projects were funded in 2011 and 2012, though the goals of this objective are similar/overlapping to those of 5.L.C, and projects coded there may also represent progress on this objective. There is a need for effective training for healthcare staff and guardians that can be delivered cost-effectively on a large scale.

<table>
<thead>
<tr>
<th>Develop at least two individualized community-based interventions that improve quality-of-life or health outcomes for the spectrum of adults with ASD by 2015.</th>
<th>Funding</th>
<th>$5,565,325</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$0</td>
<td>$509,965</td>
</tr>
<tr>
<td></td>
<td>0 projects</td>
<td>2 projects</td>
</tr>
</tbody>
</table>

### 6.L.A. Funding: The recommended budget was partially met.

### Progress: Between 11 and 18 projects were supported each year between 2010 and 2012. Progress is being made; however, a sustained effort is needed to fully achieve the goals set forth by this objective. Funding for projects specific to this objective was substantially lower in 2012 than previous years, which is a concern.

### Remaining Gaps, Needs, and Opportunities: Work focused on adults with ASD lags behind that focused on children and adolescents. This objective is similar to 6.S.A – it might be helpful to separate the outcomes of interest to better assess progress. Also, quality of life outcome measures are needed to know if interventions are working.

<table>
<thead>
<tr>
<th>Conduct one study that builds on carefully characterized cohorts of children and youth with ASD to determine how interventions, services, and supports delivered during childhood impact adult health and quality of life outcomes by 2015.</th>
<th>Funding</th>
<th>$3,986,983</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$718,290</td>
<td>$1,280,790</td>
</tr>
<tr>
<td></td>
<td>2 projects</td>
<td>3 projects</td>
</tr>
</tbody>
</table>

### 6.L.B. Funding: The recommended budget was partially met.

### Progress: More than the minimum of one recommended project was funded. However, the projects have not answered all of the questions regarding long-term outcomes of interventions, services and supports received during childhood and more research is needed in this area.

### Remaining Gaps, Needs, and Opportunities: More than one study would be useful for this objective, including a focus on the benefits of early intervention. The barrier of the high cost of conducting these types of studies could be mitigated by capitalizing on partnerships between groups and on existing infrastructure.
### Question 6 Multiyear Funding Table

**IACC Strategic Plan Objectives**

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 projects</td>
<td>2 projects</td>
<td>0 projects</td>
<td>0 projects</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**6.L.C. Funding:** The recommended budget was not met; the funding allocated to projects specific to this objective falls far short of the recommendation.

**Progress:** Not nearly enough funding and projects have been devoted to this objective much more work needs to be done.

**Remaining Gaps, Needs, and Opportunities:** Projects regarding service and support needs of older adults are needed; however, there is a question about whether there are yet enough empirically sound adult interventions to make it possible to do comparative effectiveness studies. It could be useful to separate out specific populations, topics (housing, transitions, etc.) or outcomes in order to better assess progress. A characterization of current resources and how well they’re working is needed for this objective, which is the goal of the newly released report from *The State of the States* project. The current focus of the field on the transition to adulthood should be expanded to include the full lifespan.

**IACC Recommended Budget:** $8,000,000 over 5 years

---

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 projects</td>
<td>0 projects</td>
<td>$75,000</td>
<td>2 projects</td>
<td>3 projects</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**6.L.D. Funding:** The recommended budget was not met; the funding allocated to projects specific to this objective falls far short of the recommendation.

**Progress:** There is an inadequate amount of projects and funding for this objective. The funded studies are economic analyses, but there is a lack of comparative effectiveness research in adults that are ready to be tested in real-world settings, and thus, there are no projects that move to this next level.

**Remaining Gaps, Needs, and Opportunities:** There is a huge gap in adult prevalence research, and in identifying relevant real-world settings for adults with ASD. Identifying the needs of adults with ASD remains important (a needs assessment is needed), and research involving ASD subjects beyond the age of 18 is both lacking and vital.

**IACC Recommended Budget:** $4,000,000 over 5 years

---

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>6. Core/ Other Activities</td>
<td>6. Core/ Other Activities</td>
<td>6. Core/ Other Activities</td>
<td>6. Core/ Other Activities</td>
<td>6. Core/ Other Activities</td>
<td>$2,179,302</td>
</tr>
<tr>
<td>2 projects</td>
<td>2 projects</td>
<td>3 projects</td>
<td>3 projects</td>
<td>4 projects</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Not specific to any objective (Core/Other Activities)**

**Reported funding for Question 6**

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>$9,796,491</td>
<td>$1,407,699</td>
<td>$6,643,124</td>
<td>$4,897,920</td>
<td>$3,859,177</td>
<td>$26,604,411</td>
<td></td>
</tr>
<tr>
<td>9 projects</td>
<td>7 projects</td>
<td>34 projects</td>
<td>35 projects</td>
<td>34 projects</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Adjusted funding for Question 6**

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>$527,683</td>
<td>$1,407,699</td>
<td>$6,643,124</td>
<td>$4,897,920</td>
<td>$3,859,177</td>
<td>$17,335,603</td>
<td></td>
</tr>
<tr>
<td>3 projects</td>
<td>7 projects</td>
<td>34 projects</td>
<td>35 projects</td>
<td>34 projects</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 10. Multiyear Funding Table for Question 6.**
QUESTION 7: INFRASTRUCTURE AND SURVEILLANCE

Aspirational Goal: Develop and support infrastructure and surveillance systems that advance the speed, efficacy, and dissemination of ASD research.

Research Focus of Question 7

Question 7 (“What other infrastructure and surveillance needs must be met?”) covers the topics of research infrastructure, data sharing, workforce development, ASD surveillance, and communication/dissemination of research findings and evidence-based practices. With 16 objectives, Question 7 has the greatest number of objectives of all seven questions in the Strategic Plan.

Analysis of Question 7 Portfolio 2011-2012

Objectives in Question 7 comprised 15% ($43.9 million) and 14% ($47.5 million) of the overall funding for ASD research in 2011 and 2012 respectively. While approximately 15% of the overall funding is allocated to Question 7, only 9% of the total project count in 2011 (111 projects) and 2012 (112 projects). This can partially be attributed to the high cost of large scale resources that support numerous researchers and projects such as biobanks, databases, clinics, and surveillance networks. By comparison, projects assigned to other questions are more likely to support individual research projects, and are therefore smaller in size.

In 2011, 11 of the 16 Question 7 objectives were active. Five objectives showed no progress in 2011. Table 11 provides a full list of Question 7 objectives and details of their progress. The objective that received the largest portion of funding in Question 7 (7.D) supports biobanks containing samples from individuals with ASD to be used in research (19%, $8.5 million). This was followed closely by Objective 7.N, which called for support for clinical research sites, such as the Autism Treatment Network (ATN) to collect and coordinate diagnostic, biological, medical, and treatment history data that would provide a platform for effectiveness research and clinical trials of novel autism treatments (17%, $7.4 million). Overall, 28% ($12.3 million) of the funding for projects in Question 7 was generally related to research involving infrastructure or surveillance, but not specific to an objective within that question, and thus was assigned to Core/Other (Figure 40).
In 2012, 12 of the 16 Question 7 Objectives were active. As in 2011, four objectives showed no activity in 2012, though one of those objectives (7.P) had been previously completed in 2010. The three other objectives that had no projects in 2012 and were assigned an overall red light status, including objectives to support a needs assessment toward linkage of administrative databases (7.A), replication studies (7.F), and promising practices papers about successful services delivery strategies (7.M). The Committee felt that a needs assessment toward database linkage was still a need, but the IACC was uncertain of whether the objective to develop a mechanism to support replication studies was feasible, and of whether or not promising practices papers had been replaced by other modes of dissemination. Objective 7.K, which supports investment targeted toward expansion and development of the research workforce, received the largest portion of funding in Question 7 (22%, $10.0 million). This was followed by Objective 7.I, which supplements existing Autism and Developmental Disabilities Monitoring (ADDM) Network surveillance sites to gather prevalence estimates of ASD in different regions of the country (13%, $6.0 million). Similar to 2011, 35% ($16.9 million) of the funding for projects in Question 7 in 2012 was generally related to research involving infrastructure or surveillance, but was not specific to an objective within that question, so was designated as Core/Other (Figure 40).

Objective 7.G, which calls for the development of a web-based tool that provides population estimates of ASD prevalence, had been inactive since its conception in 2010, and was reported as thus in 2011. However, in 2012, the CDC released an environmental tracking web tool which completed the requirements of this objective, changing the objective’s status to a green light in 2012. Because this web tool is used for multiple conditions and is not specific to ASD, the funding for the project was not counted in ASD research funding totals (thus in 2012, this objective had 1 project with $0).
Examples of Topics Addressed by Projects in Core/Other:
Administrative and infrastructure development
Subject assessment and recruitment for studies
Development of ASD research registries
Creation of ASD research databases

Figure 40. Roughly two thirds of ASD research projects in Question 7 were coded to specific objectives; projects that did not fit within the IACC Strategic Plan objectives were coded as Core/Other. Examples of topics addressed by projects listed in Core/Other are listed above.
**Question 7 Subcategory Analysis**

Projects within Question 7 accounted for $43.9 million of total funding in 2011 and $47.5 million in 2012. The six subcategories in Question 7 reflect the broad array of ASD research infrastructure needs that have been identified by the IACC: Biobanks; Data tools; Research infrastructure; Research recruitment and clinical care; Research workforce development; and Surveillance and prevalence studies (Figures 41 and 42).

In 2011, Question 7 funding was relatively evenly distributed across the subcategories, with funding for general Research infrastructure representing the largest area of investment, with 24% of the funding for Question 7. This was followed by support for Biobanks that collect DNA and tissue samples from autism patients, and Data tools such as the National Database for Autism Research (NDAR) and the Autism Genetics Resource Exchange (AGRE), which both received 19% of the total funding. Research recruitment and clinical care, which help increase participation in research studies and conduct medical evaluations of participants, accounts for 15% of funding. Surveillance and prevalence studies conducted through the ADDM Network and internationally received 14% of funding. Research workforce development, which supports many conferences and training for autism researchers, received 9% of Question 7 funding.

In 2012, Research infrastructure remained the most highly-funded subcategory, accounting for 32% of Question 7 funding. Investment in Research workforce development represented 22% of funding. This was followed by Data tools (17%), and Surveillance and prevalence studies (15%), Research recruitment and clinical care (8%), and Biobanks (6%). The figures also list Federal and private funders of research that fits within the Strategic Plan Question 7 category.
**2011**

**QUESTION 7: INFRASTRUCTURE AND SURVEILLANCE – Funding by Subcategories**

Total Funding: $43,855,291  
Number of Projects: 111

- **Research Infrastructure** 24% ($10,451,416)  
  16 projects
- **Biobanks** 19% ($8,531,425)  
  6 projects
- **Data Tools** 19% ($8,331,203)  
  8 projects
- **Research Recruitment and Clinical Care** 15% ($6,469,315)  
  29 projects
- **Surveillance and Prevalence Studies** 14% ($6,179,419)  
  25 projects
- **Research Workforce Development** 9% ($3,892,514)  
  27 projects

**Federal Funders**
- Centers for Disease Control and Prevention
- Centers for Medicare & Medicaid Services
- Department of Defense-Air Force
- Department of Education
- Health Resources and Services Administration
- National Institutes of Health

**Private Funders**
- Autism Science Foundation
- Autism Speaks
- Simons Foundation

Figure 41. The six subcategories in Question 7 (Infrastructure and Surveillance) encompass a diverse set of project types, with funding distributed relatively evenly across them. In 2011, **Research infrastructure** received 24% of the funding, followed by support for **Data tools** and **Biobanks**, each with 19%. **Research recruitment and clinical care** received 15% of funding, **Surveillance and prevalence studies** received 14%, and **Research workforce development** received 9%. The figure also lists Federal and private funders of research that fits within the Strategic Plan Question 7 category.
2012
QUESTION 7: INFRASTRUCTURE AND SURVEILLANCE – Funding by Subcategories
Total Funding: $47,516,197
Number of Projects: 112

- Surveillance and Prevalence Studies: 15% ($7,060,490), 24 projects
- Biobanks: 6% ($2,950,550), 5 projects
- Data Tools: 17% ($7,969,191), 11 projects
- Research Infrastructure: 32% ($14,970,199), 19 projects
- Research Recruitment and Clinical Care: 8% ($3,922,481), 29 projects
- Research Workforce Development: 22% ($10,643,285), 24 projects
- Surveillance and Prevalence Studies: 15% ($7,060,490), 24 projects

Federal Funders:
- Centers for Disease Control and Prevention
- Centers for Medicare & Medicaid Services
- Department of Defense-Air Force
- Department of Education
- Health Resources and Services Administration
- National Institutes of Health

Private Funders:
- Autism Science Foundation
- Autism Speaks
- Simons Foundation

Figure 42. In 2012, Research infrastructure received 32% of the funding in Question 7 (Infrastructure and Surveillance), followed by Research workforce development with 22% of funding. Support and development of Data tools received 17% of funding, and Surveillance and prevalence studies received 15% of funding. A smaller portion of funding was allocated to Research recruitment and clinical care (8%) and Biobanks (6%). The figure also lists Federal and private funders of research that fits within the Strategic Plan Question 7 category.
Progress Made on Question 7 from 2008-2012

Table 11 describes the progress made on the 16 research objectives within Question 7 from 2009-2012 (Question 7 was not added to the Strategic Plan until the second year of the Portfolio Analysis, though some of the objectives later moved to Question 7 were originally developed earlier). The table also provides details regarding the status of funding for each objective, the status of research/scientific progress in each objective area, and information about remaining gaps, needs, and opportunities in each research area. Figure 43 shows the trend in Question 7 funding over time. Since 2009, when the collection of projects aligning with Question 7 began, there has been an increase in funding for research infrastructure projects from a low to a moderate level, representing significant investment that have been made over time in the core infrastructure that is needed to support ASD research. Funding levels plateaued between 2010 and 2012.

In the past five years, the majority of the 16 objectives under Question 7 have progressed. Funding for Objective 7.K, which promotes expansion of the research workforce, has also been consistently well-funded, indicative of the commitment of ASD research funders to investing in the development of the next generation of ASD researchers. A handful of objectives have not shown activity as captured by the portfolio analyses over the past five years. In some cases it is possible that the overall aim of an objective has been achieved through mechanisms not captured by the Portfolio Analyses. For example, Objective 7.G—which proposes the development of a web tool that provides population estimates of ASD prevalence—was accomplished with funding that was not captured by the Portfolio Analysis because the project was not specific to ASD.

---

8Since its inception in 2009, the Strategic Plan has been updated on an annual basis; however, the 2011 Strategic Plan is the most recent iteration where the objectives within the Strategic Plan were altered. Between 2009 and 2011, the updates involved significant restructuring of the Strategic Plan. This included the addition of Question 7, the addition of new objectives in other questions, as well as the renumbering and rewording of some objectives. Data included in each Portfolio Analysis report from 2008 to 2012 was categorized with respect to the most recent iteration of the Strategic Plan where the objectives had changed at the time of the analysis. Therefore, the 2008 Portfolio Analysis used the 2009 Strategic Plan, the 2009 Portfolio Analysis used the 2010 Strategic Plan, and both the 2010 Portfolio Analysis and the 2011-2012 Portfolio Analysis used the 2011 Strategic Plan. For the purpose of this five-year comparison, the objectives were aligned with the numbering used for the objectives in the 2011 Strategic Plan.
Figure 43. Question 7 ASD Research Funding from 2008-2012. Funding for Question 7 experienced an increase over the five-year span.
## Question 7 Multiyear Funding Table

### IACC Strategic Plan Objectives

<table>
<thead>
<tr>
<th>Objective</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year</strong></td>
<td><strong>2008</strong></td>
</tr>
<tr>
<td>6.A</td>
<td>$0</td>
</tr>
<tr>
<td>7.A</td>
<td>$0</td>
</tr>
<tr>
<td>7.B</td>
<td>$311,670</td>
</tr>
<tr>
<td>7.C</td>
<td>$6,767,808</td>
</tr>
</tbody>
</table>

### Conduct a needs assessment to determine how to merge or link administrative and/or surveillance databases that allow for tracking the involvement of people living with ASD in health care, education, and social services by 2009.

**IACC Recommended Budget:** $520,000 over 1 year

**7.A. Funding:** There has been no specific funding for projects addressing this objective.

**Progress:** The Planning Group is not aware of any efforts (projects or funding) that have been made to address this objective since it was created.

**Remaining Gaps, Needs, and Opportunities:** A needs assessment remains necessary due to issues surrounding patient privacy in linked databases and also to determine how tracking the involvement of people with ASD in health care, education, and social services is possible with existing tools and resources. It remains to be decided whether this should be a government-led effort or a public/private partnership. Such resources could be utilized by both the research and services provision communities.

### Conduct an annual “State of the States” assessment of existing State programs and supports for people and families living with ASD by 2011.

**IACC Recommended Budget:** $300,000 each year (revised in 2010)

**7.B. Funding:** The recommended budget was partially met.

**Progress:** Centers for Medicare & Medicaid Services (CMS) conducted a “State of the States” project and released a report summarizing the results of the study in 2014. The book *Autism Services Across America* by Dr. Peter Doehring also reviews existing programs and services across the states.

**Remaining Gaps, Needs, and Opportunities:** The initial State of the States study, overseen by CMS, was completed and published in 2014, but the objective calls for an annual study. Since the first study required multiple years to complete and since it is not clear if services will change enough yearly to warrant an annual study, this objective should be revisited with CMS to understand whether an annual study is the best approach.

### Develop and have available to the research community means by which to merge or link databases that allow for tracking the involvement of people in ASD research by 2010.

**IACC Recommended Budget:** $1,300,000 over 2 years

**7.C. Funding:** The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.

**Progress:** IAN and Group Health Cooperative Autism Registry are two examples of projects that are responsive to this objective. This objective should be considered to be met, with funding exceeding the recommended budget and a large number of diverse projects addressing this issue. NDAR, IAN and AGRE are all publicly available databases.

**Remaining Gaps, Needs, and Opportunities:** To advance this objective we need to encourage patients and families to join the registry. Compared to registry numbers for cystic fibrosis (100%), autism is behind at ~4% of patients enrolled in a registry. A table of the numbers of registrants by year would be an informative figure. We need more organized systems to improve participation.
### Question 7 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
</table>
| Establish and maintain an international network of biobanks for the collection of brain tissue, fibroblasts for pluripotent stem cells, and other tissue or biological material, by acquisition sites that use standardized protocols for phenotyping, collection, and regulated distribution of limited samples by 2011.  
- This includes support for post-processing of tissue, such as genotyping, RNA expression profiling, and MRI.  
- Protocols should be put into place to expand the capacities of ongoing large-scale children’s studies to collect and store additional biomaterials, including newborn bloodspots, promoting detection of biological signatures.  
- Support should also be provided to develop an international web-based digital brain atlas that would provide high-resolution 3-D images and quantitative anatomical data from tissue of patients with ASD and disease controls across the lifespan, which could serve as an online resource for quantitative morphological studies, by 2014.  
IACC Recommended Budget: $82,700,000 over 5 years (revised in 2011) | 2008 | 2.1 & 2.6 | $5,018,579 | 1 project & 1 project | 7.D | $436,815 | 2 projects | 7.D | $7,814,918 | 6 projects | 7.D | $8,531,425 | 6 projects | 7.D | $2,950,550 | 5 projects | **$24,752,287** |

**7.D. Funding:** The recommended budget was partially met. In terms of autism-specific projects, $24.7 million has been spent to date. Including non-autism-specific projects called for in the objective (i.e., the brain atlas), $59.6 million has been spent to date.

**Progress:** NIH launched a new multi-disorder Neurobiobank initiative in 2013. The $5 million effort encompasses autism and other brain disorders, and is not included in the 2008-2012 projects examined by the committee for this update because it began in 2013. A private effort, the Autism BrainNet, is also underway, with several collection/storage/distribution sites governed by a scientific board which distributes samples based on scientific merit of proposed projects to use the tissue. Though these two efforts represent progress, more work is needed to increase the amount of tissues available and to ensure good stewardship of these resources. The BrainSpan Atlas, supported by the Allen Brain Institute and a consortium of government and private funders, was completed and launched in 2011 and provides a powerful new resource for data on gene expression in the brain during development, but the project is not reflected in the 2008-2012 funding figures because it is not autism specific. In 2009, NIH supported the atlas with $18.4 million dollars and in 2010, NIH provided $16.5 million. The NIMH Repository and Genomics Resource is another resource that has continued to grow to meet the needs of researchers in many fields, including ASD research. Current sample numbers in the repository are: 28,300 DNA samples, with 15,700 samples that have been processed and prepared for distribution and 6,300 cases of autism represented. There are 21 fibroblast lines and 25 induced pluripotent stem cell lines.

**Remaining Gaps, Needs, and Opportunities:** While progress has been made in establishing, maintaining and expanding tissue resources for research, this is still an area of enormous need. Currently there may be fewer brain samples available for study than there were at the inception of the Strategic Plan due to the failure of a freezer at a major brain bank in 2012, which resulted in the loss of a large number of ASD brain specimens. There is also still a need for tissue and brains from neurotypical controls. Compared to other disorders, the number of tissue samples available for ASD research is quite low.
### Question 7 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year</strong></td>
<td>2008</td>
</tr>
<tr>
<td>Begin development of a web-based toolbox to assist researchers in effectively and responsibly disseminating their findings to the community, including people with ASD, their families, and health practitioners by 2011. <strong>IACC Recommended Budget: $400,000 over 2 years</strong></td>
<td>N/A</td>
</tr>
</tbody>
</table>

**7.E. Funding:** The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.

**Progress:** The goal of objective has been achieved in terms of efforts to help researchers more effectively disseminate their findings to the community online and in lay-friendly formats, but not through a web-based toolbox. For example, several agencies, organizations and groups (CDC, NIH, Simons Foundation, Autism Speaks, ASF, IAN) publish lay-friendly summaries of recent scientific findings online, as well as lay-friendly versions of their reports. In addition, the "Data from Papers" feature in NDAR connects readers from the Pubmed citation of a study to the actual data deposited in the database.

**Remaining Gaps, Needs, and Opportunities:** Though agencies and organizations are making active efforts to assist researchers with disseminating findings to the community via the web, access to information about research findings remains limited for those communities that are resource-poor and do not have internet access. In addition, the lack of open access to most peer-reviewed journals limits the public’s ability to access fully detailed information about new findings.

| Create funding mechanisms that encourage rapid replication studies of novel or critical findings by 2011. **No recommended budget assigned by the IACC** | N/A | 7.F $0 | 7.F $0 | 7.F $0 | 7.F $0 | **$0** |

**7.F. Funding:** There has been no specific funding for this objective.

**Progress:** There are no projects categorized to this objective. The Planning Group discussed the issue that creation of funding mechanisms is not likely to be achieved through grant funding, and therefore would not be reflected in the grant portfolio.

**Remaining Gaps, Needs, and Opportunities:** The Committee still feels that this objective is relevant and that it is not too early to begin replication studies. In the databases there are 70,000 subjects, 7,000 exomes and 2,500 MRIs that can be used for replication analysis. The intent of the objective was to quickly replicate findings related to potential treatments, but to date, no special fast-track funding mechanisms have been established to support this.

| Develop a web-based tool that provides population estimates of ASD prevalence for States based on the most recent prevalence range and average identified by the ADDM Network by 2012. **IACC Recommended Budget: $200,000 over 2 years** | N/A | 7.G $0 | 7.G $0 | 7.G $0 | 7.G $0 | **$0** |

**7.G. Funding:** Autism tracking data is captured in CDC's environmental tracking tool, which became available to the public in 2012, and is not reflected in the autism grant portfolio figure because it is a general tool that encompasses multiple disorders and conditions.

**Progress:** The intent of this objective has been accomplished through the CDC project and can be considered completed.

**Remaining Gaps, Needs, and Opportunities:** No new needs or opportunities in this area were identified.

*Question 7 Multiyear Funding Table, see appendix for a color-coding key and further details.*
### Question 7 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Create mechanisms to specifically support the contribution of data from 90% of newly initiated</td>
<td>N/A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$9,583,653</td>
</tr>
<tr>
<td>projects to the National Database for Autism Research (NDAR), and link NDAR with other existing</td>
<td>7.H</td>
<td>$1,932,996</td>
<td>$2,453,253</td>
<td>$1,517,596</td>
<td>$3,679,808</td>
<td></td>
</tr>
<tr>
<td>data resources by 2012.</td>
<td>2 projects</td>
<td>3 projects</td>
<td>1 project</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IACC Recommended Budget: $6,800,000 over 2 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**7.H. Funding:** The recommended budget for this objective was met.

**Progress:** The objective to create mechanisms to support the contribution of data from newly initiated projects to NDAR has been met, and NDAR has linked with several other existing data sources such as the ATP, AGRE and IAN. In 2012, 81% of NIH-funded extramural studies were contributing data to NDAR. All NIH grants have terms that require linking of data to NDAR.

**Remaining Gaps, Needs, and Opportunities:** Infrastructure will need continued development to enable greater availability of standardized data and analytical tools for cloud computing. IAN data collection could be expanded to include locations of residence to enable geographic data collection on environmental exposures.

| Supplement existing ADDM Network sites to use population-based surveillance data to conduct at | N/A        |            |            |            |            | $23,810,274 |
| least five hypothesis-driven analyses evaluating factors that may contribute to changes in ASD | 7.1        | $6,715,815 | $6,137,128 | $4,928,453 | $6,028,878 |            |
| prevalence by 2012.                                                                            | 15 projects | 13 projects | 13 projects |            |            |            |
| IACC Recommended Budget: $660,000 over 2 years                                               |            |            |            |            |            |            |

**7.1. Funding:** The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective. (Note that the funding amount for this objective reflects the full funding of the ADDM sites and not just the supplements.)

**Progress:** The research goals in the objective have been achieved. Initially, supplements were needed to support these analyses, but now the ADDM sites are well established and are conducting some analyses using funds from the ADDM grants themselves, while outside supplements are supporting other additional analyses.

**Remaining Gaps, Needs, and Opportunities:** Supplements remain an opportunity to capitalize on this infrastructure.

---

*Question 7 Multiyear Funding Table, see appendix for a color-coding key and further details.*
## Question 7 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year</td>
<td>2008</td>
</tr>
<tr>
<td>Develop the personnel and technical infrastructure to assist States, territories, and other countries that request assistance describing and investigating potential changes in the prevalence of ASD and other developmental disabilities by 2013.</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>IACC Recommended Budget:</strong> $1,650,000 over 3 years</td>
<td></td>
</tr>
<tr>
<td>7.J. <strong>Funding:</strong> The recommended budget was met. In addition, the Autism Speaks Global Health Initiative projects address this objective, though they have been coded to their specific scientific areas and are not represented in this funding amount. Also, the CDC provides personnel and help to States, territories and countries as requested, but the budget for that assistance is not reflected in the portfolio analysis figures because this work is not done through grants.</td>
<td></td>
</tr>
<tr>
<td><strong>Progress:</strong> Progress has been made in addressing this need, but not all responsive projects were reflected in the funding amount because some of them were conducted through sources not captured in the portfolio analysis (non-autism specific funding sources) or the projects were assigned according to their scientific topics rather than to this objective. In addition to providing supplemental funding for ADDM site surveillance, Autism Speaks funds projects on surveillance conducted by sites outside of the ADDM network, such as the Kwa-Zulu-Natal Autism Study in South Africa.</td>
<td></td>
</tr>
<tr>
<td><strong>Remaining Gaps, Needs, and Opportunities:</strong> While progress has been achieved, ongoing efforts are needed in this area.</td>
<td></td>
</tr>
</tbody>
</table>

| **IACC Recommended Budget:** $5,000,000 over 3 years | | | | | | |
| 7.K. **Funding:** The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective. Many of the fellowship grants are coded according to the specific topic of the research conducted and thus are not represented in this funding figure. | | | | | | |
| **Progress:** In 2008, NIH supported 46 autism related training/fellowship grants ($5.1 million), and in 2012 NIH supported 78 such grants ($7.7 million). | | | | | | |
| **Remaining Gaps, Needs, and Opportunities:** This objective should continue to be encouraged with a possible future emphasis on services-based research. | | | | | | |

*Question 7 Multiyear Funding Table, see appendix for a color-coding key and further details.*
## Question 7 Multiyear Funding Table

### IACC Strategic Plan Objectives

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$699,304</td>
<td>$1,429,602</td>
<td>$705,552</td>
<td>$847,002</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 projects</td>
<td>8 projects</td>
<td>6 projects</td>
<td>6 projects</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**7.L. Funding:** The recommended budget was partially met, but it is noted that the full funding of the ADDM sites is reflected in Objective 7.I. and thus there may be underrepresentation of funding in this category.

**Progress:** Supplements have been provided to six ADDM sites by CDC to collect data from a younger cohort (4-year-olds) in addition to the 8 year olds currently studied; two other ADDM sites have received supplements from CDC to conduct surveillance studies among 15 to 18 year olds. Despite these expansions, further work is needed to better understand prevalence in both younger and older populations. A current project at UNC is reassembling those who participated in TEACCH to conduct a study of long-term outcomes. Also, Paul Shattuck has published studies on young adults with disabilities seeking services that have revealed a significant drop in services use and access post-high school, along with an increased likelihood to remain living with a parent or guardian. In addition, the Utah cohort (mentioned in Question 6) has been used for studies related to adults with autism, with a recent paper identifying health risks and causes of mortality.

**Remaining Gaps, Needs, and Opportunities:** While subtypes were included as part of this objective, with the changes in the DSM to eliminate subtypes, this portion of the objective may no longer be relevant. In the future it may be more useful to collect data on characteristics of children and adults with ASD who participate in studies.

### Support 10 “Promising Practices” papers that describe innovative and successful services and supports being implemented in communities that benefit the full spectrum of people with ASD, which can be replicated in other communities, by 2015.

IACC Recommended Budget: $75,000 over 5 years

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>50</td>
<td>0 projects</td>
<td>50</td>
<td>0 projects</td>
<td>0 projects</td>
</tr>
</tbody>
</table>

**7.M. Funding:** There has been no specific funding for this objective.

**Progress:** CMS is no longer supporting the program that produced the earlier promising practices papers; it is possible that other methods of disseminating best practices information are now being used.

**Remaining Gaps, Needs, and Opportunities:** Best practices information dissemination is still a high priority, but there may be other means by which this is being done. The focus should be on achieving dissemination rather than on the particular method used. Perhaps this objective should be revisited and replaced with a version that reflects current needs and practices or combined with another objective as appropriate in the future.

**Question 7 Multiyear Funding Table, see appendix for a color-coding key and further details.**
### Question 7 Multiyear Funding Table

**IACC Strategic Plan Objectives**

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enhance networks of clinical research sites offering clinical care in real-world settings that can collect and coordinate standardized and comprehensive diagnostic, biological (e.g., DNA, plasma, fibroblasts, urine), medical, and treatment history data that would provide a platform for conducting comparative effectiveness research and clinical trials of novel autism treatments by 2012.</td>
<td>N/A</td>
<td>N/A</td>
<td><strong>7.N</strong> $6,662,790</td>
<td><strong>7.N</strong> $7,419,887</td>
<td><strong>7.N</strong> $5,270,828</td>
<td><strong>$19,353,505</strong></td>
</tr>
</tbody>
</table>

#### 7.N. Funding:
The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.

**Progress:** Autism Speaks’ ATN is a care network that also has research capabilities. The ATN has a collection of biological samples collected from patients who have sought care at the ATN. However, these samples are not targeted toward research use because the samples are not broadly shared like those from other repositories and the samples were not collected systematically. As the ATN has progressed in its work, it has shifted away from the goal of creating a repository to a new focus on developing clinical guidelines, especially in the area of co-occurring conditions. Several guidelines have been published. Another network, the IAN, has piloted a new rapid method of conducting “virtual” clinical trials of low-risk or “safe” treatments. For example, IAN conducted a trial on omega 3 fatty acids – a commonly used dietary supplement – across 40 states in 10 weeks, demonstrating the value of using interactive research networks for these types of trials.

**Remaining Gaps, Needs, and Opportunities:** Clinical and patient social networks represent new ways to conduct research ("practice to research"), as well as a path for evaluating interventions that do not require extensive safety testing (e.g., alternate diets or technological interventions) quickly using large social networks.

<table>
<thead>
<tr>
<th>Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Create an information resource for ASD researchers (e.g., PhenX Project) to share information to facilitate data sharing and standardization of methods across projects by 2013.</td>
<td>N/A</td>
<td>N/A</td>
<td><strong>7.O</strong> $605,338</td>
<td><strong>7.O</strong> $1,070,941</td>
<td><strong>7.O</strong> $728,000</td>
<td><strong>$2,404,279</strong></td>
</tr>
</tbody>
</table>

#### 7.O. Funding:
The recommended budget for this objective was met.

**Progress:** A small number of projects specific to this objective were funded. In addition, there are other projects that are responsive to the goals of this objective, but are coded elsewhere. For example, NDAR has developed a data dictionary that is now widely used across the research community to standardize data terminology so that data can be uniformly shared among researchers. Funding for this project is not reflected in the total for this objective because NDAR is coded elsewhere. NDAR also has a human subject common identifier that is now broadly used by the community.

**Remaining Gaps, Needs, and Opportunities:** Funding is necessary to develop standardized methods and protocols. This is a long term project and will need to be approached carefully.

---

*IACC Recommended Budget: $1,850,000 over 1 year*  
*IACC Recommended Budget: $2,000,000 over 2 years*
## Question 7 Multiyear Funding Table

<table>
<thead>
<tr>
<th>IACC Strategic Plan Objectives</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provide resources to centers or facilities that develop promising vertebrate and invertebrate model systems, and make these models more easily available or expand the utility of current model systems, and support new approaches to develop high-throughput screening technologies to evaluate the validity of model systems by 2013.</td>
<td>N/A</td>
<td>N/A</td>
<td>7.P $1,588,780 1 project</td>
<td>7.P $0 0 projects</td>
<td>7.P $0 0 projects</td>
<td>$1,588,780</td>
</tr>
</tbody>
</table>

**7.P. Funding**: The recommended budget for this objective was met.

**Progress**: The project in the Portfolio Analysis that addresses this objective is a NIMH intramural project to produce transgenic mouse models of mental and neurodevelopmental disorders, including ASD. In addition, when mouse models are made under grants and projects coded elsewhere in the portfolio, they are shared via Jackson Laboratories, and that funding is not reflected here.

**Remaining Gaps, Needs, and Opportunities**: Emphasis on providing means to encourage development and sharing of animal models, and development of assays that can be used in animal models is still required to advance basic and translational ASD research.

| Not specific to any objective (Core/Other Activities) | N/A | 7. Core/Other Activities $1,000,000 2 projects | 7. Core/Other Activities $13,253,709 26 projects | 7. Core/Other Activities $12,314,084 18 projects | 7. Core/Other Activities $16,863,272 23 projects | $43,431,065 |

| Reported funding for Question 7* | N/A | 7. Core/Other Activities $15,809,755 46 projects | 7. Core/Other Activities $50,847,065 108 projects | 7. Core/Other Activities $43,855,291 111 projects | 7. Core/Other Activities $47,516,197 112 projects | $158,028,308 |

| Adjusted funding for Question 7† | $12,098,057 12 projects | $15,809,755 46 projects | $50,847,065 108 projects | $43,855,291 111 projects | $47,516,197 112 projects | $170,126,365 |

---

Table 11. Question 7 Multiyear Funding Table.
Summary and Conclusion

The 2011-2012 ASD Research Funding Portfolio Analysis Report is the fourth comprehensive annual review of ASD research funding across both the Federal and private sectors and provides a valuable snapshot of the current funding landscape in the U.S. Data were collected from 20 Federal and private funders, including several which were new to the Portfolio Analysis. As indicated in the Introduction, the ASD research portfolio reflects the diverse missions of different funders, and each funder contributes uniquely to the body of research represented by the seven questions of the Strategic Plan.

The current report differs from previous Portfolio Analyses in that it includes detailed data from two years, rather than just one. In 2011, funding for ASD research totaled $299,879,145 and spanned 1,227 projects. In 2012, research funding totaled $331,949,933 and spanned 1,312 projects. Now that five years of ASD research funding data are available, it was possible to conduct a trend analysis, enabling meaningful observations about the long-term progress of the field of ASD research over the period from 2008-2012. Over the five years, autism research showed a general upward trend in funding.

One of the key aims of the Portfolio Analysis Report is to evaluate the progress made in addressing the research priorities as outlined in the Strategic Plan objectives. In 2011 and 2012, significant progress was made toward completing the objectives in the 2011 Strategic Plan, with 87% (68 objectives) and 90% (70 objectives) of the 78 objectives either partially or fully completed in 2011 and 2012 respectively. Considering the period from 2008-2012, only 6% (5 objectives) of the 2011 Strategic Plan objectives were not active at any point across this five-year window, indicating that the vast majority of priority areas identified in the Strategic Plan objectives were also deemed by government and private research funders to be worthy of investment and were implemented either partially or fully.

In addition to analysis of progress made on completing the specific research objectives outlined in the Strategic Plan, the subcategory classification system, introduced in the 2010 Portfolio Analysis, provides an alternative perspective on the content of the autism research portfolio, dividing it into broad research areas. Over time, even with possible changes in Strategic Plan objectives over time, the subcategory analysis will allow tracking of growth and change in general research areas, including emergence of new fields that attract investment from research funders.

The IACC/OARC will continue to conduct annual portfolio analyses to assist the Committee with carrying out its charge to monitor autism activities and to inform the process of updating the IACC Strategic Plan for ASD Research. Trends identified via the analysis can be used by the Committee and other Federal, private, and State funders to address gap areas, identify emerging trends and new research opportunities, and guide future research directions. By tracking new developments in autism research and inviting regular input from the community, the Committee will be well-equipped to continue charting the course toward encouraging investment in research that meets the most pressing needs of families and individuals affected by ASD.
APPENDIX A

ASD-Related Research Projects Not Included in the IACC Portfolio Analysis

This section contains lists of projects that are not specifically focused on autism, but may be helpful in understanding the broader landscape of ongoing research on disabilities and other topics that may be relevant to autism.

Department of Education, Institute of Education Sciences (IES)

<table>
<thead>
<tr>
<th>AWARD PERIOD</th>
<th>INVESTIGATOR</th>
<th>TITLE</th>
<th>WEBSITE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007-2015</td>
<td>Steven Ingels</td>
<td>High School Longitudinal Study</td>
<td><a href="http://nces.ed.gov/surveys/hsls09">http://nces.ed.gov/surveys/hsls09</a></td>
</tr>
<tr>
<td>Ongoing</td>
<td>Drew Malizio</td>
<td>National Assessment of Educational Progress</td>
<td><a href="http://nces.ed.gov/nationsreportcard/aboutnaep.asp">http://nces.ed.gov/nationsreportcard/aboutnaep.asp</a></td>
</tr>
<tr>
<td>Year Range</td>
<td>Author(s)</td>
<td>Project Title</td>
<td>Project URL</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
APPENDIX B

ASD Research Progress on IACC Strategic Plan Objectives: Summary of Years 2008 to 2012

The tables include data (project numbers and funding) from Federal and private funders of ASD research for years 2008 through 2012, as aligned with the objectives of the 2011 IACC Strategic Plan. They also include summaries (based on discussions during the 2013 IACC Strategic Plan Update Workshop) of progress on reaching the goals of each objective, as well as remaining gaps, needs, and opportunities. Please note the following:

During the updating of the Strategic Plan from 2008 to 2010, the wording and numbering of objectives changed. Data included in each Portfolio Analysis Report from 2008 to 2012 was categorized at the time with respect to the most recent iteration of the Strategic Plan where the objectives had changed. For the purpose of this five-year comparison, data from the Portfolio Analyses conducted in 2008 and 2009 were aligned with the most recent objectives, found in the 2011 Strategic Plan. The full wording of the 78 objectives listed in the 2011 Strategic Plan is depicted in the left column of the table.

The middle five columns of the table contain the data (project numbers and funding) for each individual year from 2008 to 2012, with the objective number (as it appeared in the annual Portfolio Analysis) listed above it. The IACC recommended budget listed below the project data represents the most updated budget listed in the 2011 Strategic Plan. If the recommended budget has been revised since 2008, the year the revision took place is found in parentheses following the budget figure. Therefore, if there is no mention of a revision, the IACC recommended budget has remained constant from 2008 to 2011. The annual project status for each objective from 2008 to 2012 is indicated within the table by colored highlighting of the objective number. An objective is considered active if its status is green or yellow, and inactive if its status is red.

- Any objective colored green has funding which is greater than or equal to the recommended funding for that year (determined by annualizing the recommended budget associated with that objective); any objective colored yellow has actively funded projects, but with funding that totals less than the annualized recommended amount; any objective colored red has no active, funded projects.9

- Objectives whose overarching aim (e.g., the ultimate goal of the research, irrespective of the number of projects or the budget for the objective) were achieved/partially achieved either in a previous year, with less annual funding than was recommended, or with funding that was not captured in the portfolio analyses,10 are colored pale green/pale yellow.
The far right column of the table lists the sum of the total funding aligned with each objective from 2008 to 2012.

- Highlighting of each total gives an indication of the overall progress toward completing each objective.
- **Green** highlighting indicates that funding fully meets the recommend budget. **Yellow** highlighting denotes that funding for a particular objective partially meets the IACC recommended budget, while **red** highlighting indicates that there has been no funding towards the particular objective.
- Objectives whose overarching aim (e.g. the ultimate goal of the research, irrespective of the number of projects or the budget for the objective) was achieved/partially achieved either with a lower funding level than was recommended or with funding that was not captured in the portfolio analyses, are colored **pale green/pale yellow**.

---

\(^9\) Please note that while the green, yellow, and red indicators suggest a funding status for each year and that looking across all years may give some indication of a trend, some agencies and organizations provide all the funding for multiyear grants in a single year, resulting in the appearance of “decreased funding” in other years; projects completing the objectives may still have been ongoing in the years where the funding appears to be decreased. Thus, it is important to note the numbers of projects in looking across the chart, and to keep in mind that in a series, where, for example, most of the indicators are green, that the objective is likely to be largely “complete” according to the funding-based measure.

\(^{10}\) Reasons why funding for certain projects may not have been captured in the portfolio analyses include projects that were supported by funding that was not specific for autism (i.e., projects that benefited autism but were supported by general neuroscience or developmental disorder funding) or projects supported by funders that did not participate in the portfolio analysis in a given year.
APPENDIX C

Subcategory Definitions

Question 1: Screening and Diagnosis

Diagnostic and screening tools: This subcategory includes projects that are developing new autism diagnostic and screening tests, as well as those establishing the usefulness of new or revised assessments for autism symptoms. It also encompasses projects aimed at adapting clinical assessments into other languages for use in multi-lingual community settings and non-U.S. countries.

Early signs and biomarkers: Projects which use a variety of methods to search for signs of autism in very young children (generally under age 3) that could be used for diagnosis, such as eye-tracking, physiological measures, and autism-specific behavioral patterns are included in this subcategory. More examples include projects investigating metabolic measures, such as the levels of specific chemicals, hormones, or proteins in the blood that could be used as biomarkers of the disorder.

Intermediate phenotypes/Subgroups: Included in this subcategory are projects aimed at identifying distinct subgroups of people with autism, or those that share common morphological, physiological, or behavioral features. Projects in this subcategory use a variety of methods to identify and distinguish these groups.

Symptomology: These projects seek to define the broad range and severity of autism symptoms, including both biological and behavioral characteristics. Among these studies are some that examine how children and adults with autism vary in their development of social communication and language. Other projects seek to understand the emergence of problem behaviors and how neurocognitive impairments can contribute to symptom development and phenotypic variability in those with an autism diagnosis.

Question 2: Biology

Cognitive studies: These are studies of psychological and mental processes, including memory, producing and understanding language, solving problems, and making decisions. Projects in this subcategory consist of those that investigate theory of mind, social cognition and empathy, understanding facial expressions of emotion (and how and why this is impaired in ASD), and recall and memory.

Computational science: Computational methods and modeling allow for the synthesis and study of large and complex sets of data. Some projects in this subcategory collect extensive experimental biological and behavioral data and use powerful computing techniques to reveal new insights. Other aspects of computer science are also included, such as developing statistical modeling techniques to better understand the biology of autism.
Co-occurring conditions: Research on conditions that often co-occur with ASD is included here, such as seizures/epilepsy, sleep disorders, gastrointestinal dysfunction, wandering/elopement behavior, attention deficit hyperactivity disorder (ADHD), and familial autoimmune disorders.

Developmental trajectory: Projects in this subcategory often include longitudinal studies following various aspects of biological and behavioral development in the same individuals over time. Examples include brain growth, face processing, change in neural connectivity over time, and development of communication skills and language processing. These studies often compare children with ASD to typically developing children or to their unaffected siblings.

Immune/Metabolic pathways: These projects focus on understanding the biological mechanisms of metabolism and the immune system that may be altered in autism, typically in cells and animal models. This largely includes studies on inflammation and inflammatory molecules (i.e., cytokines), as well as on the role of mitochondria, energy metabolism, and oxidative stress. Also included in this group are projects seeking to identify specific immune and metabolic triggers in early prenatal and post-natal life, such as maternal infection, maternal auto-antibodies, and toxic exposures.

Molecular pathways: This subcategory includes studies on specific molecules and proteins (other than the immune and metabolic systems) that may be involved in the development of ASD and related genetic disorders (e.g., fragile X syndrome and Rett syndrome). Many of these projects use animal and cellular models to explore the biological effects of specific candidate genes and to identify common molecular pathways, including alterations in synaptic functioning and intracellular signaling cascades.

Neural systems: Studies in this subcategory explore the structure and activity of the brain and underlying neural systems involved in autism, including functional connections between brain regions. Many projects seek to identify the precise neural networks underlying communication and language processing, social interactions, and behavioral issues. These studies frequently employ imaging techniques, such as functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI), and other physiological measures of brain activity, such as electroencephalography (EEG).

Neuropathology: These projects typically include post-mortem examination of brain tissue from ASD individuals. Many of the studies in this subcategory explore how the architecture of the brain may be altered in individuals with autism or how gene expression varies in different areas of the brain.

Sensory and motor function: Projects in this subcategory explore the neural underpinnings of motor skills and abilities in children with ASD and assess visual, auditory, and other sensory processes in the brain.

Subgroups/Biosignatures: Because there is so much heterogeneity among individuals with autism, research to understand how certain subgroups of individuals that share certain behavioral or biological characteristics could help understand some of the underlying biology in ASD. This can be done by searching for certain biological
factors ("signatures"), such as hormone levels or structural abnormalities in the brain, that define a particular subgroup. Many of these projects try to make the connection between certain genes with a known or suspected link to autism and the observable characteristic, or phenotype, that they cause.

**Question 3: Risk Factors**

**Environmental risk factors:** This subcategory includes a number of projects investigating potential environmental risk factors for autism. Example projects include studies of the effects of the microbiome, environmental contaminants and toxins, maternal dietary factors, medications taken during pregnancy or to induce labor, assistive reproductive treatments, child and maternal response to immune challenge, and registries where many of these factors can be tracked simultaneously.

**Epigenetics:** Epigenetics is the study of heritable changes in gene function that occur without a change in the DNA sequence (such as methylation of DNA). Environmental factors can cause these changes in gene expression, and projects in this subcategory seek to identify some of the environmental influences that may lead to these epigenetic changes.

**Gene-Environment:** These studies search for combinations of environmental risk factors and genetic susceptibility that increase the risk for ASD. (Note: While epigenetic studies often fit this definition, they are tracked separately for strategic planning purposes.)

**Genetic risk factors:** Projects in this subcategory seek to identify new genes that are implicated in increased risk for ASD or to better understand genetic risk factors that were previously identified.

**Question 4: Treatments and Interventions**

**Behavioral:** Projects in this subcategory involve a wide array of behavioral research and training methods, including applied behavior analysis (ABA), cognitive-behavioral therapy, discrete trial training, Early Start Denver Model, imitation training, joint attention training, Lovaas method, pivotal response training, sibling-mediated interventions, and social skills training.

**Complementary, dietary, and alternative:** This subcategory includes research on acupressure; acupuncture; antioxidants; cholesterol supplementation; glutathione metabolism; nutritional supplements, vitamins, and minerals; probiotics; and special diets (e.g., gluten-free, casein-free).

**Educational:** Nearly all research in classroom settings falls under this subcategory, including curricula, educational best practices, inclusive education programs, math and reading training, positive behavioral supports, special education programs, TEACCH (Treatment and Education of Autistic and Related Communication-Handicapped Children), and the “Social Stories” approach.
Medical/Pharmacologic: This subcategory includes research on drugs (e.g., antidepressants, anticonvulsants, antipsychotics, anxiolytics, melatonin, and stimulants) to treat autism and its co-occurring conditions, as well as medical therapies such as transcranial magnetic stimulation (TMS).

Model systems/Therapeutic targets: Animal models mimicking behaviors of ASD and those that are being used to develop or test new drug treatments, as well as cell lines used to discover new drug targets or to screen potential drug candidates, are included in this subcategory.

Occupational, physical, and sensory-based: Therapies in this subcategory encompass art therapy, motor training (including fine motor skills such as handwriting as well as gross motor training involving balance and posture), music therapy, occupational therapy, pet (animal) therapy, physical activity plans and exercise therapy (bike riding, swimming), physical therapy, sensory integration, therapeutic horseback riding, training in self-care and daily living skills, and vocational rehabilitation.

Technology-based interventions and supports: Augmentative and alternative communication (AAC), computer applications and software, picture exchange communication system (PECS), social robots, teleconferencing, video modeling and virtual reality (including virtual and 3D environments to mimic social situations), and wearable sensors are all examples of the types of technology in the projects in this subcategory.

Question 5: Services

Community inclusion programs: This subcategory includes research on programs that provide instruction in social, communication, and leisure skills to enable individuals with autism to participate in sports, recreation, and social-integration activities in fully integrated settings and to build successful relationships with others.

Efficacious and cost-effective service delivery: This subcategory includes research on programs involving web-based curricula and interventions as well as telehealth methodology, all of which could benefit those in underserved areas. Various parent training projects (to deliver a behavioral therapy, for example) using web-based methods such as teleconsultation and video feedback make distributing the training programs cost-effective and accessible across the country. Studies to improve dental care are also in this subcategory for effective service delivery.

Family well-being and safety: Studies in this subcategory evaluate issues of caregiver stress and measures of quality of life for individuals with ASD and their families, as well as assess programs to help parents navigate the service system after their child receives an ASD diagnosis. It also surveys safety issues for those with autism, including wandering and bullying.

Practitioner training: Projects in this subcategory include projects to develop and evaluate programs to increase skill levels in service providers, including medical providers, direct support workers, parents and legal guardians, education staff, and public service workers.
Services utilization and access: These projects include surveys of service systems available in different states, evaluations of patterns of medical service use among children with autism, development of comprehensive online resource for autism services, and specific efforts in several states to model and evaluate coordination of services for people with autism. They also evaluate disparities in diagnosis and service utilization as well as barriers to access for racial and ethnic minorities.

Question 6: Lifespan Issues

Due to the small number of projects (35 in 2011 and 34 in 2012) and the significant overlap between topics covered in these projects, no subcategories were created for this question in the 2011-2012 Portfolio Analysis Report. As the research field grows, subcategories that encapsulate the scope of projects in this question may be defined in the future.

Question 7: Infrastructure and Surveillance

Biobanks: A biobank is a type of biorepository which stores human biological samples for use in research. Projects in this subcategory support collection of DNA and tissue samples from autism patients.

Data tools: These projects include bioinformatics databases to store genetic, phenotypic, and other medical information from autism patients. They also support infrastructure for several of these major databases to interact.

Research infrastructure: This subcategory includes coordinating centers that support multiple research projects by running tests, analyzing data, and providing statistical analyses. These projects also support facilities that operate large, shared instruments used by several scientists to test research samples.

Research recruitment and clinical care: Projects in this subcategory help increase participation in research studies and conduct medical evaluations for the participants, often collecting data that can be used for multiple studies.

Research workforce development: Workshops, conferences, and training programs that serve to expand the research workforce, enhance interdisciplinary research training, and recruit early-career scientists into the ASD field are included in this subcategory.

Surveillance and prevalence studies: Research that measures autism prevalence in the U.S. and internationally is contained in this subcategory, including the Autism and Developmental Disabilities Monitoring (ADDM) Network sites maintained by the Centers for Disease Control and Prevention (CDC).
MEMBERSHIP ROSTERS

Interagency Autism Coordinating Committee (IACC)
Office of Autism Research Coordination (OARC)
INTERAGENCY AUTISM COORDINATING COMMITTEE

MEMBER ROSTER

CHAIR

Thomas R. Insel, M.D.
Director
National Institute of Mental Health
National Institutes of Health
Bethesda, MD

FEDERAL MEMBERS

James F. Battey, M.D., Ph.D.
Director
National Institute on Deafness and Other Communication Disorders
National Institutes of Health
Bethesda, MD

Linda Birnbaum, Ph.D.
Director
National Institute of Environmental Health Sciences and National Toxicology Program
National Institutes of Health
Research Triangle Park, NC

Coleen Boyle, Ph.D., M.S. Hyg.
Director
National Center on Birth Defects and Developmental Disabilities
Centers for Disease Control and Prevention
Atlanta, GA

Francis S. Collins, M.D., Ph.D.
Director
National Institutes of Health
Bethesda, Maryland
Denise Dougherty, Ph.D.
Senior Advisor for Child Health and Quality Improvement
Agency for Healthcare Research and Quality
Washington, DC

Tiffany R. Farchione, M.D.
Medical Officer
Division of Psychiatry Products
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Silver Spring, Maryland

Alan E. Guttmacher, M.D.
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institutes of Health
Bethesda, MD

Laura Kavanagh, M.P.P.
Director
Division of Research, Training and Education
Maternal and Child Health
Health Resources and Services Administration
Rockville, MD

Donna M. Kimbark, Ph.D.
Program Manager
Congressionally Directed Medical Research Programs
U.S. Department of Defense
Frederick, MD

Walter J. Koroshetz, M.D.
Director
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD
Sharon Lewis  
Commissioner  
Administration for Intellectual and Developmental Disabilities  
Acting Principal Deputy Administrator  
Administration for Community Living  
Washington, DC

John P. O’Brien, M.A.  
Senior Policy Analyst  
Disabled and Elderly Health Programs Group  
Centers for Medicare & Medicaid Services  
Baltimore, MD

Linda K. Smith  
Deputy Assistant Secretary and Inter-Departmental Liaison for Early Childhood Development  
Administration for Children and Families  
Washington, DC

Michael K. Yudin  
Acting Assistant Secretary for Special Education and Rehabilitative Services  
Office of Special Education and Rehabilitative Services  
U. S. Department of Education  
Washington, DC

PUBLIC MEMBERS

Idil Abdull  
Parent  
Co-Founder  
Somali American Autism Foundation  
Minneapolis, MN

James Ball, Ed.D., B.C.B.A.-D.  
President and CEO  
JB Autism Consulting  
Executive Chair, Board of Directors  
Autism Society  
Cranbury, NJ

Anshu Batra, M.D.  
Parent  
Developmental Pediatrician  
Our Special Kids  
Los Angeles, CA

Noah Britton, M.A.  
Self Advocate  
Adjunct Professor of Psychology  
Bunker Hill Community College  
Salem, MA

Sally Burton-Hoyle, Ed.D.  
Family Member  
Associate Professor  
Department of Special Education  
Eastern Michigan University  
Ypsilanti, MI

Matthew J. Carey, Ph.D.  
Parent  
Contributor, Left Brain Right Brain Blog  
San Jose, CA

Jose F. Cordero, M.D., M.P.H  
Dean  
University of Puerto Rico  
Graduate School of Public Health  
Rio Piedras, Puerto Rico

Jan M. Crandy  
Parent  
Case Manager  
Nevada State Autism Treatment Assistance Program Chair  
Nevada Commission on Autism Spectrum Disorders  
Las Vegas, NV

Geraldine Dawson, Ph.D.  
Professor  
Department of Psychiatry and Behavioral Sciences  
Duke University Medical Center  
Durham, NC

David S. Mandell, Sc.D.  
Associate Professor  
Department of Psychiatry and Pediatrics  
University of Pennsylvania School of Medicine  
Philadelphia, PA
Lyn Redwood, R.N., M.S.N.
Parent
Co-Founder, Vice President and Board Member
Coalition for SafeMinds
Tyrone, GA

Scott Michael Robertson, Ph.D.
Self Advocate
Co-founder and Vice Chair of Development
Autistic Self Advocacy Network
University Park, PA

John Elder Robison
Neurodiversity Scholar in Residence
College of William and Mary
Williamsburg, VA

Alison Tepper Singer, M.B.A.
Parent and Family Member
Founder and President
Autism Science Foundation
New York, NY